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ABSTRACT 
 
 Most hepatitis B virus (HBV) vaccines consist of viral small surface protein (SHBs), 
subtype adw2*, expressed in yeast cells, i.e. recombinant HBV surface antigen (rHBsAg). In 
spite of good efficacy, several concerns exist - non-response and appearance of escape 
mutants. The vaccine is not immunotherapeutic and cannot induce a curative response. 
Expression vectors based on replication deficient recombinant Semliki Forest virus vectors 
(rSFV) were used to transduce mice for HBV surface protein expression, which in turn 
induced an antibody response. Two subtypes of SHBs protein, subtype adw2 and ayw2, 
representing HBV genotypes D and A respectively, were cloned in pSFV1 vector. 
Additionally, in order to combine both determinants of HBV binding, which are also targets 
of neutralizing antibodies, vectors encoding internally deleted LHBs protein (LHBs∆49-163, 
i. e. SHBs (subtype ayw2) linked to 48 aminoterminal amino acids (aa) of preS1) and it’s 
variants were generated. To enhance secretion of internally deleted LHBs protein the 
myristoylation motif at the amino-terminus of preS1 was inactivated by point mutation. 
Contrary to the expected results internally deleted LHBs protein with an unchanged myristic 
acid attachment site formed secretable subviral particles displaying preS1 and S antigenicity 
with higher efficiency than myristoylation site mutants. Secretion of these particles was 
dependent on the in-frame expressed SHBs. This was shown by internally deleted LHBs 
protein protein with a point mutation in the in-frame translational start codon of SHBs 
protein. Groups of 7 – 9 BALB/c mice were intravenously inoculated with 107 replication 
deficient rSFV encoding both subtypes of SHBs - adw2 and ayw2 and two variants of 
internally deleted LHBs protein. Three weeks later mice were inoculated with 108 rSFV. 
Antibodies induced to both subtypes of SHBs protein exhibited strong preference to the 
homologous subdeterminant of the yeast-derived recombinant HBV surface antigen 
(rHBsAg), however this subtype dependency was not observed with the patient-derived 
HBsAg. Immunization with rSFV encoding internally deleted LHBs protein resulted in 
induction of preS1- and S-specific immunoglobulin G (IgG), while immunization with rSFV 
encoding the mutant without SHBs start codon resulted in preS1 antibodies only. The ratios of 
subclass IgG1 of immunoglobulin G to subclass IgG2a of immunoglobulin G ranged from 
0.28 to 0.88 in the four immunized BALB/c mice groups and were lowest for the group 
immunized with internally deleted LHBs protein with active translation of SHBs indicating 
the strongest type 1 T helper cell response .Primary hepatocytes of Tupaia belangeri 
susceptible to infection with HBV were used to determine neutralizing potential of antibodies 
obtained by rSFV immunization. Antibodies were mixed with highly purified patient plasma-
derived HBV (SHBs subtype ayw2), followed by infection of primary Tupaia belangeri 
hepatocytes. Quantitative markers of HBV infection were measured. Complete inhibition of 
HBV infectio was defined as infection in presence of monoclonal antibodies directed to preS1 
and SHBs. The neutralizing power of SHBs antibodies was not dependent on HBsAg subtype 
and S/adw2 antisera neutralised HBV with SHBs subtype ayw2 with equal efficiency as 
antisera raised with S/ayw2. Antibodies induced to SHBs alone and internally deleted LHBs 
neutralized HBV infection completely, while antibodies generated to internally deleted LHBs 
with inactive in-frame translational start codon of SHBs protein neutralized HBV infection 
partially.  
 
* In this dissertation the term “subtype” (often referred to as immunological subtype, or serotype of 
HBV) which is usually in literature referred to HBsAg,  will be assigned to SHBs as well as  to HBsAg. 
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ANOTĀCIJA 
 
Lielākā daļa vakcīnu pret B hepatīta vīrusu (HBV) sastāv no vīrusa S proteīna adw2 
apakštipa* (genotips A2), kas ar gēnu inženierijas paņēmieniem ekspresēts rauga šūnās. Lai 
gan šīs vakcīnas ir efektīvas, tomēr ar tām ir saistītas dažādas nepilnības – vāja vai neesoša 
imūnā atbilde, vīrusa „bēgļu”variantu veidošanās, bez tam vakcīna nav imunoterapeitiska. Uz 
alfavīrusu pamata izveidotie vektori „svešu” gēnu ekspresijai jau ir lietoti kā rekombinantās 
vakcīnas un gēnu terapijas līdzekļi vēža terapijai. Promocijas darba izstrādē izmantoti 
rekombinantie Semliki meža vīrusa (rSMV) vektori. Darba gaitā iegūti rSMV, kas genomā 
nes gan HBV S proteīna adw2 apakštipu, gan arī ayw2 apakštipu. Turklāt, lai apvienotu abus 
noteicošos faktorus, kas atbild par HBV saisīšanos pie mērķšūnām, iegūti rSMV, kas kodē 
saīsinātu L proteīnu, kas sastāv no S proteīna, kam N galā pievienotas preS1 N gala 48 
aminoskābes (preS1.1-48/S). Lai palielinātu saīsinātā L proteīna sekrēcijas efektivitāti, 
izmainīta miristīnskābes pievienošanas vieta preS1 rajona N galā, jo miristīnskābe daļēji 
saistīta ar preS1 rajona aizturēšanu šūnās. Pretēji paredzētajam, saīsinātais L proteīns ar 
neizmainītu miristilēšanās motīvu, salīdzinot ar šī proteīna mutantiem, visefektīvāk veidoja 
sekretētas vīrusveidīgās daļiņas ar preS1 un S antigenitāti. Bez tam, proteīna sekrēcija bija 
pilnībā atkarīga no līdz-ekspresētā S proteīna, kura translācija noris no nākamā iniciācijas 
kodona. 
rSMV replikonus var nogādāt šūnās in vitro un in vivo ar trim dažādiem paņēmieniem. 
Promocijas darba izstrādei izvēlēti replicēties nespējīgi rSMV ar vienu infekcijas ciklu. Lai 
iegūtu antivielas pret S un preS1, BALB/c pelēm vēnā ievadīja 107 rSMV, un pēc trim 
nedēļām 108 rSMV.  
Antivielas, kas ierosinātas pret abiem HBsAg apakštipiem, efektīvi saistījās ar 
homologu rekombinantā HBsAg apakšdeterminanti, ar heterologu HBsAg apakšdeterminanti 
saistīšanās nebija efektīva. Turpretīm, izmantojot no pacientiem iegūto HBsAg, šādu 
saistīšanos atkarība no HBsAg apakštipa nenovēroja Imunizācija ar rSMV-preS1.1-48/S 
ierosināja preS1- un S-specifisku G klases imunoglobulīnu (IgG) veidošanos, bet imunizācija 
ar rSMV, kas kodē preS1.1-48/S0 proteīnu ar “izslēgtu” S proteīna translāciju - tikai preS1-
specifisku IgG veidošanos. IgG apakšklašu IgG1/IgG2a attiecība četrās imunizēto peļu grupas 
variēja no 0.28 to 0.88, pati zemākā šo apakšklašu attiecība bija ar rSMV- preS1.1-48/S 
imunizēto peļu grupā, liecinot par visspēcīgāko 1. tipa T līdzētājšūnu (Th1) atbildi. 
Lai pārbaudītu anti-S un anti-preS1 spēju neitralizēt HBV infekciju in vitro, izmantoja 
Belangera tupajas (Tupaia belangeri) hepatocītus, kurus var inficēt ar HBV. Hepatocītus 
inficēja ar attīrītu HBV (S proteīna apakštips ayw2), kam iepriekš pievienoja ar rSMV 
imunizāciju iegūtās antivielas pret HBV virsmas proteīniem. Novērots, ka ierosināto antivielu 
spēja neitralizēt HBV infekciju nebija atkarīga no S proteīna apakštipa: anti-S/adw2 
neitralizēja HBV/ayw2 tikpat efektīvi kā anti-S/ayw2. Anti-preS1.1-48/S un anti-S neitralizēja 
HBV infekciju pilnībā, turpretīm anti-preS1.1-48/S0  - daļēji. 
Secināts, ka rSMV spēj ierosināt no HBsAg apakštipa -neatkarīgu HBV neitralizējošu 
antivielu veidošanos, bez tam Th1 tipa atbildes ierosināšana liecina par rSMV pieejas 
potenciālu imunoterapeitiskas stratēģijas izveidei.  
 
 
* Promocijas darbā termins “apakštips” (literatūrā lietots arī apzīmējums HBV serotips) attiecināts gan, 
kā pieņemts, uz HBsAg, gan arī uz HBV S proteīnu. 
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AIM OF THE STUDY 
 
The aim of the study was generation of antibodies directed to two binding determinants of 
HBV to hepatocytes: SHBs protein in its natural conformation and combined with 
aminoterminal 48 aa of preS1 domain (genotype D numeration) and determination of 
neutralizing antibodies in an in vitro HBV infection model. Antibodies to HBs proteins were 
induced by immunization of an inbred laboratory mice strain with replication deficient 
recombinant Semliki Forest virus (rSFV) encoding the respective proteins. 
  
 
OBJECTIVES 
 
1. Clone the coding sequence of internally deleted LHBs (LHBs∆49-163; consisting of 
aminoterminal 48 aa of preS1 linked to the amino-terminus of the SHBs protein       
(further termed preS1.1-48/S)) in pSFV1 vector. Decipher the influence of the 
myristoylation motif at the amino-terminus of preS1, known to be partially responsible 
for retention of full length LHBs, on secretion efficiency and cellular distribution of 
the deleted LHBs. To elucidate the effect of the in-frame expressed SHBs protein in 
effective formation of preS1.1-48/S subviral particles, abrogate the translation of the 
SHBs protein from the translational start codon downstream of the preS1 translation 
initiaton codon. 
 
2. Establish conditions for rSFV production in BHK-21 cells after co-electroporation of 
rSFV RNA and RNA encoding SFV structural proteins and attain appropriate titer of 
rSFV (at least 109 infectious units/ml) after sedimentation through 20% sucrose (w/v) 
for immunization of an inbred laboratory mice strain BALB/c.  
 
3. Examine expression in vitro of SHBs and preS1.1-48/S and it’s variants in BHK-21 
and Huh7 cells, as well as in primary hepatocytes of Tupaia belangeri. Evaluate 
ability of preS1.1-48/S protein and it’s variants to generate subviral particles 
displaying preS1 and S antigenicity. From the preS1.1-48/S protein variants, choose 
proteins with the greatest secretion and efficiency of subviral particle formation for 
rSFV mediated immunization of BALB/c mice. Obtain rSFV encoding the selected 
preS1.1-48/S proteins.  
 
4. In preliminary experiments immunize BALB/c mice intravenously (i.v.) and 
subcutaneously (s.c.) with various infectious units of rSFV encoding SHBs, subtype 
adw2 (rSFV-S/adw2): 106, 107 and 108 to determine the most appropriate 
immunization route and scheme for induction of a humoral response to S/adw2. 
Choose the most efficient route and scheme of immunization of BALB/c mice for 
generation of antibodies directed to two subtypes of SHBs – adw2 and ayw2, and 
preS1.1-48/S proteins.  
 
5. Examine the reactivity of the generated antibodies to two subtypes of recombinant 
HBsAg produced in yeast (rHBsAg) representing homologous and heterologous SHBs 
subtype determinants. Determine the immunoglobulin class G (IgG) titer of anti-S 
antibodies and anti-preS1 antibodies in the immunized groups of mice. Detect the ratio 
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of IgG subclasses IgG1 to IgG2a (IgG1/IgG2a). Assess the binding of antibodies from 
all immunized groups to patient-derived highly purified HBsAg.  
 
 
 
6. Determine the neutralizing potential of antibodies from all immunized mice groups 
using in vitro HBV infection model of primary Tupaia belangeri hepatocytes. After 
incubation of antibodies with highly purified patient-derived HBV and infection of 
primary Tupaia belangeri hepatocytes, detect quantitative markers of HBV infection: 
viral mRNA, HBsAg and HBeAg.  
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ABBREVIATIONS 
(+) DNA plus strand (positive strand) DNA 
(-) DNA minus strand (negative strand) DNA 
(+) RNA plus strand (positive strand) RNA 
(-) RNA minus strand (negative strand) RNA 
aa amino acid 
cDNA complementary DNA 
CTL cytotoxic T lymphocytes 
EGFP enhanced green fluorescence protein 
FCS foetal calf serum 
FITC fluorescein isothiocyanate 
ELISA enzyme linked immunosorbent assay 
ERGIC endoplasmic reticulum -Golgi intermediate compartment 
HBc core protein of hepatitis B virus 
HBeAg non-particular secreted form of Hepatitis B virus core antigen 
HBV Hepatitis B virus 
HBs surface proteins of Hepatitis B virus 
HBsAg Hepatitis B virus surface antigen (also known as Australia antigen a -
particulate form of HBV surface proteins) 
IFN interferon 
IgG immunoglobulin G 
IgG1 subclass IgG1 of immunoglobulin G 
IgG2a subclass IgG2a of immunoglobulin G 
IU international units of antibodies to HBsAg 
i.v. intravenous 
LHBs large HBs 
MAb monoclonal antibody 
MDA melanoma differentiation-associated factor-5 
MEM minimal essential medium 
MHBs middle HBs 
N-glycan an oligosaccharide added to the amide nitrogen of asparagine side chains 
N-glycosylation attachment of oligosaccharides to the amide nitrogen of asparagine side 
chains 
ORF open reading frame 
OD optical density 
PBS phosphate buffered saline 
P protein HBV polymerase or reverse transcriptase 
PNGase F peptide - N glycosidase- F 
PTH primary Tupaia belangeri hepatocytes 
PKR dsRNA dependent protein kinase 
rcDNA relaxed circular DNA 
rHBsAg HBsAg produced by recombinant DNA technology in yeast 
RNase L ribonuclease L 
RIG-1 retinoic acid inducible gene-1 
rSFV recombinant Semliki Forest virus 
s.c. subcutaneous 
S/CO signal/”cut-off” ratio 
SD standard deviation 
SFV Semliki Forest virus 
SHBs small HBs 
SIN Sindbis virus 
Th1 type 1 T helper cells 
Th2 type 2 T helper cells 
PEG polyethylene glycol 
PTH primary hepatocytes from Tupaia belangeri 
THM Tupaia belangeri hepatocyte medium 
TLR toll-like receptors 
VEE Venezuelan equine encephalitis virus 
wt wild type 
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1. REVIEW OF THE LITERATURE 
1.1 Hepatitis B virus (HBV) 
 
HBV is the prototype virus for a family of Hepadnaviridae. The hepatotropic DNA 
viruses of the Hepadnaviridae family cause acute and chronic infection of the liver. The 
mammalian viruses - HBV, woodchuck hepatitis virus and ground squirrel hepatitis virus - 
form the genus Orthohepadnavirus. Genus Avihepadnavirus include viruses of birds. The 
breakthrough leading to the discovery of HBV was the findings of B. Blumberg in 1965 that 
an antigen in the serum sample of an Australian aboriginee reacted specifically with an 
antibody in the serum of a hemophilia patient. The antigen was named Australia antigen, now 
known as hepatitis B virus surface antigen, HBsAg. Krugman and co-workers had by 1967 
distinguished two distinct types of hepatitis, the parenterally transmitted „serum hepatitis” is 
now known as hepatitis B. In 1967 it was postulated that a link exists between the Australia 
antigen and serum hepatitis. Direct association of Au antigen with serum hepatitis B was put 
forward by Prince in 1968. The complete hepatitis B virion – double-shelled 42 nm particle 
(Fig.1A panels 1 and 4) was identified by Dane in the serum of patients with Australia antigen 
(Hollinger and Lau, 2006;Gerlich, 2013). 
HBV virions (Fig. 1A) consist of an outer hepatocyte-derived lipoprotein envelope, 
which contains three related membrane spanning envelope glycoproteins – large (L), middle 
(M) and S (small) surface proteins (HBs proteins). The virion contains icosahedral 
nucleocapsid with T4 or T3 symmetry (Dryden et al., 2006), the majority of capsids in virions 
bear T=4 symmetry. The capsids which bear T=4 symmetry have a diameter of 36 nm, while 
capsids with T=3 symmetry are 32 nm (Crowther et al., 1994; Kenney et al., 1995). Details of 
capsid architecture can be found in excellent studies by Crowther et al. (Crowther et al., 
1994), Wynne et al. (Wynne et al., 1999) and Zlotnick et al.(Zlotnick et al., 1996). The capsid 
encloses partially double stranded circular 3.2 kb DNA genome and an endogenous DNA 
polymerase – viral reverse transcriptase (Fig. 1B, Fig. 7). According to cryo-
electronmicroscopy analysis virions can be divided in two morphologically distinguishable 
phenotypes: compact particles are characterized by an invisible boarder between nucleocapsid 
and the envelope (Fig. 1 A panel 4, upper row), whereas gapped particles have a clear 
“boarder” between the nucleocapsid and envelope (Fig. 1A panel 4, middle row ). There are 
also chimeric particles which are a mixture of both phenotypes (Fig. 1A panel 4, bottom row) 
(Seitz et al., 2007).  
 
1.1.1. Epidemiology of HBV 
With around 240 million persistently infected persons HBV presents an enormous 
health problem. Each year 650 000 people die from HBV-associated liver failure, cirrhosis 
and hepatocellular carcinoma (http://www.who.int/mediacentre/factsheets/fs204/en/). In 
highly endemic areas the prevalent mode of transmission is perinatally from HBV infected 
mothers, while in low endemic areas the main transmission route is by sexual contact and 
percutaneously. After contraction of HBV 5%-10 % of adults develop chronic infection, while 
the remaining clear it. While about 90% of adults clear the infection, 40% - 90% of infected 
neonates progress to persistent infection (Dienstag, 2008).  
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1.1.2. HBV surface proteins 
HBV envelope proteins are encoded by a single open reading frame. Each of them is 
produced from alternative translational start sites, but with a common stop codon. SHBs, 
being most abundant in HBV and subviral particles, is comprised of 226 amino acids (aa) 
which is also present as S domain in the MHBs and LHBs. M protein contains in addition a 
preS2 N-terminal extension of 55 aa. The L protein has further N-terminal 108, 118 or 119 aa 
depending on the HBV-genotype, termed preS1, for schematic representation see Figure 2. 
All HBs proteins are referred as HBsAg. The proportion of S:M:L in the virion envelope is 
about 7:2:1 (Heermann et al., 1984). HBV-infected cells and transfected cells secrete 
nucleocapsid free spherical and filamentous (Fig. ,1A panels 3 and 2) subviral HBsAg 
particles, 20-22 nm in diameter.Spherical particles consist primarily of SHBs, while filaments 
have a larger proportion of L protein. The non-infectious subviral particles are produced in up 
to 10 000-fold excess over virions (Bruss, 2007). The spherical 22 nm subviral particles are 
composed of dimers and are octahedral (Gilbert et al., 2005). 
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Figure 1. A. Electron micrographs of HBV and subviral particles. (A) 1-3 shows virions and 
subviral particles purified from HBV carrier serum . The panel 4 and 5 of A shows image processed 
images of cryo-electron microscopy of infectious HBV virions purified from chronically infected 
patient. Panel A 4 depicts HBV particles with compact morphology, middle row shows particles with 
gapped morphology and bottom row - particles with mixed morphology. The white line around 
particles in the bottom row indicate gapped morphology. Bar: 20 nm. A 5 shows electron micrograph 
of purified HBV particles, including filamentous and spherical subviral particles. B. Schematic 
presentation of HBV. The LHBs, MHBs and SHBs stand for large, middle and small HBV surface 
proteins, L consisting of S, preS2 and preS1 domains, while M – of S and preS2. The nucleocapsid 
(core or HBc) is shown in black. DNA is shown as a single or double line. Subviral HBsAg particles 
are depicted in filamentous and spherical form. The diameter of the virion and the subviral HBsAg 
particles in nm is indicated. Fig. 1A panels 1-3 and Fig. 1B adapted from Gerlich W.H. (2013) 
Medical Virology of Hepatitis B: how it began and where we are now.Virology Journal 10:239. Fig.A 
panels 4 and 5 adapted from Seitz S. et al. (2007). Cryo-electron microscopy of hepatitis B virions 
reveals variability in envelope capsid interactions. EMBO J. 19;26(18):4160-7. 
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Figure 2. Schematic representation of HBs proteins. The 226 aa S domain is shared by all three 
proteins. The 55 aa extension, termed preS2 is unique to the M and L proteins, while the preS1 
extension is unique to the L protein. The preS1 domain consists of 108 aa, 118 aa or 119 aa depending 
on the genotype. N-glycosylation is indicated by NG, O-glycosylation by OG. The partial 
glycosylation is shown by the parenthesis. The L protein is myristoylated at the N-terminus (Myr), and 
the M protein at the N-terminus is acetylated (Ac). Adapted from Glebe D., Urban S. (2007). Viral 
and cellular determinants involved in hepadnaviral entry. World J Gastroenterol. 13(1): 22-38. 
 
The three HBs proteins are partially co-translationally N-glycosylated at the Asn146  
in the S domain (Figure 2). The preS2 bears a N- glycosylation site at Asn 4, which is 
employed in M protein, but not in the L protein. The preS2 in the M protein, and in the L 
protein, can be O-glycosylated at Thr 37 in genotypes B – H (Glebe and Urban, 2007). The 
preS1 contains an additional potential N-glycosylation site at Asn4, however, the preS1 
chains fail to be co-translationally translocated to the ER lumen and due to the orientation of 
the preS1 domain to the cytosolic side of the ER membrane, these sites remain unmodified 
(Bruss et al., 1994). An artificially added signal sequence at the N-terminus of L protein 
forces the co-translational translocation of preS1 to the ER lumen where glycosylation at 
Asn4 may take place (Bruss and Vieluf, 1995). The N-terminus of the L protein additionally 
bears a Met-Gly myristoylation motif (Towler et al., 1988), which is recognized by cellular N-
myristoyltransferase. Gly 2 of the preS1 is myristoylated and this modification is a common 
feature of all hepadnaviruses (Persing et al., 1987). Myristoylation of the L protein is 
indespensible for viral infectivity, since it has been shown that myristoylation-defective 
virions completely lost infectivity for susceptible cultures (Gripon et al., 1995; Bruss et al., 
1996; Glebe et al., 2005).  
1.1.3.Topology and function of the HBs proteins 
HBV envelope proteins are synthesised at the endoplasmic reticulum (ER), the 
morphogenesis of HBV S protein was reviewed in 2007 by a study of Patient et al., which, 
interestingly, resolved that SHBs forms branched filaments of 22 nm in diameter in the lumen 
of ER, which are transported to ER-Golgi intermediate compartment (ERGIC), packed in 
folded and bridged crystal-like structures, which are relaxed in ERGIC. However, it remains 
unresolved how the spherical particles, necessary for the progression through a secretory 
pathway, are formed (Patiet et al. 2007).  
The orientation of the SHBs at the ER membrane results in the region between aa 99 
and approximately 169 facing the lumen of the ER, which is most exposed on the surface of 
virus  particles. The “a” determinant of HBsAg is comprised of the antigenic loop in a specific 
conformation and is located between aa 101 and 164 - the transmembrane domain II and the 
hydrophobic C-terminus (Salisse and Sureau, 2009). The “a” determinant contains the 
protective, virus neutralizing B cell epitopes (Ganem and Schneider, 2001). Besides, they are 
disulphide-dependent (Glebe et al., 2003), with the cysteines having a fundamental role at the 
viral entry step (Abou-Jaoude and Sureau, 2007). The role of SHBs protein in binding is 
emphasised by the findings that antibodies against a conformational, but not linear S epitope, 
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could inhibit HBV infection (Glebe et al., 2003). Amino acids 100 to 170 of the S protein 
form the hydrophilic loop which is essential for infectivity (Jaoude and Sureau, 2005) and 
specifically aa 119-128 of the antigenic loop are of crucial importance (Jaoude and Sureau, 
2005).  
The preS2 domain of the M protein is translocated to the lumen of the ER by signal I 
in the S domain (Eble et al., 1990; Stibbe and Gerlich, 1983). The preS2 domain does not 
participate in the binding and is not necessary for virus entry (Ni et al., 2010). M protein is 
not necessary for virion secretion (Bruss and Ganem 1991, Sureau 1994), however, later work 
identified that 5 aa ( aa109 – 113) at the N-terminus of the pre-S2 region are essential for 
virion release, while deletions from aa 114 to 163 (numeration from the start of L protein at 
the preS1) still supported virion secretion (Le et al., 1998). The role of preS2 in virion 
assembly was revised by a study of Ni et al. which showed that deletions of aa 114 to 143 and 
114 – 163 interfered with virion formation. By a frameshift mutation of aa 114 – 143 they 
demonstrated that this region may serve as a spacer between the capsid binding site in preS2 
and the transmembrane domain at the N-terminus of S protein (Ni et al., 2010). 
After translation half of the L protein chains position their preS region into the ER. It 
has been proposed that  the ER chaperone BiP regulates the process of post-translational 
translocation (Awe et al., 2008). The other possible mechanisms of this post-translational 
translocation are reviewed by Bruss V. (Bruss, 2007). This results in the virions establishing 
the dual topology of the L protein - the preS1 and preS2 domains face the external and 
internal side of the viral envelope (Bruss et al., 1994,Lambert, Prange et al. 2001). From the 
dual topology of the L protein (Fig. 3A) the dual function of the preS domains arise:preS1 
mediates binding of the HBV to the susceptible cells (Le Seyec et al., 1999; Engelke et al., 
2006; Glebe et al., 2005; Gripon et al., 2005) as well as envelopment of the capsid (Bruss, 
2007). The first 75 N-terminal aa are responsible for infectivity (Blanchet and Sureau, 2007), 
while work by D. Glebe et al. postulates that N-terminal 48 aa are responsible .The essential 
binding domain of preS1 is comprised of aa 9-18, while aa 28-48 comprise the accessory 
domain (Glebe et al., 2005). It has been proposed that the attachment site in the preS1 
mediates binding of the virus to cell surface heparan sulfate proteoglycans (Leistner et al., 
2008). Recently, sodium-dependent taurocholate cotransporting polypeptide has been 
identified as a receptor for preS1 attachment site (Yan et al., 2012). The signal for 
encapsidation resides in the C-terminal part of the preS. The exact interaction of the caspid 
and the HBs still remains unresolved. Sequence between Arg 103 and Ser 124 involving the 
very N-terminal part of preS1 has been proposed to directly interact with the nucleocapsid 
(Bruss, 1997). Glu 77 and Asp 78 at the tip of the capsid spike play a role in envelopment 
(Bottcher et al., 1998). Later work by Bruss (Ponsel and Bruss, 2003) identified 11 aa at the 
groove around the base of the capsid spike essential for particle envelopment and virion 
formation (Dryden et al., 2006), although the study by Seitz et al (Seitz et al., 2007) was not 
able to elucidate that base of the spike is directly interacting with the envelope. Current 
evidence suggests that binding of HBs to the nucleocapsid is mediated by specific types of 
electrostatic interactions between the negative charges at the tips of the spikes and cytosolic 
loop of HBs which contain three arginine residues (Arg 73, 78 and 79) (Seitz et al., 2007). 
Study by Dryden et al. (Dryden et al., 2006) suggested a random packing of HBs (Fig. 3B 
panel 1), whereas work by Seitz et al. also recognized some degree of variability in 
organization of HBs proteins, but proposed a model towards an organized icosahedral packing 
of HBs in the envelope (Fig. 3B panel 2) (Seitz et al., 2007). 
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Figure 3. A. Transmembrane topology of the HBs proteins at the ER. S, M and L denote the S 
HBs, MHBs and LHBs proteins. The open boxes stand for N-terminal and internal signals of the S 
protein determining its transmembrane folding. The thinner line in the M protein represents the preS2 
domain.The filled circle denotes N-glycosylation of the preS2 domain, the open circles denote partial 
N-glycosylation of the S domain. The dual topology of the L protein resulting from ~50% of the 
molecules post-translationally translocating to the ER lumen during maturation is shown. Internal preS 
and external preS denotes the orientation of the preS domains in the mature virus particle after 
budding. The boxed area represents the potential interaction site with the capsid. The proposed 
position of the N-terminal myristate group (filled box) is shown. Adapted from Bruss V. (2007). 
Hepatitis B virus morphogenesis. World J Gastroenterol. 13(1): 65-73.B. Interaction of preS 
domains with the capsid. Panel 1. Cartoon of interpretation of x-ray crystal structure of recombinant 
capsid docked into the cryo-EM density map of the virion capsid. L, M and S (yellow boxes) denote 
the HBs proteins. Residues in the capsid tip are colored according to charge and hydrophobicity 
(negative: red; positive: blue; hydrophobic: gold; hydrophilic:gray). ~50% of the L molecules have an 
interior loop that according to Dryden et al.(Dryden et al., 2006) is predicted to be disordered, which 
interacts with specific residues in HBcAg (green spheres) (Ponsel and Bruss, 2003). Adapted from 
Dryden et al. (2006). Native Hepatitis B Virions and Capsids Visualized by Electron Cryomicroscopy. 
Mol. Cell 22:  843–850. Panel 2. The two dimers in the asymmetric unit (Wynne et al., 1999) fitted 
into the density map of compact virions reflecting the side views of the two types of spikes in contact 
to the envelope. Negatively charged amino acids at the tips of the spikes are shown in yellow. 
 
1.1.4. Secretion of HBs proteins 
Cells infected with HBV as well as cells transfected with HBs encoding constructs 
secrete spherical and filamentous particles of 20-22 nm in diameter. SHBs and MHBs are 
efficiently secreted from transfected cells (Ou and Rutter, 1987;Patient et al., 2007) 
Although LHBs is abundant on the surface of mature HBV virions, it comprises only 
1-2% of the secreted filamentous subviral particles from HBV infected cell (Heermann; 
1984). Full length LHBs is not secreted from transfected cells or secreted in minor quantities 
1 
A 
B 
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(Persing et al., 1986;McLachlan et al., 1987;Ou and Rutter, 1987). Moreover, the secretion of 
SHBs is impaired if S is expressed simultaneously with full length L or with preS1 domain 
(Persing et al., 1986; Ou and Rutter, 1987; McLachlan et al., 1987; Chisari et al., 
1986;Standring et al., 1986). Specifically the preS1 domain is implicated in retention of the 
LHBs. Studies on genotype A, HBsAg subtype adw2, mapped the retention signal to aa 6-19 
(Kuroki et al., 1989). Gallina et al. (Gallina et al., 1995) postulated that the retention signal 
resides in the region aa 77-99 of preS1. Another determinant involved in the retention of the L 
protein is the N-terminal myristic acid (Prange et al., 1991;Gallina et al., 1995;Gazina et al., 
1996), while some studies assign only partial role to the N-terminal myristate (Gallina et al., 
1995; Gazina et al., 1996). Topology of the L protein at the ER (Bruss and Vieluf, 
1995;Ostapchuk et al., 1994;Bruss et al., 1994) is also responsible for the secretion block of 
the L protein.  
 
1.1.5. Genetic variability of HBV. HBV genotypes and subgenotypes. Subtypes of HBsAg 
10 genotypes can be distinguished for human HBV: A, B, C, D, E, F, G, H (Schaefer, 
2007), I (Yu et al., 2010) and J (Tatematsu et al., 2009). HBV genotypes differ by more than 
8%. HBV genotypes can be divided in subgenotypes, with the exception of genotypes E and 
G, wich differ by at least 4% (Schaefer, 2007). The geographic distribution of the HBV 
genotypes and subgenotypes is shown in Figure 4. The HBV genotypes dealt with in this 
dissertation are genotype D and genotype A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Geographic distribution of HBV genotypes and subgenotypes. From from Gerlich W.H. 
(2013) Medical Virology of Hepatitis B: how it began and where we are now.Virology Journal 
10:239. 
 
HBsAg has nine immunological subtypes, which are represented as a combination of a 
common immunodominant a with subtype determinants d or y, and w1-w4 or r. HBsAg 
subtype adr is additionally subdivided into q+ and q- categories The nine HBsAg subtypes are 
ayw1, ayw2, ayw3, ayw4, adw2, adw4, ayr, adrq+ and adrq- (Norder et al., 2004). Exchange 
from Lys to Arg at the positions 122 and 160 determines the change from allelic variatons d/y 
and w/r (Purdy et al., 2007). The d determinant is distinguished by Lys at position 122, while 
y determinant by Arg at the position 122. Lys at position 160 distinguishes the w determinant, 
while Arg – r determinant (see Fig. 5).w1-w4 variation is determined by Pro, Thr and Leu at 
aa 127 and it distinguishes w1/w2, w3 and w4 reactivity respectively. The complete decision 
tree for HBsAg subtype determination can be found in an article by Purdy and others (Purdy 
et al., 2007). One subtype of HBsAg may be specified by several HBV genotypes. Subtype 
adw2 dealt with in this dissertation is associated with genotypes A, B, C, F and G, while 
HBsAg subtype ayw2, also described here, is specified by genotypes D and E. The complete 
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association between HBV genotypes and subtypes is described in detail by Norder et al. and 
Purdy et al. (Norder et al., 2004; Purdy et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Genotype and vaccine induced specific exchanges in the a determinant of SHBs. The a 
determinant consists of 2 loops: aa 124-137 and aa 138-147 or 149, held together by disulfide bridges, 
schematically represented by lines. The capital letters in black denote the genotypes of HBV. Adapted 
from Schaefer et al. in Doerr & Gerlich: Medizinische Virologie, Thieme 2010, p. 356. 
 
   
Figure 6. Replication cycle of HBV genome. After binding and uptake of the virions, capsids 
containing relaxed-circular DNA (RC-DNA) are released in the cytoplasm. RC-DNA is transported to 
the nucleus and repaired to form cccDNA. Viral mRNAs are transcribed by RNA polymerase II from 
cccDNA. Pregenome RNA serves as a template for core protein and P protein (reverse transcriptase) 
synthesis, it is encapsidated with P protein into nucleocapsid where reverse transcription takes place. 
New RC-DNA is formed by (+) DNA synthesis from the (-) DNA strand. The subgenomic transcripts 
for translation of HBs proteins and X protein are shown. Adapted from Beck. J., Nassal M. Hepatits B 
virus replication. (2007). World J Gastroenterol. 13(1): 48-64 and modified by author. 
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                                                              Figure 7. HBV genome and encoded proteins. The thick, 
black lines denote the partially double-stranded relaxed-circular 
HBV DNA. The (+)-strand is incomplete. P protein – viral 
reverse transcriptase is covalently linked to the 5’ end of the 
negative strand DNA, the zig-zag line denotes the RNA primer, 
which is linked to the 5’end of the positive strand DNA. DR1 
and DR2 are the direct repeats. The outer circle shows the 
terminally redundant pgRNA with hairpin structure 
(encapsidation signal and takes part in replication initiation ) 
close to the 5’ end and poly A at the 3’ end. The four open 
reading frames – C (core), X (X protein), preS/S (HBs proteins) 
and P (reverse transcriptase) are shown inside. TP – terminal 
protein domain of P. Adapted from Beck. J., Nassal M. 
Hepatits B virus replication. (2007). World J Gastroenterol. 
13(1): 48-64. 
 
1.1.6. HBV entry and replication cycle 
Several important findings have predecessed discovery of preS1 receptor on liver 
surface membranes common to man and Tupaia belangeri.– Among them are findings that 
HBV via preS1 binds to the cell surface heparan sulfate proteoglycans (Leistner et al., 2008). , 
It has ben shown that cholesterol in the viral envelope is necessary for the HBV entry and 
proposed that it might play a role in fusion of HBV (Bremer et al., 2009). Insights into early 
events of hepadnaviral infection have ben gained from experiments with duck HBV (DHBV) 
using primary duck hepatocytes. DHBV is internalized by endocytosis and acidification is not 
necessary for fusion with the membrane, which is an unusual mechanism (Kock et al., 1996). 
Trafficking of incoming DHBV viral particles is dependent on intact and dynamic 
microtubules (Funk et al., 2004). By using HepRG cells which allow the infection with HBV 
(Gripon et al., 2002) it was concluded that entry of HBV is mediated by caveolin-1, major 
constituent of caveolae. Caveolae are small invaginations of the cell surface (Macovei et al., 
2010). Experiments with SHBs as a model of an enveloped HBV revelaed that entry of 
HBsAg occurs via a caveolin-mediated endocytotic pathway and that the movement of 
internalized particles is actin-dependent (Hao et al., 2011).  
The next steps in HBV life cycle are transport of the capsids to the nucleus, 
disassembly and re-assembly of the capsids and genome replication. Hepadnaviruses employ 
the step of reverse transcripton for the replication of their genome,but there are a number of 
fundamental features which differentiate them from retroviruses, which also replicate via 
reverse transcription. After uncoating and release of the capsid, the capsid is transported to the 
nucleus. The trafficking of the capsids to the nucleus has been described in fine details by 
Kann et al. (Kann et al., 2007)., The transport is microtubule-mediated. Phosphorylation of 
the carboxy-terminus triggers an exposure of the nuclear localization signal (Rabe et al., 
2003). The 39 nm diameter of the nuclear pore (Pante and Kann, 2002) allows entry of the 
capsids, which are complexed with nuclear transport receptors importin α and β. The details 
of the capsid entry into the nuclear pore and interactions in the nuclear basket can be found in 
a study by Schmitz et al. (Schmitz et al., 2010). After RanGTP mediated dissociation of 
importin α and β capsids directly interact with nucleoporin 153 - a protein of the nuclear 
basket (Schmitz et al., 2010) and disassemble at the karyoplasm side of the nuclear pore to 
core protein dimers (Rabe et al., 2009). Importantly, only mature capsids (rc genome) 
disassemble, while immature capsids are trapped (Schmitz et al., 2010) The core protein 
dimers may reassemble again in the nucleus facilitated by the presence of cellular RNA (Rabe 
et al., 2009). It is unique among viruses that capsid disassembles and reassembles. The rc 
genome in complex with polymerase is released from the nuclear basket after which the so 
called genome repair takes place. The formation of covalently closed circular DNA (ccc) (Fig. 
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6) requires removal of the P protein attached to the (-)strand and RNA oligonucleotide primer 
attached to the 5’end of the (+) strand (Fig. 7). The completetion of the (+) strand of the 
relaxed circular genome requires activity of viral polymerase, host cell specific factors may be 
involved in the formation of ccc DNA (Beck and Nassal, 2007).From the ccc DNA template 
the cellular polymerase II transcribes the pregenome RNAs and the subgenomic RNAs. The 
pregenome RNA relevant for virus replication is translated into the core protein and the P 
protein (reverse transcriptse) from an overlapping reading frame. The sg RNAs are translated 
into the three envelope proteins and X protein. P protein binds to the hairpin–like ε structure 
on pg RNA and triggers the encapsidation of pg RNA. The capsid multimers are recruited to 
form an intact capsid. The interaction of the extra terminal protein domain of the P protein 
with the ε initiates reverse transcription of pregenome. The initiation of reverse transcription 
is also dependent on actvation of P protein by cellular chaperones (Nassal, 2008). The unique 
feature of hepadnaviruses is that the reverse transcritption can only occur in intact capsids. Pg 
RNA is transcribed to (-) strand DNA, which serves as a template for (+) strand sythesis 
generating a rc DNA. Detailed overview of the HBV replication can be found in an article by 
Beck and Nassal (Beck and Nassal, 2007).  
It is important to note that the newly synthesized capsids are structurally identical to 
the in-coming capsids from the endosome, therefore retrograde transport of the mature 
genome containing capsids to the nucleus occur (Kann et al., 2007). Mature capsids can be 
enveloped once the envelope proteins are synthesized in sufficient quantity to generate HBV 
virions which are released out of the cell. It was shown by Prange et al. that HBV is 
transported out of the cell by multivesicular bodies assisted by γ2-adaptin (Lambert et al., 
2007). 
 
1.1.7. Non-structural HBV proteins 
From the precore RNA which is 29 aa codons longer than the pg RNA, the precore 
precursor protein of 25 kDa is translated, the hydrophobic signal sequence directs the protein 
to ER and translocates it to the lumen. After cleavage along the secretory pathway 16-18 kDa 
e protein or HBeAg is secreted (Beck and Nassal, 2007). It serves as a marker of HBV 
infection of susceptible cells (Gripon et al., 2005;Engelke et al., 2006;Glebe et al., 2003) . 
The HBV X protein is a 154 aa protein and its role is still largely unresolved, but it is 
generally accepted that the protein and its encoding x gene of HBV plays a role in the 
pathogenesis of HBV-induced hepatocellular carcinoma (Kew, 2011). A number of cellular 
interaction partners have been identified for the HBV X protein, as well as the influence of the 
protein on HBV replication and pathogenesis has been recognized. A detailed review on the 
functions of the X protein and its significance in HBV life cycle and pathogenesis has been 
published (Benhenda et al., 2009). 
 
1.2. Vaccine types 
Since the first protocols of Edward Jenner in 1796 vaccination by today has evolved 
as an important public health instrument for control and prevention of infectious disease. 
Vaccines include live attenuated, whole killed, subunit vaccines and those produced by 
recombinant DNA technology. The first vaccines were live attenuated bacteria or viruses. 
Live attenuated vaccines induce powerful humoral and cellular responses. The presentation 
of antigen by live attenuated and replicating vaccines mimic the natural viral infection, but 
the major disadvantage of live attenuated vaccines is the risk of revertion to virulent strains. 
Although inactivated or killed bacteria or viruses alleviate the biosafety problem, they are 
less effective. The subunit vaccines include purified antigenic components of a pathogen, 
proteins produced by recombinant DNA technology and synthetic peptides. Although they 
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completely eliminate the issue of biosafety and their composition is well charactrerized, they 
are often poor immunogens, and need to be administered with an adjuvant. Moreover, 
recombinant proteins induce primarily humoral response (Payette and Davis, 2001). 
Tremendous advantages have been brought to area of public health by vaccination, for 
example, vaccination has lead to a complete eradication of smallpox in 1980 (Graham, 2013). 
Nevertheless, the scientific community is concentrating the efforts on novel improved 
vaccines, as well as on research and development on vaccines to such important pathogens as 
HIV and hepatitis C to which a widely available vaccine is not yet available. The activation 
of humoral and cellular arms of the immune system is a prerequisite for an effective vaccine. 
Effective vaccine should combine the efficacy of live attenuated vaccines and safety of 
subunit vaccines. Plasmid DNA vaccines with their ease of manipulation and potent 
induction of humoral and cellular responses in small animal models appeared as a very 
promising approach, however, the human clinical trials have been disappointing (Liu, 2011). 
Besides, plasmid DNA vaccines pose a risk of integration into a host genome, RNA vaccines 
may overcome this problem, but they are unstable. 
1.3. HBV vaccines 
1.3.1. Plasma derived vaccines  
Due to inability to grow HBV in cell culture and its restricted hoast range to humans 
and higher primates a different strategy was needed for the HBV vaccine. The first plasma 
derived HBV vaccines were obtained from the plasma of asymptomatic, human HBV carriers 
and consisted of purified , formalin or heat inactivated, alum-adsorbed HBsAg (Hollinger and 
Liang, 2001). In 1981 and 1982 the first plasma-derived hepatitis B vaccines were licensed 
(Heptavax B®, Merck & Co., Hevac B®, Institut Pasteur) 
(http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index4.html). 
1.3.2.Recombinant yeast derived vaccine 
The development and introduction of HBV vaccine based on HBsAg produced by 
recombinant DNA technology was an important milestone in the vaccine development. The 
vaccine has been commercially available since 1986. It consists solely of SHBs. The HBsAg 
is produced from recombinant Escherichia coli derived plasmid in transformed yeast 
Saccharomyces cerevisiae cells (McAleer et al., 1984). HBsAg is not secreted from the yeast 
cells, but released by homogenization or disruption with glass beads. The HBsAg produced in 
yeast cells is not glycosylated. The vaccine genotype is A2, HBsAg subtype adw2. The two 
most widely used recombinant HBV vaccines are Engerix-B® (GlaxoSmithKline) and 
Recombivax HB® (Merck).The vaccine is moderately immunogenic, 3 doses of 20 µg 
required for the Engerix-B® vaccine and 3 doses of 5 µg for the Recombivax HB® 
(http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index4.html). This vaccine 
is included in worldwide vaccine programs (Komatsu, 2014). 
 
1.4. Significance of SHBs as a HBV vaccine component and rationale for 
inclusion of preS1 in the HBV vaccine 
 
After vaccination with rHBs, antibodies are induced which recognize exclusively the 
conformational epitopes of the „a” determinant of SHBs. Although, the predominant role in 
binding of HBV to hepatocytes is assigned to preS1, SHBs has a secondary role. Aa 119-128 
of the antigenic loop are of crucial importance for infectivity (Jaoude and Sureau, 2005), with 
the cysteines having a fundamental role at the viral entry step and for the structure of the 
“a”determinant (Abou-Jaoude and Sureau, 2007). The secondary role of SHBs in entry of 
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HBV could be attributed to attachment, binding, and particle disassembly (Salisse and Sureau, 
2009). 
It is known that inclusion of preS1 augments anti-S response and can overcome non-
responsiveness to SHBs in mice and humans (Neurath et al., 1986a; Neurath et al., 1989; 
Milich et al., 1986; Shouval et al., 1994; Hellstrom et al., 2009). Significance of preS1 aa 
residues 21-47 (genotype A numeration, correspond to 10-36 in genotypes D, E and G) in 
mediating binding to HepG2 cells has long been established (Neurath et al., 1986b). Role of 
N-terminal preS1 region mediating virus binding has been reinforced by later studies 
employing cells susceptible to HBV infection (Le et al., 1999; Gripon et al., 2005; Engelke et 
al., 2006; Glebe et al., 2003). Aa 2-48 of the preS1 domain (genotype D) with the 
myristoylation at Gly2 have been shown to mediate attachment of HBV to primary 
hepatocytes of Tupaia belangeri (Glebe, 2006). Synthetic myristoylated peptide spanning aa 
2-48 of preS1 analogues were able to inhibit the HBV infection in primary Tupaia belangeri  
hepatocytes (Glebe, 2006) and HepaRG cells (Engelke et al., 2006). Moreover, preS1 region 
is highly immunogenic and contains T and B cell epitopes (Milich et al., 1987; Kuroki et al., 
1990; Maeng et al., 2000; Park et al., 2000; Hong et al., 2004). The preS1 region spanning the 
first N terminal 48 aa residues has been identified as bearing the main immunogenic domains 
(Milich et al., 1986;Hu et al., 2005), and Hu et al. have identified  preS1 23-48 (genotype D 
numeration) as the major immunogenic region. Recent data of Bremer et al. (Bremer et al., 
2009) showed that preS1.1-48 but no other preS sequences carry neutralising B cell epitopes. 
1.5. Immune escape mutants 
 
The protection mediated by the current vaccine is based on the recognition and 
interaction of vaccine induced neutralizing anti-HBs with the tertiary structure of the “a” 
determinant. Therefore mutations affecting the binding domains of the neutralizing anti-HBs 
may escape the anti-HBs mediated protection. Immune escape mutants arise as a result of 
vaccine-induced immune selection, long term use of HBV immunoglobulin and natural 
infection (Golsaz et al., 2014) . The reverse transcription step of the HBV replication is error-
prone and HBV variants associated with immune escape may be appear spontaneously during 
HBV infection and may be selected in the presence of the host’s immune response or as a 
consequence of appearance of anti-HBs. Reactivation of occult hepatitis B virus infection also 
may lead to selection of HBsAg escape mutants (Gerlich et al., 2010). Mutations associated 
with the immune escape frequently occur in the hydrophilic part of SHBs - from aa 99 to 169 
(Carman, 1997). The prevailing variant induced by pressure of immune selection isolated 
from the vaccinated individuals is with a substitution of glycine in position 145 to arginine, 
G145R (see Fig. 5). It is the first reported escape mutant desribed. The mutant virus is stable 
(Carman et al., 1990) and horizontal transmission has been reported (Gao et al., 2015). The 
G145R variant is infectious in vitro, with the infection being by 27% more efficient than of wt 
virus (Salisse and Sureau, 2009). Having shown that the G145R variant is pathogenic in 
chimpanzees (Ogata et al., 1997), Ogata and co-authors then performed a study where they 
challenged sero-negative chimpanzees with the G145R mutant after vaccination with the 
licensed HBV vaccine and development of anti-HBs. Animals were not infected and did not 
develop HBV infection (Ogata et al., 1999), but the challenge with the virus was done shortly 
after development of anti-HBs. Acute hepatitis B was reported in a vaccinated person, with a 
mutation Q129H within “a” determinant (Luongo et al., 2015). A repertoire of of monoclonal 
antibodies to rHBsAg could weakly react with K141E, T143K, D144A and G145R HBsAg 
variants (Golsaz et al., 2014). Up to date ability of human, HBV vaccine induced atibodies to 
neutralize virus escape mutants in vitro are lacking. Among vaccinated persons with 
breakthrough infections G145R and T126A/S account for 48% of mutants detected (Chang, 
2010). Numerous spontaneously arisen “a” determinant mutations and those selected under 
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selection pressure are listed with references in Cooreman et al. (Cooreman et al., 1999) and 
summarized by Pumpens et al. (Pumpens et al., 2002a).  
Long-term nucleotide/nucleoside analog therapy of chronic HBV carriers also 
contributes to the selection of immune escape mutants. Nucleotide/nucleoside analogs affect 
the catalytic domains of the polymerase, and can introduce changes in the “a” determinant and 
other regions of HBsAg. Pol and SHBs encoding reading frames overlap (Fig. 7) and 
therefore alterations in the Pol reading frame not only contributes to the emergence of 
antiviral resistant HBV variants, but also affect neutralizing antibody binding domains of 
HBsAg and thus may contribute to the emergence of immune-escape variants. Antiviral 
therapy induced changes reduce the immunoreactivity of HBsAg to neutralizing antibodies 
(Torresi et al., 2002; Sloan et al., 2008). It has been shown in a chimpanzee model that despite 
protective anti-HBs levels achieved by the HBV vaccine, antiviral resistant HBV mutants 
with the changes in the pol gene affecting the HBsAg, were able to successfully infect the 
experimental animals (Kamili et al., 2009).  
 
 1.6. Alternative HBV vaccines  
 
Vaccines have been developed which consist of SHBs with additional preS2 and 
preS1 components produced in yeast and, as an alternative, in Chinese hamster ovary cells 
(Shouval et al., 2015). These vaccines have not gained widespread use (Gerlich, 2013), 
although mammalian cell derived vaccine licensed in Israel and several countries of South 
East Asia containing preS1, preS2 and S has recently showed promising results in a clinical 
trial (Shouval et al., 2015).  
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1.7. Alphaviruses. Semliki Forest virus (SFV) expression system 
 
Alphaviruses are enveloped positive strand RNA viruses of Togaviridae family. At 
least 24 members of Alphaviruses have been described representing seven serocomplexes 
(Powers et al., 2001). Alphaviruses induce a persistent infection in mosquitoes where they 
accumulate to high titers in salivary glands (Weaver and Barrett, 2004) and are transmitted to  
vertebrate hosts - birds, rodents, horses (in case of VEE) or humans. SIN has also been 
isolated from mites and ticks. In cultured mosquito cells a persisent infection can be 
established, while in cell lines of vertebrate origin the infection is cytolitic due to the 
alphavirus induced apoptosis (Strauss and Strauss, 1994). Infection of vertebrate hosts by 
alphaviruses gives rise to rash, arthritis, or encephalitis. 
Two viruses routinely studied in the laboratory are Sindbis virus and SFV. These are 
considered avirulent for humans, but one fatal case of human encephalitis caused by infection 
with SFV in a laboratory worker has been described (Willems et al., 1979). SFV has served as 
a model virus to study the replication of RNA viruses, molecular mechanisms of viral 
pathogenicity, virus assembly, protein trafficking and transport (Atkins et al., 1999). 
Alphaviruses are classified in Old World and New World viruses, depending upon the 
geographic distribution. Interestingly, the symptoms caused by alphaviruses can also be 
distinguished by this division – New World viruses cause encephalitis, while Old World 
viruses cause fever, rash and arthritic symptoms (Jose et al., 2009). 
Phylogenetically SFV is classified in the Old World Alphavirus branch (Powers et al., 
2001). SFV was first isolated from mosquitoes in Uganda in 1944. Most laboratory SFV 
strains have derived from the two isolates. L10 is the original SFV isolate and is neurovirulent 
in mice. Aavirulent A7 strain was isolated in 1961. The SFV strains from which the SFV 
vectors are derived stem from highly attenuated strains (Atkins et al., 1999). 
The SFV RNA genome of positive polarity is about 11.5 kB long. Functionally the 
genome is divided in two parts. Two thirds of the genome code for the replicase complex 
comprised of non-structural proteins (nsP) 1-4, one third, which is the subgenomic 26S RNA 
codes for the viral structural proteins C, E3, E2, 6K and E1 (see Fig. 8A) (Schlesinger and 
Schlesinger, 2001). Structural and non-structural proteins are formed from the polyprotein 
precursors. E1 is responsible for the membrane fusion during virus entry and is present on the 
envelope. E3 is not retained in the envelope of most alphaviruses, while E2 is present in the 
enevelope and responsibe for receptor attachment. 6K protein may contain proton-specific ion 
channel activity necessary for virus entry/budding. Alphaviral structural and non-structural 
proteins and their functions are listed in table 1. 
The replication cycle of alphaviruses will be overviewed briefly, for an extensive 
review on alphavirus life cycle and replication see an article by Jose et al. (Jose et al., 2009). 
After the release of the genome from the capsid in the cell cytoplasm, the replication complex 
nsP1-4 is translated from the viral genome, which early in infection then synthesizes the (–) 
RNA strand. Later in infection replicase transcribes the (+) strand subgenomic RNA, from 
which the precursor polyprotein of the viral structural proteins is translated. The capsid 
protein (C protein) possesses an autoproteolytic activity and cleaves itself off the nascent 
polyprotein chain co-translationally. The p62 is a precursor of E2 and E3 forms a heterodimer 
with E1 in the ER (Barth et al., 1995). 6K in small amounts is incorporated in the virus 
particle, and soon after synthesis associates with the p62/E1 heterodimer (Jose et al., 2009). 
At a very late (post-Golgi) stage of transport, the p62 protein is cleaved by host furin-like 
proteases (Klenk and Garten, 1994) to mature E2 and E3. The packaging signal is located in 
nsP2 in SFV and nsP1 in SIN (Frolova et al., 1997). It is recognized by  the C protein, and 
assembled nucleocapsids are enveloped by E1/E2 heterodimers and bud from the plasma 
membrane (Jose et al., 2009). The structure of the mature alphavirus virion has been revealed 
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by cryo-electron microscopy and further image processing. The mature alphavirus particle is 
spherical, 70 nm in diameter, and possesses T = 4 icosahedral symmetry (Mancini et al., 
2000; Forsell et al., 2000; Mukhopadhyay et al., 2006).  
 
  
Table 1. Functions of non-structural and structural proteins of Alphaviruses 
 
 
Non-structural 
proteins 
Activity Function 
nsP1 Guanine-7-methyltransferase 
Guanyltransferase enzymatic activity 
RNA capping and methylation 
nsP2 Helicase activity 
Protease activity 
RNA triphosphatase activity 
Cysteine protease activity 
Methyltransferase domain 
RNA duplex unwinding, cleavage 
of viral non-structural polyprotein 
nsP3 ADP-ribose-1’-phosphate phosphatase 
RNA binding activity  
(-) strand and subgenomic RNA 
synthesis 
nsP4 RNA dependent RNA polymerase activity RNA replication 
Structural proteins Function 
E1 Membrane fusion during entry 
E2 Receptor attachment 
6K Proton specific ion channel activity 
C Capsid  
 
 
SFV, along with Sindbis virus (SIN) (Xiong et al., 1989) and Venezuelan equine 
encephalitis virus (VEE) (Pushko et al., 1997), has been manipulated on a cDNA level to 
develop an efficient expression vector system (Liljeström and Garoff, 1991). Structural 
proteins of the virus are encoded on a separate ORF in subgenomic RNA (Fig. 8 A), therefore 
it allows subgenomic RNA to be manipulated without replication capacity of the system being 
affected. cDNA plasmid contains SP6 or T7 promoter to enable transcription in vitro by SP6 
or T7 polymerase to produce recombinant RNA (Fig. 9). In the vector system structural genes 
are replaced by the sequence encoding the gene of interest under the control of subgenomic 
S26 promoter. The term often used in context of alphavirus derived vectors is “replicon”. It 
denotes the self-amplifying alphavirus genome, which contains all the necessary elements for 
self-amplification and transgene expression (Piver et al., 2005). The replication deficient SFV 
expression vectors allows three ways of delivery in vitro as well as in vivo of the SFV 
replicon (Fig. 9). SFV replicon DNA which is under control of the RNA polymerase II 
promoter (CMV promoter) may be transfected in vitro or may be delivered to the 
experimental animals in vivo according to conventional plasmid DNA vaccination protocols 
(Berglund et al., 1998; Nordstrom et al., 2005). In cell nucleus RNA polymerase II transcribes 
the expression casette to RNA, which is transported to cytoplasm, where it is translated to 
viral replicase which subsequently takes over the replication. This is the reason why SFV 
replicon plasmids are referred to as self-replicating DNA plasmids. In vitro transcribed, naked 
SFV replicon RNA can be delivered to cells in vitro by electroporation or lipofection, or by 
injection in experimental animals in vivo as RNA vaccine (Fleeton et al., 2001; Andersson et 
al., 2001).  
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Another method allows to use recombinant SFV. The recombinant SFV are produced 
after electroporation of BHK-21 cells with the recombinant SFV RNA (Fig. 8 B) and helper 
vector RNA (Fig. 8 C). The helper vector provides virus structural protein genes in trans. The 
fundamental difference between the formation of fully infectious SFV and recombinant, non-
replicative SFV particles, is the packaging step. The packaging of the viral genome in the 
SFV capsid and formation of fully infectious SFV is dependent upon the interaction between 
the SFV capsid and a sequence within the nsP2. The helper vector does not contain the 
“packaging” signal (Fig. 8 C) and thus is not encapsidated. Only the SFV vector RNA bearing 
the sequence of the desired gene is encapsidated in recombinant SFV particles. When cells are 
infected with replication deficient viruses progeny virions are not formed, rendering the 
system suicidal.  
Wild type SFV is classified as a Biosafety Level 2 virus in EU, as well as the SFV 
vectors lacking structural genes (Atkins et al., 1999). Recombinant SFV particles are suicidal 
and non-replicating, after infection of cells they undergo a single replication cycle. 
Nevertheless a possibility exists that two RNA strands may recombine during the packaging 
step resulting in generation of wild-type SFV genomes (Tubulekas et al., 1997). Several 
approaches have been developed to overcome it. One of them is to use a helper vector 
encoding structural precursor rotein p62 (of E2 and E3 membrane proteins) with a mutation 
that prevents the cleavage of it and it has to be cleaved by protease prior to infection 
(Berglund et al., 1993). Another way is to use two-helper system where spike and capsid 
proteins are encoded by separate helper vectors (Smerdou and Liljeström, 1999). Alternative 
approach to exclude the possibility of trans-complementation is to use RNA of a heterologous 
origin in the packaging step. Vesicular stomatitis viral glycoprotein (VSV-G) has been used to 
encapsulate full length SFV genome (Dorange et al., 2004). For a detailed review of 
developments and improvements to the alphavirus expression system, including SFV, see the 
review by Zajakina et al. 2008. In the work described here first generation SFV-1 vector was 
used without the modifications to the original vector system (Liljeström and Garoff, 1991).  
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Figure 8. A. Schematic representation of Alphavirus genome organization. B. Replication–deficient 
SFV expression vector. Asterisk denotes the packaing signal in the nsP2. C. Helper vector, with the 
the deleted nsP1-4 (∆nsP1-4) region. SP6 denotes SP6 polymerase promoter (filled arrow), 26S 
denotes 26S subgenomic promoter (empty arrow).  
 
1.8. Alphavirus replicons for vaccine and cancer therapy purposes 
 
Recombinant Alphaviruses are increasingly used as gene delivery tools for recombinant 
vaccine or cancer therapy purposes. A wide selection of viral, bacterial and protozoal proteins 
have been successfully expressed from alphaviral replicons. Their potential to induce specific 
immune response has been evaluated in numerous studies where potent humoral, cellular and 
mucosal immune responses have been induced, this has been reviewed by Zajakina and others 
(Zajakina et al. 2008), and Ljungberg (Ljungberg and Liljeström, 2015). 
Alphavirus replicons can be delivered to experimental animals packed in recombinant 
alphaviruses, in a form of RNA or “layered” DNA plasmid (Fig. 9). Considerable effort has 
been put into studies employing alphaviral replicons carrying virus antigen genes of viruses 
against which a vaccine already exists with the objective to improve the existing vaccines. 
Alphavirus replicons have been used as vaccine tools for pathogens against which there is not 
yet a vaccine available (Ljungberg and Liljeström, 2015). Although RNA is more unstable 
compared to recombinant RNA packaged in recombinant viruses or an alphavirus replicon 
plasmid, vaccination approach employing naked RNA was one of the pioneering studies. 
rSFV replicon encoding the influenza nucleoprotein gene was inoculated into the quadriceps 
muscle of mice leading to a strong humoral response (Zhou et al., 1994). Recently intradermal 
delivery of naked RNA replicons followed by topical electroporation has been described with 
induction of strong immune responses (Johansson et al., 2012). 
rSFV replicons have been employed for delivery of genes encoding numerous 
important viral proteins – examples include NS3 and E2 of Hepatitis C virus (Vidalin et al., 
2000; Brinster et al., 2002), HA and NP of Influenza A (Berglund et al., 1998;Berglund et al., 
1999;Zhou et al., 1995; Huckriede et al., 2004) and env and clade C antigens of HIV-1 (Brand 
et al., 1998; Sundback et al., 2005; Forsell et al., 2007). Among other antigens are E6 and E7 
of human papilloma virus (Daemen et al., 2002; Riezebos-Brilman et al., 2005) and F and G 
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nsP1    nsP2       nsP3    nsP4        C      p62   * 6K
 
E1 
26S 
  A     Alphavirus genome 
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proteins of RSV (Fleeton et al., 2001; Chen et al., 2002). Replicon based on Chikungunya 
virus cDNA clone, which is an alphavirus, has been examined as a potential vaccine tool for 
the re-emerging Chikungunya virus, which is a mosquito-borne and mosquito-spread virus 
(Hallengard et al. 2014). 
Another prominent branch of use of alphavirus replicons is for immune therapy. 
Cytokines and other immunoregulatory proteins that enhance anti-tumor immune responses 
and/or inhibit tumor cell growth have been delivered by alphavirus vectors (Atkins et al., 
2004), for example IL-12 (Rodriguez-Madoz et al., 2009). A single intramuscular injection of 
SFV-LacZ can prolong the survival time of mice with established tumors and protects from 
tumor challenge (Ying et al., 1999). SFV based vectors are superior at eliminating tumor to 
the first-generation adenovirus vector expressing IL-12 (Rodriguez-Madoz et al., 2005). It has 
been shown that SIN vectors direct transient expression of tumour associated antigens in the 
lymph nodes draining the injection site. This is followed by long lasting memory T cell 
response (Granot et al. 2014). Applications of alpavirus vectors in tumour therapy have been 
extensively reviewed by Lundstrom (Lundstrom, 2015). 
 Semliki Forest virus replicons and other alphavirus replicons embody a number of 
advantages which makes them extremely versatile and attractive tools for vaccine purposes. 
One of the advantages is that immunity to the vector is not widespread, which is a major 
hurdle in the application of adenovirus-derived vectors (Bangari and Mittal, 2006). The short 
persistence due to induction of apoptosis is often stated as an advantage, but this depends 
upon what is wanted to achieve by use of alphavirus replicons. Stimulation of innate 
immunity mechanisms due to the presence of ds RNA replicative intermediates are among the 
positive traits of the replicon system. The both latter topics will be reviewed in detail below. 
The risk of chromosomal integration, which is a concern in case of plasmid DNA 
administration (Nichols et al., 1995), is alleviated, because the amplification of the replicon 
occurs exclusively in the cytoplasm. The alphavirus-derived vaccine tools may combine the 
efficacy of live attenuated vaccines with the safety of RNA vaccination.  
 
1.9 Other Alphavirus-derived vectors 
 
Sindbis virus (SIN) and Venezuelan equine encephalitis (VEE) virus of Togaviridae 
family have also been developed into efficient expression vector systems (Xiong et al., 
1989;Pushko et al., 1997). The three vector systems developed from Togaviridae family have 
distinguished characteristics relative to each other, which stem from the “original” viruses 
they are derived from. Despite of sequence similarity of structural and non-structural proteins, 
wt alphaviruses differ in their pathogenicity (Petrakova et al., 2005). VEE, cause severe 
encephalitis in humans and animals and has caused serious epidemics with an inclination to 
reemergence (Anishchenko et al., 2006). VEE system is a basis of a patented Alphavirus 
replicon vector system developed by the University of North Carolina at Chapel Hill and the 
U.S. Army Medical Research Institute of Infectious Diseases. The replicon is used by the 
company Alphavax. Several vaccines based on VEE replicon particles have entered Phase I 
and II clinical trials (http://www.alphavax.com/Pipeline.html). VEE are naturally targeted to 
dendritic cells. After s.c. injection of recombinant VEE the expression of VEE encoded GFP 
is observed in Langerhans cells - the resident dendritic cells of the skin and in dendritic cells 
in the draining lymph node (MacDonald and Johnston, 2000). Delivery of VEE replicons for 
immunization to achieve immunity mostly to viral targets, has been carried out using 
recombinantviruses, while SFV replicons have been mostly delivered in form of DNA, 
recombinant particles, and rarely - RNA. Recombinant SIN virus particles are known to 
posess affinity to 67 kDa laminin receptors on mammalian cells which are upregulated in 
several cancers and remain relatively unoccupied by laminin (Wang et al., 1992; Nelson et al., 
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2008). SIN can infect human dendritic cells and this ability is conferred by Gly at position 
160 of E2 protein (Gardner et al., 2000). 
 
Figure 9. Three modes of delivery of replication deficient Alphavirus-derived vectors. Self-
replicating RNA carrying the gene of interest can be delivered into cells by transfection of cells with a 
self-replicating DNA plasmid under control of CMV promoter, introduction of in vitro transcribed 
RNA by electroporation, and infection of susceptible cells with recombinant alphaviruses. Translation 
of the in-coming alphavirus recombinant RNA produces non-structural proteins which form the 
replicase complex. The replicase is responsible for formation of (-) RNA intermediate which serves as 
a template for (+) RNA synthesis. At the subgenomic promoter (26S) the replicase produces 
subgenomic RNA from which foreign gene is translated. Adapted from Zajakina et al. (2008). 
Alphaviruses: Multiplicity of vectors and their promising application as vaccines and cancer therapy 
agents.  
 
1.10. Persistence and distribution of SFV vectors 
An important issue when application of SFV vectors in vivo is considered, is their 
persistence and distribution after delivery to an experimental animal. In a study  conducted by 
Morris-Downes (Morris-Downes et al., 2001) SFV based self-replicating plasmid and 
conventional plasmid were compared after injection in tibialis anterior (T.A.) muscle of mice 
and chickens. Recombinant SFV particles persisted for 7 days at the injection site, while SFV 
replicon based plasmid 93 days. Conventional plasmid could be detected up to 246 days. Both 
plasmids could be detected up to 3 months in the tissues distal from the site of injection, 
indicating dissemination (Morris-Downes et al., 2001). In chickens, however, the transgene 
could be detected up to 1 day at the injection site in case of recombinant SFV, up to 17 days 
for the SFV-based plasmid and 25 days for the conventional plasmid. The shortest persistence 
was shown by rSFV in mice and chickens. Compared to conventional plasmid the SFV-based 
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replicons showed shorter persistence. Localization and persistence of replicon RNA is also 
dependent on the route of injection as shown by P. Colmenero et al. (Colmenero et al., 2001). 
I.v. administration resulted in a systemic distribution, and the reporter gene was detectable in 
spleen and lymph nodes as well as in non-lymphoid tissues. S.c. injection lead to a local 
distribution in the draining lymph node and skin surrounding the injection site. Intramuscular 
injection resulted in distribution in the local lymph nodes and injection site. This study 
confirmed the transient nature of rSFV in vivo – reporter gene was almost undetectable by day 
6 after injection by all injection routes. Intratumoral injection of rSFV lead to localization of  
rSFV-RNA in the tumour cells and draining lymph node only (Colmenero et al., 2002). The 
short persistence renders the rSFV particles as a safe vaccine tool, but not relevant for 
applications where prolonged gene expression in vivo is desired.  
1.11. Alphavirus derived vectors induce apoptosis of the infected or 
transfected cells 
 
The ability to induce apoptosis or programmed cell death of the infected cells is the 
inherent propoperty of the alphaviruses and hence the first generation vectors derived from 
them, including SFV1. The induction of apoptosis of the first generation alphavirus vectors, 
certainly is a major limitation for the purposes of recombinant protein expression in vitro, 
therefore non-cytopathic vectors have been developed with the aim to improve the survivial of 
the host cells and prolong the expression of the foreign protein. One of the factors responsible 
for the cytotoxicity resides in the nsP2 protein of the replicase complex, therefore appropriate 
mutations bearing mutations in the nsP2 region which overlaps with the nuclear localization 
signal (Fazakerley et al., 2002) render the vectors con-cytopathic (Dryga et al., 1997; 
Lundstrom et al., 2003; Fazakerley et al., 2002). 
Multiple pathways are held responsible for the induction of apoptotic programme in the 
infected or transfected cells bearing alphavirus replicons, of which the presence of ds RNA 
intermediates (Diebold et al., 2009) is the major trigger. Upon copying the (+)-strand RNA 
alphavirus genome to (–) RNA and back, ds RNA intermediates are produced, this is valid 
also for Alphavirus-derived vectors. Production of ds RNA after transfection of Vero cells 
with SIN replicon vector has been shown (Diebold et al., 2009) and in wt SFV infected bone-
marrow dendritic cells (Schulz et al., 2010). The major role in the execution of the apoptosis 
is played by the host protein kinase R. This kinase is activated via binding to viral ds RNA.  
As a result the host cell translation initiation factor, eIF2α, is phosphorylated preventing the 
translation of the host cell proteins (Stark et al., 1998). Importantly, the eIF2α is not necessary 
for the translation of viral subgenomic RNA. PKR also directly triggers apoptosis (Tan & 
Katze 1999), with the involvement of Bcl-2 and caspases (Lee et al., 1997). Additionally, 
mitochondrial and death receptor pathways (Li and Stollar, 2004 ;Nava et al., 1998) have also 
been shown to play a role in the execution of the apoptotic programme, namely 
mitochondrial, Bak-mediated, caspase-8-dependent and Bid-mediated death signalling 
pathway (Urban et al., 2008).  
However, the intrinsic property of the alphavirus vectors to provoke apoptosis of the 
transduced cells may be advantageous for in vivo applications of these vectors for vaccine 
purposes and cancer therapy. Apoptotic death caused by viral infection has been attributed an 
immunostimulatory and adjuvant effect (Restifo, 2000). A link between alphavirus-induced 
apoptotic death of transfected cells and improved efficacy of the alphavirus replicon-based 
vaccine and enhanced response to an aggressive tumor challenge has been demonstrated 
(Leitner et al., 2004; Ying et al., 1999). Induction of apoptosis by replicase-based nucleic acid 
vaccines is essential for activation of antigen presenting cells (Leitner et al., 2004). Processing 
of apoptotic bodies has been shown to generate T-cell epitopes (Bellone et al., 1997). 
Acquisition of antigen from the apoptotic bodies by dendritic cells stimulates these cells.  
They, in turn, stimulate class I-restricted CD8+ CTLs. This is the basis for phenomenon of 
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cross-priming or cross presentation (Albert et al., 1998). Another hallmark of the presence of 
ds RNA intermediates in the cell is the induction of 2’-5’ oligoadenylate synthetase, which 
catalyzes formation of short 2’-5’ oligoadenylates from ATP. These bind to endoribonuclease 
L which after dimerization degrades mRNA, thus leading to block of host protein synthesis 
(Goodbourn et al., 2000). Activation of PKR and 2’-5’ oligoadenylate synthetase results in 
“shut-off” of protein synthesis,  leading to apoptosis, which affects level of expressed foreign 
protein (Terenzi et al., 1999). The apoptosis resulting from virus infection induced cell death 
and the subsequent activation of dendritic cells by the apoptotic death is classified as 
“immune apoptosis” (Fig. 10)(Restifo, 2001). 
The apoptosis triggered by replicon activity generating biologically active ds RNA 
definately does not favour the increased or prolonged antigen expression in vivo to be dealed 
by the adaptive immune system (Leitner et al., 2003). However, it is a powerful adjuvant 
signal and stimulates innate antiviral pathways, where the increased immunogenicity and 
increased efficacy of alphavirus replicon vaccines may reside (Leitner et al., 2003).    
 
1.12. Stimulation of innate immunity by Alphavirus replicons 
 
Stimulation of innate immune responses by alphavirus derived replicons occurs via ds 
RNA intermediates, as described above. The major players are the toll-like receptors (TLR), 
which play a key role in innate immunity and are a bridge between innate and adaptive 
immunity and recognize molecular patterns of microbial pathogens. Family of TLRs contains 
10 members recognized so far in humans and 13 in mice (Thompson et al., 2011). TLR which 
must be mentioned in context of Alphavirus derived replicons are TLR3, TL3 7 in mouse and 
TLR 8 in humans. They are membrane associated receptors located on the endosomal 
membranes. dsRNA is a ligand of TLR3 (Alexopoulou et al., 2001), which is expressed 
specifically by dendritic cells (Muzio et al., 2000). ss viral RNA is recognized by TLR 7 in  
mice and TLR 8 in humans (Crozat and Beutler, 2004). While the activation of TLR 3 in 
response to presence of alphavirus replicon has been investigated (Saikh et al., 2003; Diebold 
et al., 2009), the reports of TLR7/8 dependent activation in response to wt or recombinant 
Alphavirus are lacking. There is a view  that replication of SFV does not trigger TLR 
depenent pathways (Piver et al., 2005) and it was shown by Naslund et al. that for induction 
of a CD8+ response by rSFV TLR3 was not necessary (Naslund et al. 2011). For Hepatitis C 
virus TLR7/8 dependent activation of innate immunity pathways has been shown (Zhang et 
al., 2009). 
Upon activation TLR induce pathways leading to transcription of type I interferon 
(IFN) response genes, and synthesis of interferon α and β (Bowie and Haga, 2005). Synthesis 
of type I IFNs is a cell defense reaction of cells in response to virus infection. Interferons 
contribute significantly to stimulation of adaptive immune response (Tough, 2004). As a 
consequence of both types of interferon synthesis, cells establish “antiviral sate”, either by 
interfering with virus replication or increasing their susceptibility to apoptosis. Two 
milestones of the “antiviral state” of the cells induced by IFN is 2’-5’oligoadenylate 
synthetase and dsRNA dependent protein kinase (PKR). Recombinant SFV is a strong inducer 
of type I interferon. It has been demonstrated that suicidal rSFV particles can induce rapid and 
transient IFN α/β response in mice, which can be detected in mice serum at 4 to 6 h after 
immunization (Hidmark et al., 2005). Immunogenicity of alphavirus replicon based vaccines 
is dependent on induction of interferon α/β (Leitner et al., 2006). Additionally, cells 
transfected with alphavirus replicon bearing plasmids show activation of 2’-5’oligoadenylate 
synthetase system, which is important for immunogenicity and increased efficacy of 
alphavirus replicon based vaccines (Leitner et al., 2003). The role of PKR in IFN α/β 
induction has been largely revised, since discovery of cytoplasmic RNA helicases which 
detect dsRNA - retinoic acid inducible gene (RIG-1) and melanoma differentiation-associated 
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factor-5 (MDA 5) which lead to IFN α/ β gene transcription (Pichlmair and Reis e Sousa, 
2007). The induction of IFN α/ β by SFV is mainly dependent on MDA5, not to a such large 
extent to RIG-I (Schulz et al., 2010).  
 
 
 
 
 
Figure 10. Illustration of immune apoptosis. Immune apoptosis results from viral infection and 
activation of type I interferon-inducible, double-stranded RNA–dependent protein kinase (PKR), 
which can induce both death as well as the upregulation of key cytokines like IL-12 and TNF-α. 
Adapted from Restifo N. Vaccines to die for: Induction of apoptotic death by modified caspases 
enhances the function of “naked” DNA vaccination. Nat.Biotechnol. 2001; 19(6): 527–528. 
 
1.13. Cross priming 
 
The term “cross-priming” is mentioned very frequently in context of alphavirus 
derived replicon vaccines. The ability of dendritic cells to capture, ingest or acquire and 
present cellular material to CD8+ cells, which are consequently activated, is referred as cross  
presentation or coss priming (Albert et al., 1998). Cross presentation is very important in 
context of Alphavirus replicon bearing cells. Plasmocytoid dendritic cells in mice are the 
major antigen presenting cells (APC) which drive antiviral CTLs. CD8α+ cells are a subset of 
cells involved directly in the generation of CTL immunity to viruses (Belz et al., 2004). In 
mouse the CD8α+ dendritic cells are the mouse antigen presenting cells primarily involved in 
cross-priming (Villadangos and Schnorrer, 2007). But, SFV is not able to infect in vitro 
CD8α+ subset of mouse spleen dendritic cells when presented as free virus, however, this 
subset can be activated in TLR3 dependent manner after uptake of material from Sindbis virus 
replicon based plasmid- transfected cells (Diebold et al., 2009). Dendritic cells can be 
activated if cultured with SFV infected Vero cells. (Schulz et al., 2005). In case of a virus 
which does not infect antigen presenting cells cross-presentation is crucial for the 
development of effective adaptive immunity (Chen et al., 2004; Rovere-Querini and 
Dumitriu, 2003). Plesa and others (Plesa et al., 2006) have concluded that greater cytopathic 
capacity lead to a more efficient cross-priming to CD8+ T cells and enhanced short-term 
humoral and cellular responses, being in line with several other authors (Nowak et al., 2003; 
Racanelli et al., 2004; Schaible et al., 2003) who have provided evidence that apoptosis 
induction mediates greater cross-priming.  
  
1.14. Recombinant alphaviruses as adjuvants 
 
   Replication deficient rSFV particles which are co-immunized with the protein are able 
to function as adjuvants and potentiate humoral response to protein antigens by delivering 
strong adjuvant signals. Additionally, immunization of protein alone results in generation of 
IgG1 dominance. With the co-delivered rSFV it was possible to shift the response to IgG2a 
dominance (Hidmark et al., 2006), which indirectly signals about the activation of Th1 cells 
and hence CTLs. Immunization with the protein vaccines stimulates mainly IgG1, indicating 
activation of Th2 cell subset, which aids in generation of antibody responses. Several studies 
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have shown that recombinant Venezuelan equine encephalitis virus (rVEE) can also exert an 
adjuvant activity by activation of innate immune response (Tonkin et al., 2010).  
1.15. Tupaia belangeri model of HBV infection 
 
HBV is hepatotropic and extremely species specific virus and early events of infection 
are strictly host restricted. It was assumed that in vivo human HBV infects exclusively 
humans and higher primates, therefore a small animal model of HBV infection has not been 
available. Studies on early events of HBV infection have been dependent on the limited 
availability of primary human hepatocytes.  
It has been demonstrated that HBV can specifically infect primary hepatocytes of 
Asian tree shrews (Tupaia belangeri) (Kock et al., 2001; von et al., 2004). The dynamics and 
course of infection resembles HBV infection of scarcely available human hepatocytes  
(Gripon et al., 1988; Galle et al., 1994) including the significant early steps of attachment 
(Glebe et al., 2003). Tree shrews are classified within an order of Scandentia and are about 
10-15 cm in size, their natural habitat is tropical forests of southeast Asia. After infection of 
Tupaia belangeri with HBV, the virus can replicate in vivo with the infection being similar to 
self-limited, acute HBV infection in humans (Walter et al., 1996). Primary hepatocyte 
cultures from Asian tree shrews Tupaia belangeri livers represents an in vitro model for HBV 
infection. The hepatocytes of Tupaia belangeri have been useful in studying the potential of 
characterized HBV monoclonal antibodies generated against surface proteins of HBV to 
inhibit binding of the virus (Glebe et al., 2003). Primary Tupaia hepatocytes (PTH) have been 
employed for investigation of early events of HBV infection (Glebe et al., 2005; Leistner et 
al., 2008; Bremer et al., 2009). Tupaia belangeri can be in vivo and in vitro infected with 
hepatitis C virus which is another virus for which a small animal model has not been 
available. PTH has served as an in vitro model for study of early events of HCV infection 
(Zhao et al., 2002; Tong et al., 2011). PTH model of HBV infection has enabled to elucidate 
numerous aspects of HBV biology and pathogenesis, for example factors affecting HBV 
replication (Xu et al., 2011), characterization of clinically significant HBV variants (Baumert 
et al., 2005) and the inhibitory potential of antiviral drugs for treatment of chronic HBV 
infection (Kock et al., 2003). Use of PTH has been described for assessment of neutralizing 
capacity of antibodies induced by immunization of mice with recombinant HBc with inserted 
C- and N-terminal peptides of preS1 (Bremer et al., 2010). 
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2. METHODS AND MATERIALS 
2.1. Cell lines and primary cells 
 
Cell lines and primary cells employed in this study are summarized in table 2.  
 
Table 2. Cell lines and primary cells employed in the study 
 
Cell line Origin, organ Morphology Propagation 
Continuous cell 
lines 
   
BHK-21 Mesocricetus 
auratus (Syrian 
golden hamster), 
kidney 
Fibroblast Dulbecco's Modified Eagle's 
Medium (DMEM) (Invitrogen), 
foetal calf serum (FCS), 10% 
tryptose phosphate broth, 2mM 
glutamine, 20 mM HEPES, 
penicillin and streptomycin at 
10 U/ml  
Huh7 Homo sapiens, 
human 
hepatocellular 
carcinoma, liver 
Epithelial RPMI-1640 (Invitrogen), 2mM 
L-glutamine, 25mM HEPES, 
10% FCS, 2% sodium selenite, 
penicillin and streptomycin at 10 
U/ml  
HepG2 Homo sapiens, 
human 
hepatocellular 
carcinoma, liver 
Epithelial Dulbecco’s MEM Nut Mix F-12 
(Invitrogen) supplemented with 
10% FCS, penicillin and 
streptomycin at 10 U/ml 
Primary cells    
Primary 
hepatocytes 
 Asian tree 
shrews (Tupaia 
belangeri), liver 
 PTH medium: DMEM 
(Invitrogen) supplemented with 
0.1% bovine serum albumin 
(crystallized) 5µg/ml insulin, 5 
µg/ml transferrin, 5 ng/ml sodium 
selenite, 50 µM hydrocortisone, 
0.1µM dexamethasone, 2% 
dimethyl sulfoxide, 100 µg/ml 
gentamicin, 0.25 µg/ml 
amphotericin B. 
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2.2. Antibodies 
 
Monoclonal and poloyclonal antibodies to HBs proteins used in this study are 
summarized in table 3.  
 
Table 3. Antibodies to HBs proteins used in the study 
 
Monoclonal antibodies Recognize: 
MA 18/7 aa 20-23 (DPXF) of preS1* 
(Sominskaya et al., 1992; 
Heermann et al., 1984)  
C20/02 correctly folded S domain 
between aa 118 and 149 subtype-
independent (W. Gerlich, 
unpublished)  
1-9C1 Linear epitope in S domain,  
(Sobotta et al., 2000) 
HB1 Linear S domain (A. Zvirbliene, 
unpublished) 
Polyclonal antibody  
H 863** preS1 and preS2 (H. Schaller) 
*Genotype D numeration, correspond to aa 31-34 in genotype A 
** Generated in rabbit 
All antibodies were a kind gift of Dr. D. Glebe, Justus Liebig University, Giessen, Germany. Polyclonal 
antibodies H 863 were a gift from Heinz Schaller, Heidelberg, to Dr. D. Glebe and prof. W.H. Gerlich 
 
2.3. Recombinant plasmids 
 
To generate the plasmids the fragments were cloned in pSFV1 vector at the Bgl II and Sma I 
sites, except pSFV1-S/adw2. Table 4 summarizes the generated SFV-1 constructs. 
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Table 4. SFV1- based plasmids employed in the study 
 
pSFV1-EGFP  Described by Zajakina et al., Aleksejeva et al. (Zajakina et al., 
2004;Alekseeva et al., 2009) 
SFV1 plasmids encoding SHBs  
 
pSFV1-S/ayw2 Described by Zajakina et al. (Zajakina et al., 2004) 
pSFV1-S/adw2 S/adw2 gene was amplified from plasmid pRVHBV (kindly 
provided by Volker Bruss, Göttingen) with forward primer  
5’TGCCTCTCACATCTCGTCAATCTC3’ and reverse primer 
5’CCCATGAAGTTTACCCGGGATCCCCATCTTTTTG3’. The 
resulting segment was cut with Sma I and Avr II, and inserted into 
pSFV-1 which had been digested with Sma I and Avr II.  
SFV1 plasmids encoding deleted L protein variants, e.g. fusion proteins of aa 1-48 of 
preS1 with the S protein (subtype ayw2, genotype D) 
 
pSFV1- preS1.1–48/S 
(encodes a fusion protein of aa 
1-48 of preS1 with S protein) 
Fusion protein of preS1.1 – 48 and S,  including a stretch of 6 His 
at the C terminus of S, from the plasmid pFD GlyPr[13-59]S 
(kindly provided by Prof. K. Sasnauskas, Vilnius) was amplified 
by forward primer 
5’GACACAGATCTGCCGCCACCATGGGTCAGAATCTTTCC
AC3’ and reverse primer 
5’CTCTGTACCCGGGTTATTAGTGATGGTGATGGTGATGA
ATG3’. A Bgl II site was introduced by the forward primer and a 
SmaI site by the reverse primer. Vector pSFV-1 was prepared 
from the plasmid pSFV1-S/adw2 by excision of the S gene with 
BamH I and Sma I.  
pSFV1-preS1.1-48/S0 
(encoding the fusion protein of 
preS1.1-48 and S0, internal 
translation of the S protein 
abrogated) 
 
Generated by site directed mutagenesis of the template plasmid 
pSFV1- preS1.1–48/S using the QuikChange II XL site directed 
mutagenesis kit (Stratagene). Point mutation ATG to GTG in the 
beginning of the S gene to prevent translation of the S was 
introduced by the forward primer 
5’GTGGATCTGGTGGAGTGGAGAACATCAC3’ and reverse 
primer 5’GTGATGTTCT CCACTCCACCAGATCCAC3’, 
according to PCR conditions indicated by the manufacturer. The 
introduced mutation was confirmed by sequence analysis. 
pSFV1-Ser2.preS1.1-48/S 
(encoding the fusion protein of 
preS1.1-48 and S, G at the 2nd 
position of preS1 substituted 
by S) 
The corresponding gene was amplified from the plasmid pFD 
Pr[13-59]S (kindly provided by Prof. K. Sasnauskas) by forward 
primer 5’ 
GACACAGATCTGCCGCCACCATGTCTCAGAATCTTTCCA
C 3 and reverse primer  5’ 
CTCTGTACCCGGGTTATTAGTGATGGTGATGGTGATGAA
TG 3’. A Bgl II site was introduced by the forward primer and a 
Sma I site by the reverse primer.  
pSFV1-Ala2.preS1.1-48/S 
(encoding the fusion protein of 
preS1.1-48 and S, G at the 2nd 
position of preS1 substituted 
by A) 
Generated  by forward primer 5’ 
GACACAGATCTGCCGCCACCATGGCCCAGAATCTTTCCA
C 3’ from plasmid pFD GlyPr[13-59] (kind gift from Prof. K. 
Sasnauskas). The reverse primer was as described for the plasmid 
pSFV1-Ser2.preS1.1-48/S.  
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2.4. Sequencing 
 
Sequencing of the newly constructed plasmids was performed to verify the sequence 
of the introduced gene in SFV1 vector and to verify the introduced mutations by site-directed 
mutagenesis using the Sequencing kit from Applied Biosystems (5x buffer (400mM Tris-HCl, 
pH 9.0, 10mM MgCl2) and BigDye® ). Sequencing was performed in forward and reverse 
directions, with the forward primer 5’CCATGACCACCTTGGCGAGGGAC3’ 
complementary to the bp 7290 – 7313 in SFV1 vector and reverse primer 
5’CCACCGGCGGCCGTAAAACGTTTG3’ complementary to nucleotides 7457 – 7434 in 
SFV1 vector. The conditions for the PCR were as follows: 25 cycles of denaturation at 96 ºC - 
10 s, annealing at 50 ºC – 5 s, and extension at 60 ºC - 4 min, using a PCR apparatus 
GeneAmp PCR System 9700 (Applied Biosystems, UK). Samples were purified by 
precipitation with 3M sodium acetate  and ethanol. Sequence analysis was performed with 
ABI 3100 Sequencer (Applied Biosystems, UK). Sequencing chromatograms were viewed 
manually using the Vector NTI Suite v. 6.0 software. 
 
2.5. Transformation of SFV1 plasmids 
 
XL1-Blue cells (recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZ∆M15 Tn10 (Tetr)] were thawed on ice, and 4 µl of the PCR reaction (of site directed 
mutagenesis) mixes were added to 100 µl of XL1-Blue cell suspension and incubated on ice 
for 10 min. Cells were heat-pulsed for 35 sec at 42 ºC and incubated on ice for 2 min. LB 
medium with ampicillin (100 µg/ml) was added and incubated for 1 h at 37 ºC with shaking. 
200 µl was spread on plates with LB/agar medium with ampicillin (concentration of 200 
µg/ml). Plasmid pUC18 was transformed as a control. Transformed clones were selected for 
ampicillin resistance, picked and grown in 1 ml of 2xTY medium with ampicillin (100 µg/ml) 
at 37 ºC overnight. 
After plasmid DNA extraction according to standard protocol of plasmid DNA isolation, 
plasmids were retransformed in DH5α cells, clones selected for ampicillin resistance, and 
grown in 250 ml 2xTY medium with ampicillin (100 µg/ml). Plasmid DNA was extracted 
according to standard protocol (Sambrook et al., 1985). 
 
2.6. Generation of rSFV particles 
2.6.1.Transcription in vitro 
SFV1 plasmids were linearized prior to transcription in vitro with restriction 
endonuclease NruI (Bsp681, Fermentas). SFV Helper plasmid was linearized with SpeI 
(Fermentas). Transcription in vitro was performed as follows: 5 µl of rNTP mix (1mM ATP, 
1mM UTP, 1 mM CTP, 0.5 mM GTP), 2,5 µl 100 mM DTT (final concentration 10 mM), 2,5 
µl 10mM Cap (final concentration 1 mM, New England Biolabs), and 5 µl 5× transcription 
buffer (Fermentas) was mixed and kept at RT for 5 min. 0.75 µg of linearized SFV or helper 
DNA was added, followed by 2 µl ribonuclease inhibitor (40 u/µl, Fermentas) and 2 µl SP6 
polymerase (20 u/µl, Fermentas). Deionized water was added up to 25 µl. Transcription mix 
was incubated at 37 ºC for 1 h 20 min. Presence of RNA was confirmed by 1% TBE agarose 
gel electrophoresis. 
 
2.6.2. Electroporation of BHK-21 cells 
RNA was transcribed in vitro with SP6 polymerase (Fermentas) from SFV1 plasmids, 
mixed 1:1 with in vitro transcribed SFV helper RNA encoding the SFV envelope proteins and 
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transfected to BHK-21 cells by electroporation as described (Berglund et al., 1993). Briefly, 
BHK-21 cells were trypsinized, collected and resuspended in 700 µl PBS and transferred to 1, 
5 ml Eppendorf tube. 25 µl of transcription mix from SFV RNA and SFV helper RNA was 
added and the mix transferred to electroporation cuvette (Biorad). Electroporation was 
performed with two consequent pulses at 850 V and 25 µF (Gene Pulser, Biorad). 
 
2.6.3. Concentration of rSFV particles 
After incubation of the cell cultures at 33 ºC for 36-40 h, the medium was transferred 
to 12 ml tubes and clarified by centrifugation at 40, 000 × g (18, 000 rpm) in a SW40Ti rotor 
(Beckman) for 30 minutes at 4 ºC. It was followed by sedimentation of rSFV through 5 ml 
20% sucrose (w/v) in 35 ml Beckman tubes by centrifugation at 140, 000 ×g (27, 000 rpm) in 
a SW28Ti rotor for 5 hours at 4ºC. The pellets were resuspended in 500 µl TNE buffer (50 
mM Tris-HCl, pH 7.4, 100mM NaCl, 0.5 mM EDTA) and left in the centrifuge tubes on ice at 
4 ºC for 12 h. The virus stocks were frozen in liquid nitrogen and stored at -70 ºC. The titer of 
rSFV stocks was determined as described (Karlsson and Liljeström, 2003).  
 
2.7. Assessment of rSFV-driven SHBs and deleted L protein expression in 
vitro 
2.7.1. Cell infection with rSFV particles 
For infection of BHK-21 cells, virus stocks were diluted in Eagle minimal essential 
medium (MEM), (Invitrogen) supplemented with 0.2 % bovine serum albumin (BSA), 2mM 
L-glutamine and 20 mM HEPES. Prior infection cells were washed with PBS  and BHK-21 
cells were infected at MOI 20, and incubated for 1 h at 37 ºC. Thereafter virus inoculum was 
removed, and cells cultured with complete medium containing 1% FCS for 20 h at 37 ºC. At 
desired time point after infection cells were lysed with buffer containing 1% Nonidet P40 
(NP40), 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, and 1 µg/ml 
phenylmethanesulfonylfluoride (PMSF). 
For infection of Huh7 cells at MOI 10, virus stocks were diluted in PBS++ (with Ca2+ 
and Mg2+; Invitrogen) supplemented with 1% FCS and 2 mM L-glutamine. After infection, 
cells were cultured for 20 h at 37 ºC in complete Huh7 medium with 5% FCS. Cells were 
lysed with a buffer containing 0.5% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 2 
mM EDTA and 1 µg/ml PMSF.  
To infect HepG2 cells, the virus stocks were diluted in PBS++ (with Ca2+ and Mg2+; 
Invitrogen) supplemented with 1% FCS and 2 mM L-glutamine and after infection, cells were 
cultured for 20 h at 37 ºC in HepG2 medium, but with 5% FCS. 
For infection of PTH, virus stocks were diluted in PBS++ (with Ca2+ and Mg2+; 
Invitrogen) and cells infected at MOI 10 and incubated for 90 min at 37 ºC, after removal of 
virus inoculum, Tupaia hepatocyte medium (PTH) medium was added and cells incubated for 
20 h at 37 ºC. After PTH was collected, cells were washed with ice cold PBS++ and lysed 
with buffer containing 1% Nonidet P40 (NP40), 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 
mM EDTA, and one Complete Protease Inhibitor Cocktail tablet (Roche) per 10 ml of buffer. 
2.7.2. Metabolic labelling of rSFV encoded proteins  
Labelling of newly synthesized proteins in infected cells was performed as follows: 20 
h after infection, methionine-free medium (MEM, 2mM L-glutamine, 20 mM HEPES) was 
added and cells incubated at 37 ºC for 30 minutes. Radiolabelling with 100 µCi/ml [35S]-
methionine (15 mCi/ml, Amersham Biosciences) was performed for 30 minutes.
.
 After 
removal of medium containing [35S]-methionine, fresh medium (MEM, 2mM glutamine, 10 
mM HEPES, 150 µg/ml methionine) was added and cells incubated as required by the 
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experiment. Thereafter cells were lysed with 1% NP 40 containing lysis buffer supplemented 
with 1 µg/ml PMSF.  
2.7.3. Peptide N-glycosidase F (PNGase F) digestion  
500U of PNGase F (New England BioLabs) was added to 10 µl of Huh7 cell lysates 
diluted in reaction buffer (50mM sodium phosphate buffer, pH 7.5, containing 1% NP40,  
New England BioLabs), and incubated for 1 h at 37 ºC. To perform reaction under denaturing 
conditions, glycoprotein denaturing buffer (New England BioLabs) was added to 10 µl of cell 
lysates and incubated for 10 min at 100 ºC.  
2.7.4. Western blotting 
Proteins were separated by SDS-PAGE as described (Zajakina et al., 2004) and 
transferred to Hybond-P membrane (Amersham Biosciences) in the semi-dry electroblotter 
(ApolloTM, CLP). Membrane was reacted with MAb MA18/7, followed by goat anti-mouse 
antibodies conjugated with horseradish peroxidase (Pierce). For developing, 
SuperSignal®WestFemto Stable Peroxide Buffer was mixed with SuperSignal®WestFemto 
Luminol (Pierce) 1:1, dripped on the membrane and incubated for 5 min at room temperature. 
After exposure to a photography film (HyperfilmTM, Amersham Biosciences) proteins were 
visualised by developing solution (Dental Readymatic; Kodak). 
2.7.5. ELISA for HBsAg and preS1Ag  
96 well flat bottom microtiter plates (MaxiSorpTM; Nunc,) were coated with MA18/7 
or C20/02, diluted in 0.1 M sodium phosphate buffer, pH 7.4, at 1 µg/ml, overnight at 4 ºC. 
The plates were washed twice with 0.1 % Tween 20/PBS buffer, and twice with PBS, and 
washing performed between each of the steps. After blocking with 10% FCS /TNE, pH 7.4, at 
4 ºC  overnight 100 µl of sample were added in each well and incubated for 2 h at 37 ºC. 
Thereafter biotin-labeled anti-HBs (Dade Behring, Marburg, Germany) was added for 1 h at 
37 ºC. 100 µl of peroxidase-conjugated streptavidin (Dade Behring) was added, and incubated 
for 1 h at 37 ºC  followed by 100 µl/well of o-phenylenediamine/H2O2 substrate (Sigma) in 
0.05 M citrate-phosphate buffer, pH 5, and incubated for 15 min at room temperature in dark. 
The reaction was stopped with 0.5 M sulfuric acid and absorbance was measured at 492 nm. 
The concentration of HBsAg was calculated according to dilution series of HBV carrier 
reference plasma ranging from 1 ng to 0.01 ng. ELISA kit Enzygnost® (Dade Behring) was 
used for quantification of HBsAg expressed in BHK-21 cells using recombinant HBsAg 
(Rhein Biotech) with a predetermined concentration as a standard as well as for determination 
of HBsAg in BALB/c mice sera. 
2.7.6. Immunofluorescence 
 BHK-21 cells were infected with rSFV encoding S/adw2, S/ayw2, preS1.1-48/S, 
preS1.1-48/S0, Ser2.preS1.1-48/S, Ala2.preS1.1-48/S, Ala2.preS1.1-48/S0 and L protein 
(HepG2 cells) at MOI 20 and incubated at 37 ºC. After 20 hours, the cells were fixed with 
3.7% formaldehyde (Sigma) for 20 min at 37 ºC and washed with PBS (Invitrogen). The cells 
were then incubated with PBS for 15 min at room temperature followed by permeabilization 
with 0.25% Triton X-100 /PBS for 15 min at room temperature. Afterwards, the cells were 
blocked in a 3% FCS/PBS solution for 20 min at room temperature. Cells were incubated with 
MAb 1-9C1 or with polyvalent rabbit antibodies H863 (in case of L protein) for 12 h at at 4 
ºC. Fluorescein isothiocyanate (FITC) conjugated anti-mouse IgG or tetramethyl rhodamine 
iso-thiocyanate (TRITC) conjugated anti-rabbit IgG (Sigma)  were applied in the dark for 1 h 
at room temperature. For double staining of HBsAg and preS1 antigen, 1-9C1 antibodies were 
applied first, followed by FITC-conjugated anti-mouse IgG, then H863 antibodies were 
applied followed by TRITC-conjugated anti-rabbit IgG. Summary of immunofluorescence 
analysis is shown in table 5. Cell nuclei were counterstained with DAPI (4 µg/ml; Sigma). 
 39
Fluorescent images were generated by microscope Leica DM 6000 B and camera Leica DFC 
480 and confocal images with Leica TCS SP2 SE.  
 
Table 5. Summary of immunofluorescence analysis of HBs proteins 
 
 
 
 
 
 
 
 
 
 
 
2.7.7. Electron microscopy  
BHK-21 cells were electroporated by 2 pulses at 850 V/25 µF with recombinant in 
vitro transcribed SFV RNA encoding preS1.1-48/S and Ser2.preS1.1-48/S. After 22 hours 
incubation at 37 ºC, medium was collected and concentrated using an Amicon Ultra-15 
centrifugal filter device (Millipore) at 5000 × g for 30 min. The suspension of preS1.1-48/S 
particles was adsorbed on carbon-formvar coated grids. To detect presence of preS1 antigen, 
MAb MA18/7 followed by anti-mouse IgG conjugated with 5 nm gold particles (Sigma) was 
added as described (Louro and Lesemann, 1984). The grids were examined with a JEM-1239 
electron microscope (IEOL Ltd., Tokyo, Japan).  
 
2.8. Immunization of mice and evaluation of HBV antibody response 
 Groups of 6-8 week old female BALB/c mice were obtained from the Animal Breeding 
Centre of the Institute of Microbiology and Virology, Riga, and kept in the Biomedical 
Research and Study Centre. For the initial immunization experiments with rSFV-S/adw2 106 
rSFV  were inhjected i.v. and s.c. followed by 107 rSFV after two weeks by the same route. 
Mice were immunized with rSFV-S/adw2, rSFV-S/ayw2, rSFV-preS1.1-48/S, rSFV-preS1.1-
48/S0 and rSFV-EGFP according to the following scheme: 107 rSFV particles in 200 µ PBS 
(Invitrogen) were injected i.v. in the tail vein, followed by booster injection of 108 rSFV 
particles in 200 µl PBS by the same route after 3 weeks. Three weeks after the booster 
injection, sera were collected. 
2.9. ELISA for HBV antibody response  
Flat bottom microtiter plates (PolySorbTM; Nunc, Thermo Fisher Scientific, Germany) 
were coated with recombinant HBsAg of subtypes adw2 and ayw3, expressed in 
methylotrophic yeast Hansenula polymorpha (Janowicz et al., 1991) (Rhein Biotech, 
Düsseldorf, Germany), at 10 µg/ml in 50 mM sodium carbonate buffer, pH 9.6, for 12 h at 4 
ºC. Thereafter plates were washed three times with PBS/0.05% Tween 20 and blocked with 
PBS/1% BSA for 1 h at 37 ºC. Alternatively, plates were coated with a synthetic peptide 
corresponding to aa 124 to 148 of S protein, adw2 (CTTPAQGNSMFPSCCCTKPTDGNCT). 
For detection of anti-preS1, flat bottom microtiter plates (MaxiSorbTM; Nunc) were coated 
with a synthetic peptide aa 10-36 of preS1 (genotype D numeration - 
PLGFFPDHQLDPAFRANTANPDWDFNP; both synthetic peptides were from Peptron, 
South Korea). Sera were serially diluted in PBS/ 0.05% Tween 20/0.5% BSA, incubated for 1 
h at 37 ºC and bound antibodies detected as above. Antibody end point titers were calculated 
Protein Cell line 
expressed in 
Antibodies 
S/adw2 BHK-21 1-9C1 
S/ayw2 BHK-21 1-9C1 
preS1.1-48/S BHK-21 1-9C1 followed by H863 
preS1.1-48/S0 BHK-21 1-9C1 
Ser2.preS1.1-48/S BHK-21 1-9C1 followed by H863 
Ala2.preS1.1-48/S BHK-21 1-9C1 followed by H863 
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as dilution which gave an absorbance value three times higher than the pre-immune serum. 
Statistical significance was determined with ANOVA (p <0.05) and Tukey’s multiple 
comparison method (α=0.05). 
Additionally, flat bottom microtiter plates (MaxiSorbTM; Nunc, Thermo Fisher 
Scientific, Langenselbold, Germany ) were coated with highly purified, human plasma-
derived HBsAg particles, subtype ayw2 (genotype D), at 2 µg/ml in 0.1 M sodium phosphate, 
pH 7.4, for 12 to 18 h at 4 ºC. After washing two times with PBS/0.1% Tween 20 and two 
times with PBS, wells were blocked for 2 h at 37 ºC with 10% FCS in TNE, pH 7.4, and 
washed as above. Serially diluted sera in 1%BSA/PBS were applied and incubated for 12 h at 
4 ºC and plates subsequently washed. Peroxidase-conjugated anti-mouse IgG in 1% BSA/PBS 
was added and plates were incubated for 1 h at 37ºC. Thereafter o-phenylenediamine/H2O2 
(tablets from Dako or Sigma) substrate was added, incubated for 15 min at room temperature, 
OD was measured at 492 nm. 
Additionally, anti-HBs was determined quantitatively in IU/L by ELISA based on 
microparticles coated with recombinant HBsAg ad and ay (AxSym; Abbot Laboratories, 
Wiesbaden, Germany) according to manufacturer’s instructions.  
To determine serum IgG1 and IgG2a titers in the sera of rSFV immunized BALB/c 
mice, flat bottom microtiter plates (PolySorbTM; Nunc) were coated with recombinant HBsAg 
of subtypes adw2 and ayw3 for the mice sera obtained from rSFV-S/adw2 and rSFV-S/ayw2 
immunized mice respectively. For detection of IgG1 and IgG2a in mice sera immunized with 
rSFV-preS1.1-48/S and rSFV-preS1.1-48/S0 flat bottom microtiter plates (MaxiSorbTM; Nunc) 
plates were coated with a synthetic peptide aa 10-36 ( genotype D numeration). Anti-mouse 
IgG1 and IgG2a antibodies from goat were used followed by peroxidase-conjugated anti-goat 
IgG (Sigma). Detection was performed as described above.  
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Table 6. HBsAg and peptide used in ELISA for detection of anti-HBs and anti-preS1 IgG 
 
 
 
 
 
 
 
 
 
2.10. HBV and HBsAg particles from human plasma 
 
Hepatitis B virus (genotype D) and subviral HBsAg (subtype ayw2) particles were 
isolated as described (Glebe and Gerlich, 2004) from plasma of an asymptomatic, HBeAg-
positive, chronic HBV carrier (ID 326) which contained 8×109/ml HBV genome equivalents 
and 120 µg/ml HBsAg. HBV DNA containing fractions at 40-45% sucrose were identified by 
quantitative real-time PCR (LightCycler system, Roche, Germany) using primers and 
hybridization probes against the HBV X-region as described (Jursch et al., 2002). The assay 
was calibrated using the Eurohep reference plasma which has been converted to a WHO 
international standard sample (Saldanha et al., 2001). 
 
2.11. Isolation and culture of primary Tupaia belangeri hepatocytes 
 
Primary hepatocytes of Tupaia belangeri were isolated by the modified two-step 
collagenase method essentially as described (Glebe et al., 2003). Briefly, the livers were 
perfused via the portal vein with HANKS solution (Invitrogen) containing 5 mM EGTA, 
followed by perfusion with DMEM (Invitrogen) containing 0.05% collagenase (Sigma). 
Hepatocytes were separated from other cell types by pelleting 3 times at 40 g for 6 minutes at 
4 °C. Hepatocytes were resuspended in PTH and plated on 12-well plates coated with 
MatrigelTM ,105 hepatocytes/well. Plating efficiency and viability were measured prior to 
infection and at the end of the experiment by a modified MTT assay as described (Glebe et 
al., 2003). Variability as determined by MTT assay for each preparation was 10% or lower 
(data not shown). The organ harvest from Tupaias had been approved by the animal 
protection committee at Justus-Liebig University, Giessen, Germany.  
                                    Anti-S response 
Recombinant HBsAg/adw2 and 
HBsAg/ayw3 (Rhein Biotech, 
Düsseldorf, Germany)  
Expressed in methylotrophic yeast 
Hansenula polymorpha (Janowicz et al., 
1991)  
                                    Anti-S and anti-preS1 response 
subviral HBsAg (subtype ayw2) 
particles, include preS2 and preS1  
Isolated as described (Glebe and Gerlich, 
2004) from plasma of an asymptomatic, 
HBeAg-positive, chronic HBV carrier (ID 
326) which contained 8×109/ml HBV 
genome equivalents and 120 µg/ml HBsAg 
                                    Anti-preS1 response 
Peptide of aa 10-36 of preS1 
(Peptron, South Korea) 
genotype D numeration, (correspond to aa 
21-47 of genotype A)  
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2.12. Detection of HBV neutralizing antibodies 
2.12.1. Incubation of HBV with BALB/c mice sera  
To remove nonspecific serum factors enhancing the susceptibility of PTH for HBV, 
IgG was precipitated by addition of Na2SO4. In brief, 50 µl of mice sera were mixed with 
50µl of 0.2 M sodium phosphate buffer, pH 7.2, and 100 µl saturated Na2SO4 solution (36% 
(w/w) were added and incubated for 15 minutes at room temperature. After centrifugation for 
1 min at 20, 000 × g supernatant was removed. The pellet was dissolved in 50 µl 0.1 M 
sodium phosphate buffer and again precipitated three times with 50 µl sodium sulfate 
solution. Antibodies were dissolved in 100 µl PBS and immunoglobulin concentration was 
measured at OD280 assuming a factor of 1.35 for 1 mg/ml. For each well of a 12-well plate, 
5×105 genome equivalents (ge) of HBV were incubated with 50, 100 or 250 µg IgG in 100 µl 
of PTH for infection (DMEM  supplemented with 0.1% bovine serum albumin, 2% dimethyl 
sulfoxide, 100 µg/ml gentamicin, and 0.25 µg/ml amphotericin B) for 1 h at 16 ºC with mild 
shaking. Thereafter, 200 µl of PTH medium were added and PTH cultures (105 cells/ well) 3 
days after plating were infected with HBV/antibody mixture for 18 h at 37 ºC. After removal 
of the viral inoculum, cells were washed twice with DMEM/ 0.1% BSA/ 20 mM HEPES, and 
further cultured in PTH medium for 14 days. At days 3, 6, and 10 PTH medium was collected 
and replaced with a fresh medium. 
 
2.12.2. Assessment of cell viability 
Fourteen days after infection, cell viability was measured by a modified MTT assay 
(assessment of cell viability/metabolic activity)(Glebe et al., 2003) which is based on the 
metabolic conversion of tetrazolium salt WST-1 (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium; Roche) producing highly water soluble formazan exclusively 
in metabolically intact cells, which can be directly measured with an ELISA Reader by 450 
nm. Briefly, in every well 300 µl of WST-1 which was diluted in DMEM without the 
phenolred was added and incubated at 37 ºC for 1 h. 100 µl was transferred to an ELISA plate 
and absorbance at 450 nm (reference filter 620 nm) measured. 
 
2.12.3. Monitoring the progress of PTH infection/Assessment of HBV infection of PTH 
Concentration of newly secreted HBsAg in the supernatant from days 3, 6, 10 and 14 
was determined using the ELISA with C20/02 as described above. HBeAg was detected 
quantitatively in the supernatants from day 14 by a commercially available ELISA (AxSym; 
Abbott Laboratories, Wiesbaden, Germany). Results were obtained as signal to cut-off (S/CO) 
ratio. When appropriate, after assessment of cell viability, cells were washed with DMEM 
without phenol red, followed by two washes with ice cold PBS and lysed with lysis buffer 
containing 0,5% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl pH 7.6 and 5 mM MgCl2. 
Cytoplasmic and nucleic fractions were separated by centrifugation at 420 × g for 2 min at  
4 ºC. Cytoplasmic and nucleic fractions were frozen in liquid nitrogen and stored at -70 ºC for 
isolation and quantification of ccc DNA and HBV mRNA. 
 
2.12.4. Isolation of HBV cccDNA 
The frozen cell pellets were defrosted on ice and episomal DNA extracted according to  
Hirt (Hirt, 1967): 400 µl of 0,6% w/v SDS, 10 mM EDTA was added to the cell pellet, mixed 
carefully by invertion of the tube and left for 20 min at RT. 100 µl of 5 M NaCl was added in 
order to precipitate chromosomal DNA o/n at 4 ºC. Samples were centrifuged at 4 ºC in a pre-
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cooled centrifuge for 4 min at 14.000 rpm (20, 800 × g). From the supernatant fraction ccc 
DNA was isolated with the High Pure Viral Nucleic Acid Kit (Roche) according to 
manufacturer’s instructions.   
 
2.12.5. Quantification of ccc DNA 
For real-time PCR for the quantification of ccc DNA in PTH LightCycler® FastStart 
DNA Master Hybridization Probes Kit  (Roche, Germany) was used. Primers and HybProbes 
for ccc DNA PCR were from TIB MOLBIOL, Germany. C1 sence primer:  
5’-TGCACTTCGCTTCACCT ( from nucleotide 1580 to 1596), C1 antisense primer:  
5’-AGGGGCATTTGGTGGTC (from nucleotide 2314 to 2298). The primers are specific for 
the detection of HBV DNA without nick and gap, the ccc DNA. 3FL CB HybProbe: 5’ 
CAATGTCAACGACCGACCTT –FL- 3’ (correspond to nucleotide 1678 to 1697, FL – 
donor dye fluorescein); 5LC CB HybProbe: 5’-LC Red 640-
AGGCMTACTTCAAAGACTGTKTGT-PH-3’, M=A/C and K=G/T (correspond to 
nucleotide 1699 to 1722, acceptor dye – Light Cycler Red 640). 
PCR conditions: 1 cycle of denaturation at 95 ºC for 10 min; 45 cycles of amplification – 10 s 
at 95 ºC, 20 s at 57 ºC and 32 s at 72 ºC. The standard for the quantification was the plasmid 
pBs HB 991 T7 Dimer (107 – 102 copies). Serum standard  - human plasma derived virions 
(2x105 ge HBV) was also used, and expected to  give a negative signal, since it is not 
covalently closed.  
Afterwards, the amplificate was recovered from capillaries by centrifugation, and 12  µl of the 
total 20 µl was subjected to 2% agarose gel (Tris-acetate buffer) electrophoresis, and 
visualized by ethidium bromide staining. 
 
2.12.6. Quantification of HBV mRNA 
mRNA was isolated from cytoplasmic fractions of HBV infected PTH with oligo(dT) 
coated paramagnetic beads (Dynal; Invitrogen) and purified by  Dynabeads® mRNA DirectTM 
Micro Kit (Invitrogen) according to manufacturer’s instructions followed by digestion with 
1.5 U of RNase-free DNase (Applied Biosystems) for 30 min at 37 ºC. HBV mRNA was 
quantified using the one-tube real-time reverse transcription kit for LightCycler (Light 
Cycler® RNA Amplification Kit Hybridization Probes Kit;   Roche, Germany) and primers 
and hybridization probes for the X region. X2 sense primer: 
5’ GACGTCCTTTGTYTACGTCCCGTC 3’ (Y= C/T, correspond to nucleotide 1413 to 
1436); X antisense primer: 5’ TGCAGAGTTGAAGCGAAGTGCACA 3’ (correspond to 
nucleotide 1579 to 1601). The primers have been described (Jursch et al., 2002;Glebe et al., 
2003). 3FL XB HybProbe: 5’ ACGGGGCGACCTCTCTTTACGCGG-FL 3’ (correspond to 
nucleotide 1519 to 1543), 5LC XB HybProbe: 5’-LC Red 640-
CTCCCCGTCTGTGCCTTCTCATCTGC 3’ (correspond to 1545 to 1570). In vitro 
transcribed X region of HBV from plasmid pCX (Schuster et al., 2000) (transcription using 
the T7 in vitro transcription kit (Roche) according to manufacturers instructions) was used as 
a standart. After determining copy number by measuring OD 260 nm it was serially diluted 
and used as a standard in quantitative RT-PCR. Conditions of RT-PCR: reverse transcription 
step at 55 ºC for 12 minutes, with the denaturation step at 95 ºC for 10 s and amplification at 
95 ºC for 10 s, 64 ºC for 15 s and 72 ºC for 13 s.  
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3. RESULTS 
 
3.1. Expression of SFV1 vector encoded HBs proteins in vitro 
 
The natural and modified HBs proteins expressed from the SFV1 vector will be referred 
in the text as “HBs proteins”. Genes encoding SHBs, subtype adw2 (genotype A2) and ayw2 
(genotype D) and five L protein deletion variants generated by fusion of aa 1-48 of preS1 
(genotype D numeration, subtype ayw2) to N-terminus of subtype ayw2 S protein (preS1.1-
48/S) were cloned in the pSFV1 vector (Fig. 11). The pSFV1 contains SP6 polymerase 
promoter to enable transcription in vitro after linearization of the pSFV1 plasmid, followed by 
nsP1-4 replicase complex. The gene of interest is preceeded by the SFV 26S subgenomic 
promoter. The pSFV1 carries gene for ampicillin resistance and site for its linearization with 
appropriate restriction endonuclease.  
The second amino acid of preS1 domain is glycine, which is the myristic acid 
attachment site, some variants of modified HBs proteins preS1.1-48/S contained unmodified 
myristic acid attachment site at the 2nd position at the N-terminus. Variants with modified 
myristic acid attachment site contained serine (Ser2.preS1.1-48/S) and alanine (Ala2.preS1.1-
48/S) in the 2nd position. Three of the modified HBs variants of preS1.1-48/S contained the 
natural codon of translational initiation of SHBs downstream of the codon initiating 
translation of the deleted L protein. To determine the influence of in-frame expressed SHBs 
on formation and release of subviral preS1.1-48/S particles, the second initiation codon at the 
beginning of SHBs was mutated to GTG (variant termed preS1.1-48/S0). The schematic 
representation of the SFV1 constructs with the inserted natural and modified HBs protein 
coding genes is shown in Figure 11. A more detailed scheme of deleted L proteins is depicted 
in Figure 12. Addionally, the list of the natural and modified HBs proteins cloned in pSFV1 is 
depicted in table 7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Schematic representation of the SFV1 expression vectors. SP6 RNA polymerase 
promoter is shown by the filled arrow. HBV surface protein genes are placed under the control of SFV 
26S subgenomic promoter (empty arrow). Asterix denotes the missing translation start site of the 
S/ayw2 encoding sequence. The space between the regions encoding aa 1-48 of preS1 and S/adw2 
denotes the “spacer” encoding aa LEGGSGG. The filled triangle denotes the modified myristic acid 
attachment site, where Gly was replaced with Ala and Ser 
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Table 7. HBs proteins expressed by SFV1 vector 
 
HBs proteins Modification 
SHBs, adw2 (subgenotype A2) - 
SHBs, ayw2 (genotype D) - 
Deleted L proteins Fusion of aa 1-48 of preS1 to N terminus of 
SHBs, ayw2 
preS1.1-48/S As above 
preS1.1-48/S0 Start codon of S (ATG) mutated to GTG 
Ser2.preS1.1-48/S 2nd Gly replaced by Ser 
Ala2.preS1.1-48/S 2nd Gly replaced by Ala 
  
*HBV L protein coding sequence was cloned in SFVC vector, other HBs protein coding sequences were cloned 
in SFV1 vector 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Schematic representation of LHBs deletion variants consisting of aminoterminal 48 
aa of preS1 fused to the amino terminus of the S domain showing the myristoylation site and 
potential glycosylation sites 
 
The sequence of cloned HBs proteins was confirmed by sequence analysis as 
described in Materials and Methods section. Sequences of the deleted L protein genes beared 
the desired exchanges. The SFV1 plasmids bearing the HBs protein genes were selected, 
isolated and amplifed according to standard procedures briefly outlined in Materials and 
Methods section. After linearization of the SFV1 plasmids with restriction endonuclease NruI, 
transcription in vitro with SP6 polymerase was performed yielding recombinant SFV RNA. 
Recombinant SFV were produced after electroporation of BHK-21 cells with the in vitro 
transcribed recombinant SFV RNA and helper vector RNA. rSFV were concentrated as 
described in Materials and Methods section, followed by the determination of the rSFV titer.  
The expression of HBs proteins was examined mostly in BHK-21 and Huh7 cells. 
HepG2 cells were used once. Expression of the chimeric preS1.1-48/S proteins was shown 
also in PTH after infection with rSFV. Cells were infected with rSFV or the recombinant SFV 
replicon RNA was introduced by electroporation. The transcription of HBs protein encoding 
sequences is initiated at the 26S subgenomic promoter on the (-) RNA strand, producing (+) 
RNA subgenomic RNA, from which the HBs proteins are translated (refer to Fig. 9).   
It has been established and we have also shown (Zajakina et al., 2004;Braun et al., 
2007) that 20-24 hours after infection with rSFV is optimal to assess the expression of the 
desired protein in vitro. 20-24 hours after infection cells were lysed and cell medium was 
collected. We observed that electroporation with recombinant SFV RNA is more cytotoxic to 
transfected cells compared to infection with rSFV particles. 
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3.1.1. Expression in vitro of the SHBs. 
BHK-21 and Huh7 cells were infected at MOI 20 with rSFV encoding S/adw2 protein. 
20 h after infection cells were pulsed with [35S]-methionine and chased for the indicated time 
(Fig. 13), up to 24 hours. “Pulse-chase” experiments and examination of cell lysates by SDS-
PAGE at indicated times after addition of “chase” medium showed the characteristic pattern 
of the SHBs - the 27 kDa glycosylated (GP27) and 24 kDa non-glycosylated form (P24) in 
equal proportions in BHK-21 cell lysates (Fig.12A), while in Huh7 cells the glycosylated 
form was more prominent (Fig. 13B).  
 
 
 
Figure 13. Analysis of rSFV driven  
SHBs expression in BHK-21 cells (A)  
and Huh7 cells (B). Cells were infected  
at MOI 20 with rSFV-S/adw2. 20 hours  
after infection cells were pulsed with 
 [35S] methionine, and „chased” for the  
time indicated with the medium  
containing unlabelled methionine. Cells  
were lysed and subjected to SDS-PAGE  
followed by autoradiography. 
 
 
 
 
 
 
 
 
Secreted [35S] labeled SHBs in BHK-21 or Huh7 medium was detected by SDS-PAGE after 
precipitation with 20% trichloroacetic acid at 1.5 h, 3 h and 24 h after addition of chase 
medium (not shown). HBsAg specific ELISA showed a peak concentration in the medium of 
BHK-21 cells between 36 and 48 h after infection, with the secretion declining at 72 hours 
after infection, detection was performed by commercially available HBsAg assay (Dade 
Behring) (Fig. 14).  
 
Figure 14. Expression of rSFV driven SHBs  
expression in BHK-21 cells. At indicated 
times post infection BHK-21 cell medium and 
cell lysates were subjected to ELISA using 
rHBsAg with a predetermined concentration as 
a standard. rSFV-HCV/core represents cells 
infected with rSFV particles encoding core 
protein of hepatitis C virus as a negative 
control. Mock infected cells during infection 
were treated with medium. Error bars show 
standard deviation (SD). Dark bars denote 
intracellular HBsAg, light bars extracellular 
HBsAg. 
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A                                  B 
It was not possible to detect S/ayw2 (genotype A), expressed in BHK-21 cells, with the 
commercial HBsAg assay (Dade Behring), neither in the infected BHK-21 cell lysates, nor in 
the infected cell medium. However, this commercial assay could detect rHBsAg, subtype 
ayw2, produced in yeast (not shown). S/ayw2 expressed in mammalian cell lines could be 
detected, however, with the in-house ELISA using C20/02 antibodies. This was not 
investigated further. 
 
Immunofluorescence analysis with MAb 1-9C1 of BHK-21 cells infected with rSFV-S/adw2 
and rSFV-S/ayw2 demonstrated a cytoplasmic, granular distribution of the SHBs (Fig. 15). 
 
 
 
 
 
 
 
 
 
 
Figure 15. Immunofluorescence analysis of SHBs expressed in BHK-21 cells. Infection of BHK-21 
cells and immunofluorescence analysis was performed as described in Materials and Methods section. 
S/adw2 (A) and S/ayw2 (B) proteins were detected by MAb 1-9C1 followed by FITC conjugated α-
mouse IgG. Cell nuclei were stained with DAPI. The size bar corresponds to 20 µm. 
3.1.2. Expression of preS1.1-48/S proteins in vitro  
BHK-21 and Huh7 cells were infected at MOI 20 and MOI 10 respectively with rSFV 
encoding the preS1.1-48/S proteins. Analysis of BHK-21 and Huh7 cell lysates for the deleted 
L proteins and its variants with the changed myristic acid attachment site Ser2.preS1.1-48/S 
and Ala2.preS1.1-48/S revealed P24 and GP27 bands, indicating an effective internal 
translation initiation at the second translational start site (Fig. 16A, B). Three bands at 
approximately 32, 35 and 38 kDa could be detected corresponding to the chimeric proteins 
preS1.1-48/S, Ser2.preS1.1-48/S and Ala2.preS1.1-48/S (Fig. 16 A, B), and their glycosylated 
forms as verified by the PNGase F digestion (Fig. 17).  
 
 
 
 
 
 
 
 
 
 
Figure 16. BHK-21(A) and Huh7 (B) cells were infected with rSFV encoding LHBs deletion 
variants. Cells were lysed 20 hours after infection with 0.5% Triton X-100 containing lysis buffer and 
subjected to SDS-PAGE and Western blotting with MAbs HB1 recognizing linear S domain. The 
three bands corresponding to preS1.1-48/S .proteins are marked by the white dots. (A) - preS1.1-48/S; 
(B) - preS1.1-48/S (lane 1), Ser2.preS1.1-48/S (lane 2) and Ala2.preS1.1-48/S (lane 3). 
 
The modified HBs proteins bear three potential N-glycosylation sites: at Asn4 in the 
preS1 fragment, and at Asn3 and Asn146 in the S domain (see Fig. 12). In full length L 
protein the preS1 site is not used due to lack of a signal peptide governing co-translational 
translocation (Bruss and Vieluf, 1995;Ostapchuk et al., 1994). The Asn 3 site of the S protein 
is not glycosylated in natural S protein, while Asn-146 is partially used in all 3 HBs proteins. 
Thus, a doublet of nonglycosylated (ca. 30 kDa) and glycosylated (ca. 33 kDa) fusion protein 
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was expected. However, Western blot analysis with preS1 specific MAb MA18/7 of Huh7 
cell lysates (Fig. 17) unexpectedly revealed three bands at approximately 32, 35and 38 kDa. 
To confirm the presence of glycosylated forms of preS1.1-48/S proteins were deglycosylated 
with peptide N glycosidase F (PNGase F ), which cleaves all N-linked glycans. PNGase F 
digestion in denaturing conditions shifted the three bands to one 30 kDa position (Fig. 17). 
This suggested that all three N-glycosylation sites were partially linked with glycans 
generating a mixture of mono-, di- and tri-glycosylated glycoproteins. PNGaseF digestion of 
preS1.1-48/S proteins was performed in native conditions in order to distinguish between 
preS and SHBs linked glycans. SHBs linked glycan at Asn 146 under native conditions is 
protected from the cleavage with PNGase F in native conformation of SHBs, whereas preS 
linked glycan is still removed in native conditions (Tolle et al., 1998). Under these conditions, 
the major product of the digest was the 32 kDa protein, but the nonglycosylated 30 kDa 
product was also observed. This result suggests that the majority of the preS1.1-48/S proteins 
is glycosylated at Asn146 and at one or both of the other sites. The preS1.1-48/S proteins with 
Ser and Ala at position 2, showed identical glycosylation pattern to the protein with the 
unchanged myristic acid attachment site. Glycosylation pattern of the preS1.1-48/S0 variant 
did not differ from the preS1.1-48/S with the unchanged translational start site (Fig. 17). 
Thus, the presence internally translated SHBs did not change the ER related topology of the 
preS1.1-48/S protein. 
 
Figure 17. N-Glycosylation pattern of 
preS1.1-48/S proteins.  
Huh7 cells were infected at MOI 10 with rSFV 
encoding preS1.1-48/S, Ala2.preS1.1-48/S, 
Ser2.preS1.1-48/S and preS1.1-48/S0.  20 h  
after infection cells were lysed with lysis 
buffer containing 0.5% Triton X-100, 150 mM 
NaCl, 50 mM Tris-HCl pH 7.5, 2 mM EDTA 
and 1 µg/ml phenylmethanesulfonylfluoride. 
Five-hundred units of PNGase F were added to 
membrane was reacted with MAb MA18/7, 
followed by goat anti-mouse antibodies 
conjugated with horseradish peroxidase. ”+”, 
treated with PNGase F; ”-”, untreated. Black 
dots indicate the three glycosylated bands of 
truncated LHBs.10 µl of Huh7 cell lysates 
diluted in reaction buffer (50mM sodium 
phosphate buffer, pH 7.5) containing 1% 
NP40, and incubated for 1 h at 37 ºC. To 
perform the reaction under denaturing 
conditions, glycoprotein denaturing buffer was 
added to 10 µl of cell lysates and incubated for 10 min at 100ºC, whereas for digestion under native 
conditions denaturing buffer was omitted. After separation by SDS-PAGE, proteins were transferred 
to a Hybond-P membrane in a semi-dry electro blotter. The membrane was reacted with MAb 
MA18/7, followed by goat anti-mouse antibodies conjugated with horseradish peroxidase. ”+”, treated 
with PNGase F; ”-”, untreated. Black dots indicate the three glycosylated bands of truncated LHBss. 
 
 
To detect, if the preS1.1-48/S proteins synthesized in Huh7 cells exhibit preS1 and 
SHBs antigenicity, Huh7 cells 20 h after infection with rSFV encoding preS1.1-48/S proteins 
were lysed and cell lysates subjected to ELISA with preS1 specific MAb MA18/7 and MAb 
detecting correctly folded SHBs - C20/02. The ELISA demonstrated more preS1 antigen than 
correctly folded HBsAg antigen exposed by the preS1.1-48/S proteins, while the S0 variant 
(preS1.1-48/S0) without start codon for the SHBs showed a very low C20/02 specific signal, 
which was marginally above the cut-off (Fig. 18A). Aditionally, PTH were infected with 
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rSFV encoding preS1.1-48/S and preS1.1-48/S0 at MOI 10 and PTH lysates subjected to 
.preS1 and S-specific ELISA (Fig. 18B).   
 
3.1.3. Secretion and antigenicity of HBs proteins   
To examine the secretory phenotype of the preS1.1-48/S proteins, 20 h after infection 
of Huh7 cell infection with rSFV encoding the respective proteins the cell medium was 
replaced with the fresh medium, the medium was collected 24 hours later and examined with 
ELISA. The proteins exhibited preS1 antigenicity, and to a smaller extent S antigenicity. This 
was demonstrated by binding to S-conformation dependent MAb C20/02 (Table 8). Binding 
to C20/02 could originate either from the chimeric preS1.1-48/S particles and/or from the 
independently secreted SHBs particles. Secretion of the preS1.1-48/S proteins is summarized 
in table 8. The protein with wt myristic acid attachment site was secreted most efficiently, the 
inactivation of the myristoylation signal had a minor negative effect on the release of the 
particles. Neither preS1, nor SHBs antigenicity was detectable in the medium of Huh7 cells 
infected with rSFV encoding preS1.1-48/S0 Since the preS1.1-48/S0 was not secreted, it can 
be assumed that secretion of SHBs particles with preS1 domains on the surface happens only 
in the presence of independently expressed SHBs.  
Huh7 additonally were infected with rSFV encoding LHBs (schematic representation 
of the construct is shown in Fig. 11). Cell infection with the rSFV particles encoding the L 
protein served as non-secreted control, since C terminal part of the preS1 domain contains 
topological (Bruss and Vieluf, 1995; Ostapchuk et al., 1994; Bruss et al., 1994) and retention 
signals (Gallina et al., 1995) which prevent secretion of the LHBs and SFV-expressed LHBs 
could not be detected in infected cell medium up to 48 h after infection with rSFV (not 
shown)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Analysis of preS1.1-48/S and it’s variants’ expression in Huh7 (A, B) and PTH by 
preS1 (MA 18/7)  and S (C20/02) specific ELISA. Huh7 cells (A) and 105 PTH (B) were infected at 
MOI 10 for 20 h. (A) Huh7 cells lysates with 5 µg/ml cell protein. (B) Lysates of PTH represent 
material from 5x104 cells. The viability of rSFV infected PTH ranged 20 h after infection from 59 to 
68% of mock infected cells. Cut-off is represented by the dashed line and was set as the value shown 
by rSFV-HCV/core infected Huh7 cell lysate (A) or by mock infected PTH lysate (B), representing 
5x104 cells in ELISA employing C20/02. Results of one of three independent experiments showing 
similar results are shown.  
 
 
 
  
 
 
 50
 
Table 8. Secretion of LHBs deletion variants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Huh7 cells were infected at MOI 10 with rSFV encoding respective proteins. 18 h after infection 
cell medium was collected and replaced with a fresh medium, which was collected after 24 h and 
100 µl of 2 ml of medium were analyzed by ELISA on microtiter plates coated with MAbs 
MA18/7 and C20/02. Mean values are shown ± SD. * The difference to preS1.1-48/S, myr wt is 
significant at α=0.05. 
 
To examine if addition of preS1 sequences 1-48 with unmodified and modified myristic acid 
attachment site to N-terminus of S protein allow formation of intact subviral particles, BHK-
21 cells were electroporated with rSFV RNA encoding the respective proteins and after 22 
hours the cell medium was collected and concentrated as described in Materials and Methods 
section. Electron microscopy of the medium revealed spherical, 22 nm diameter HBsAg-like 
particles (Fig. 19A). Binding of MA18/7 followed by gold conjugated anti-mouse IgG 
verified that these particles exposed accessible preS1 antigen on the surface. The preS1.1-48 
and the Ser2preS1.1-48/S supported the assembly of HBs-like subviral particles, their 
secretion, and expose preS1 epitopes on their surface recognized by anti-preS1 antibodies 
(Fig. 19B). Naked SHBs-like particles without the immunogold label were also found (Fig. 
19A). Thus, preS1/S particles with preS1 antigen on surface were secreted from the infected 
or transfected cells, along with unmodified, only SHBs containing particles. Moreover, the 
secretion of the chimeric preS1.1-48/S proteins occurred only in the presence of in-frame 
expressed SHBs.  
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Electron microscopy analysis of immunogold-labelled preS1.1-48/S (A) and 
Ser2preS1.1-48/S (B) after reaction with MAb MA18/7 recognizing preS1. 
The suspension of the particles was adsorbed on carbon-formvar coated grids and incubated with MAb 
MA 18/7, followed by anti-mouse IgG conjugated with 5 nm gold particles (Sigma), as described 
(Louro and Lesemann, 1984). The grids were negatively stained with 2% uranyl acetate aqueous 
solution and examined with a JEM-1230 electron microscope (JEOL Ltd.,Tokyo, Japan) at 100 kV. 
The scale bar corresponds to 25 nm. There are two immunocomplexes (white arrows) and one naked 
particle (black arrow). 
L deletion variant MAbs 
 MA18/7 C20/02 
preS1.1-48/S, myr wt 1.10 ± 0.16 1.00 ± 0.12 
Ala2preS1.1-48/S, myr- 0.52 ± 0.06* 0.56 ± 0.09* 
Ser2preS1.1-48/S, myr- 0.67 ± 0.08* 0.43 ± 0.06* 
preS1.1-48/S0, myr wt 0.17 ± 0.01* 0.14 ± 0.01* 
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3.1.4. Immunofluorescence analysis of preS1.1-48/S proteins 
To determine the subcellular localization of the preS1.1-48/S proteins and effect of the 
mutation in the myristoylation site on it, BHK-21 cells were infected with rSFV encoding the 
respective proteins. Cells were stained with SHBs specific antibodies 1-9C1 directed to a 
linear epitope in the S domain followed by preS1 specific polyclonal antibodies H863. The 
anti-S antibodies bind to the in-frame expressed SHBs, as well as to the S domain in the 
preS1.1-48/S, Ser2.preS1.1-48/S and Ala2.preS1.1-48/S. Immunofluorescence analysis of 
rSFV-preS1.1-48/S (wt) infected cells revealed colocalization of both antigens with a strong 
perinuclear staining (Fig. 20, upper sections of panels A and B). In contrast to the restricted 
distribution of preS1.1-48/S protein in the perinuclear area (Fig. 20, section A, upper panel), 
the Gly 2 mutant proteins showed a granular dispersion throughout the cell cytoplasm (Fig. 
20, section A, middle and bottom panels). Anti-preS1 signal displayed brighter intensity at the 
cell peripheries (Fig. 20, section A, bottom panel), while the perinuclear Golgi-like area 
showed weaker red staining for rSFV-Ser2.preS1.1-48/S infected cells (Fig.20, section A, 
bottom panel). To exclude the effect of presence of internally translated SHBs on the 
localization of the deleted L proteins, we BHK-21 cells were infected with the rSFV-preS1.1-
48/ revealed compact staining pattern, which localized strictly around the nucleus in a ring-
like pattern (not shown), resembling the pattern of preS1.1-48/S protein with the in-frame 
expressed SHBs. These results are in line with the matrix protein Z of Lassa virus where 
mutation of aminoterminal Gly to Ala altered the subcellular localization from a punctuate to 
a diffuse pattern (Strecker et al., 2006). The stronger colocalization of the preS1 and SHBs 
epitopes in cells transfected with the wt variant than with the variant without myristoylation 
signal suggests that the myristate supports the interaction between the LHBs and SHBs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Confocal microscopy analysis of preS1.1-48/S, Ala.2preS1.1-48/S and 
Ser2.preS1.1-48/S proteins BHK-21 cells were infected with rSFV encoding the respective 
proteins and stained with MAb 1-9C1 (α-S), followed by polyvalent rabbit antibodies H863 (α-preS1). 
The cell nuclei were stained with DAPI. Panel A depicts images of cells, panel B shows the 
fluorescence intensity of each fluorophore - FITC, TRITC and DAPI (y axis, relative numbers) along a 
line (x axis, m) drawn across a selected cell which is marked by the white arrow. 
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3.2. Selection of conditions for rSFV production 
rSFV are produced after co-electroporation of BHK-21 cells with the in vitro 
transcribed SFV RNA and helper vector RNA. The intended use of rSFV for immunization of 
BALB/c mice determined the necessity to obtain rSFV particles in high titres in infectious 
units/ml after incubation of BHK-21 cells, and concentration of rSFV. One of the essential 
factors that influence the final outcome of rSFV particles is the temperature of cell incubation 
after electroporation. 33 ºC was chosen rather that 37 ºC, because at lower temperatures the 
cytotoxic effects of SFV replicons for the host cells are diminished and incubation at longer 
times can be performed (A. Merits, personal communication). Incubation of BHK-21 cells at 
33 ºC resulted in 10-fold higher titer that incubation at 37 ºC for 24 hours. To increase rSFV 
particle outcome cells were incubated for 36 – 48 hours at 33 ºC. The experiments for 
optimization of rSFV production were performed with the rSFV/EGFP particles. Fig. 21 
illustrates assessment of rSFV encoding EGFP after optimal conditions for rSFV production 
were selected. 
 
 
     
 
 
 
 
 
 
 
Figure 21. Infection of BHK-21 cells with rSFV/EGFP. The titer of the rSFV1/EGFP was 2,9 x 109 
infectious units/ml. A. BHK-21 cells were infected with rSFV1/EGFP at MOI 3 and incubated for 20 
h. B. BHK-21 cells in the light microscope corresponding to the field of vision depicted in A. The 
cells are not fixed. C. BHK-21 cells were infected with the rSFV/EGFP at MOI ranging from 0.1 to 
50, 6 h after infection the infected BHK-21 cells were labeled with100 µCi/ml [35S]-methionine for 30 
min and lysed with SDS lysis buffer, followed by SDS-PAGE. Material corresponding to 1.5 x105 
cells was loaded in one lane. The band slightly below the molecular weight marker of 34 kDa 
corresponds to the EGFP protein. 
 
3.3. Immunization of BALB/c mice with rSFV 
 
The initial experiments of immunization of BALB/c mice with rSFV were performed 
with rSFV encoding S/adw2. The dose of 106 rSFV per one animal was chosen according to 
studies where authors had immunized mice with rSFV encoding other viral antigens or 
reporter genes (Berglund et al., 1999). The described immunization regimens with rSFV are: 
106 rSFV followed by 106 after two weeks with the detection of immune response 2-3 weeks 
after the last immunization (Fleeton et al., 2000).  
In the current study immunization i.v. and s.c. route with rSFV was chosen. I.v. 
immunization was performed in the tail vein. I.v. immunization with rSFV enables systemic 
delivery, while the s.c. route ensures local distribution. In case of systemic delivery the naked 
rSFV may be subjected to host’s acquired humoral immunity to SFV generated after the first 
administration of rSFV. S.c. route ensures local distribution of the vector (Colmenero et al., 
2001). The groups of BALB/c female mice are depicted in table 9, one group was comprised 
of 6 animals. 
 
 
 
 
 A                                     B                                                    C                         
MOI  0.1        1      10       50 
34      
kDa 
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Table 9. Groups of BALB/c mice, route of immunization and doses of rSFV 
 
Group Dose of rSFV, 
immunized twice 
at two week 
intervals 
Route of 
immunization 
rSFV-S/adw2 
1 10 6                  s.c. 
1A 106    i.v. 
2 10 7 s.c 
2A 107   i.v. 
rSFV-EGFP 
3 107       s.c.                         
3A 107 i.v.     
 
2 weeks after immunization mice were repeatedly immunized with the same dose of 
rSFV. The anti-HBs response was analyzed 2 weeks after the second immunization by ELISA 
with the serially diluted sera of each individual mouse, using the peptide spanning aa 124-148 
of antigenic loop of S/adw2.The serum of BALB/c mice was collected before immunization 
and 2 weeks after second immunization. Serially diluted serum was applied to microtiterplates 
coated with the peptide aa 124-148 and the difference between sera collected before 
immunization and after s.c. and i.v. immunization with rSFV-EGFP was determined as 
statistically significant with the Student’s paired t-test (p=0.05). The result indicates 
unspecific binding of rSFV-EGFP sera to peptide 124-148 of S/adw2 at a dilution 1:40. The 
serial dilutions of BALB/c mice sera were prepared: 1:20; 1:40; 1:80; 1:160 and 1: 320. For 
the statistical analysis dilution 1:40 was chosen. First experiments showed that 2 doses of 106 
rSFV-S/adw2 at two week intervals by i.v. or by s.c. subcutaneous route were not sufficient to 
generate a detectable anti-HBs response. A weak response was detected two weeks after two 
immunziations with 107 rSFV injected by the i.v. route, not by the s.c. subcutaneous route. 
According to the Student’s paired t-test (p=0.05) there was significant difference between the 
groups immunized with with 107 rSFV-S/adw2 when compared to mice immunized with 107 
rSFV/EGFP.  
Additionally, rHBsAg, subtype adw2, was used in ELISA to determine group- (a) and 
subdeterminant (d) specificity. The unspecific binding of rSFV-EGFP immunized mice serum 
was considerably reduced when rHBsAg was employed for ELISA instead of peptide 124-148 
of S/adw2 (Fig. 22). 
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Table 10. Student’s paired t-test (p=0.05) of rSFV-S/adw2 immunized  mice sera and rSFV-
EGFP immunized mice sera 
 
 
                 rSFV-EGFP 
rSFV-S/adw2 107 s.c. 10 7 i.v. 
10 6 s.c. Not significant - 
107 s.c. Significant  
106 i.v. - Not significant 
   
10 7 i.v. - Significant 
 
 
 
 
Figure 22. Mice were immunized 
twice with 107 rSFV at two week 
interval. Sera was collected 2 weeks 
after the second immunization and 
tested by ELISA using peptide 
spanning aa 124-148 of S/adw2 and 
rHBsAg. The results of the sera diluted 
1:40 are depicted. The bars denote SD 
(standard deviation) of the mean of 6 
mice.  
 
 
 
 
The anti-HBs response after two administrations of 107 rSFV particles was low. Other 
authors (Berglund et al., 1999;Fleeton et al., 2000) report markedly higher humoral responses 
after administration of 107 rSFV particles or even 106 rSFV particles. Anti-HBs response was 
not significantly different (p=0.05) from the control group mice (rSFV-EGFP) immunized s.c. 
and i.v. with 106 rSFV. Groups immunized s.c. and i.v. with 107 rSFV showed statistically 
significant difference from the rSFV-EGFP immunized groups (Table 10 ). The anti-HBs 
response was variable between individual animals (Fig.23).  
 
                       
Figure 23. Reciprocal 
ELISA titers two weeks 
after the second 
immunization with  107 
rSFV via i.v. route. 
rHBsAg, subtype adw2, 
was employed for 
ELISA. For the rSFV-
EGFP immunized group 
mean of six mice is 
shown, the bars denote                       
SD. The “#” in the 
legend denotes the 
numbering of the  6 
mice. 
Tree weeks after the second immunization two mice of i.v. group (mouse #1 and 
mouse #3) were administered 108 rSFV i.v. and two weeks after the sera was collected and 
subjected to ELISA using rHBsAg/adw2 (expressed in yeast Hansenula polymorpha). 
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Additionally, sera of one animal who did not receive the boost of 108 rSFV was tested with 
ELISA . The ELISA endpoint titers are depicted in Fig 24. The signal obtained from the 
serum collected two weeks after immunization with 108 rSFV showed pronounced increase in 
anti-HBs (Fig. 24).  
 
                                                                                        Figure 24. Anti-HBs after immunization of BALB/c 
mice with 107 rSFV at two week interval, followed by 
immunization with 108 rSFV. The sera were tested with 
ELISA using rHBsAg. The open triangle with an asterisk 
denotes a mouse which did not receive a “boost” of 108 
rSFV. The mean of 6 rSFV-EGFP immunized mice twice 
with 107 rSFV was 0.04 OD at 492 nm and the mean of 
two mice immunized with 107 twice, followed by 108 
rSFV once was 0.048 OD at 492 nm. Anti-HBs titer of 
1:100 indicates cut-off, shown by the dashed line. The 
“#” in the legend denotes the numbering of the animals. 
 
 
 
 
 
 
 
 
 
107  rSFV immunized by i.v. or by s.c route was necessary to induce a weak, but 
detectable immune response, while 108 were a prerequisite for induction of a pronounced 
increase in anti-HBs after immunization with 107 rSFV. The detection of the anti-HBs 
response was performed with a homologous subtype of HBsAg - adw2. Subsequently HBsAg 
subtype ayw3 was used for ELISA. The anti-HBs response was markedly lower and only 
slightly above the signal obtained with the rSFV-EGFP immunized mice. This showed an 
exclusive subdeterminant preference of anti-HBs induced by rSFV encoding S/adw2 to 
rHBsAg of homologous subdeterminant, and a weak reactivity to the HBsAg 
ysubdeterminant. . 
 
                                                                                                              Figure 25. Reactivity of anti-HBs induced 
in BALB/c mice by rSFV-S/adw2 to 
rHBsAg of homologous (adw2) and 
heterologous (ayw3) subdeterminant. 
BALB/c mice were immunized twice with 
107 rSFV-S/adw2 at two week intervals 
followed by 108 rSFV-S/adw2 three weeks 
after the second immunization. Serum was 
collected two weeks after the last 
immunization and tested with ELISA using 
rHBsAg adw2 and ayw3. The result 
represents serum from one animal (#3), 
previously being tested with ELISA using                       
                                                                                                             rHBsAg, adw2 (see Fig. 24).  
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It was shown that 108 rSFV-S/adw2 were required to elicit a pronounced increase in the anti-
HBs generated by immunization with rSFV-S/adw2. The induced antibodies were 
subdterminant specific. Therefore a question was raised wheather anti-HBs generated by 
immunization of BALB/c mice with rSFV encoding S/ayw2 would react in ELISA using 
rHBsAg of homologous and heterologous subdeterminant with the same pattern – i.e. show 
limited reactivity to HBsAg, subtype adw2. Therefore rSFV encoding S/ayw2 were generated. 
Subsequently three groups of 9 mice in each group were created. The groups of immunized 
mice are outlined in table 11. Mice were inoculated with rSFV i.v. First, mice were inoculated 
with 107 rSFV followed by 108 three weeks later. Another reason to use an increased dose of 
rSFV after the first immunization was the eventual anti-SFV response to virus structural 
proteins which may form after the first administration. Although the general assumption is 
that since virus structural proteins are not expressed due to one round of infection ensured by 
the non-replicative nature of the rSFV, justifyiung the use of rSFV in repeated immunizations 
(Berglund et al., 1999), an increased dose was used three weeks after the first immunization to 
circumvent the eventual neutralizing effect of potential anti-SFV response. Sera were 
collected three weeks after the second immunization.  
 
 
Table 11. Groups of BALB/c mice and their immunization regimen with rSFV encoding 
S/adw2, S/ayw2 and EGFP 
 
 
 
 
 
 
 
 
3.3.1. HBsAg in BALB/c mice sera after injection of rSFV 
  HBsAg could be detected in the medium of cells infected with rSFV-S/adw2 in vitro. 
In natural HBV infection hepatocytes secrete HBsAg to the blood stream. Therefore it was 
assumed that rSFV-transduced cells of BALB/c mice would secrete the HBsAg to the blood 
stream. We determined whether HBsAg could be detected in the blood of BALB/c mice 18, 
48 and 72 h after i.v. injection of 108 rSFV-S/adw2. 35 µl of blood from retroorbital sinus of 6 
rSFV-S/adw2 imunized mice were collected, pooled, and immediately after collection 100 µl 
of the pooled sera were tested by a commercially available ELISA (Dade Behring) at a 
detection limit of 0.2 ng/ml. The HBsAg signal was marginally (13% and 1%) above the cut-
off value (100%) at 18 and 48 h after injection respectively and 41% below the cut-off at 72 h 
post immunization. The HBsAg of the control injection with rSFV-EGFP were 38% to 55% 
below the cut-off at 18 and 48 h after injection.  
 
3.3.2. Immune responses in BALB/c mice after immunization with rSFV-S/adw2 and 
rSFV-S/ayw2  
Serially diluted sera were tested by ELISA using recombinant HBsAg subtype of 
adw2 or ayw3 produced in yeast to determine group- (a) and subdeterminant-specific (y or d) 
end point titers. All nine rSFV-S immunized mice in both groups seroconverted and showed a 
specific immune response. In line with the previous results, the anti-HBs/adw2 reacted 
specifically with the homologous subdeterminant d, but showed a very weak binding to a 
heterelogous subdeterminant y (Fig. 26A). The difference between anti-S/ayw2 sera with 
Group rSFV- Immunization 
scheme 
Route of 
immunization 
1 rSFV-
S/adw2 
107 followed by 108 
after three weeks 
i.v. 
2 rSFV-
S/ayw2 
As above As above 
3 rSFV-EGFP As above As above 
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HBsAg adw2 or ayw3 was not so pronounced as with anti-S/ayw2 (Fig. 26A), but it was 
statistically significant, see the statistical analysis below. The highest reactivity of anti-HBs 
were displayed when the anti-S/adw2 and anti-S/ayw2 antibodies were tested using the 
HBsAg with homologous subdterminant.  
This is reflected also in Figure 26 B, when anti-HBs titers were determined using 
rHBsAg of homologous and heterologous subdeterminants.  
 
Figure 26. A. . Sera were diluted 1:75. B. Anti-HBs end point titers after immunization with rSFV-
S/adw2 and rSFV-S/ayw2. Serially diluted mouse sera were tested by ELISA in microtiter plates 
coated with yeast-derived HBsAg adw2 or ayw3. The horizontal bars represent the median, the dashed 
line denotes the “cut-off” - anti-HBs titer of 1:100, above which mice were classified as responders.  
3.3.2.1. Statistical analysis 
 To analyse the differences in reactivity of anti-S/adw2 and anti-S/ayw2 sera when 
HBsAg/adw2 or HBsAg/ayw3 was exploited for ELISA, ANOVA (Single factor analysis of 
variance, One way ANOVA) was used. The test determines if a significant difference exists 
between the 6 group means (means of the three groups tested using rHBsAg adw2 and ayw2), 
(see table 12 a). Critical value F was exceeded at 0,05 level of significance, thereforea 
difference existed between at least two means tested. To determine which groups means are 
different, Tukey’s multiple comparison method (α=0.05) was used to differentiate which 
group means differ – comparison of sample means with the “control” group (EGFP) and 
between each other was performed. The calculations were performed manually. The results of 
the statistical analysis are shown in table 12 b).  
A statistically significant difference of OD signals was found with antisera from mice 
injected with rSFV-S/adw2 or rSFV-S/ayw2 when yeast-derived HBsAg/ayw3 was used as 
antigen for ELISA. Moreover, the anti-HBs reactivity of anti-S/adw2 sera with HBsAg/ayw2 
did not statistically differ with that of negative control mice (see table 12 a)  
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Table 12. Statistical analysis of anti-HBs response 
                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
                                
 
 
 
 
 
 
 
 
To determine binding of anti-HBs to HBsAg purified from a plasma of a highly 
viremic chronic HBV carrier, microtiter plates were coated with filamentous subviral particles 
containing all three HBs proteins. The subviral particles represent a source of natural HBsAg 
particles. The subtype of HBsAg used to determine binding was ayw2, genotype D. Pooled 
sera were precipitated with 36% Na2SO4 and IgG concentration measured at OD280 assuming 
a factor of 1.35 for 1 mg/ml IgG. Sera were tested at 1.5 mg/ml. Binding of IgG to purified 
filamentous HBsAg particles from the plasma of a chronic HBV carrier was not dependent on 
SHBs subtype used for immunization (Fig. 27).  
Probably, conformation-based differences exist in the natural HBsAg particles 
compared to yeast-derived HBsAg particles. Natural HBsAg may contain conformational, 
correctly folded S domain. This can determine the stronger binding capacity of the induced 
mouse antibodies to natural HBsAg particles which is not dependent on HBsAg subtype. It 
may be assumed that correctly folded S domain was also present on the rSFV vector-
expressed SHBs, but not on the yeast-derived SHBs. 
 
Figure 27. Binding of anti-HBs induced 
after rSFV mediated immunization to HBsAg 
ayw2 purified from a plasma of a chronic HBV 
carrier. Microtiter plates were coated with 
subviral HBsAg/ayw2 particles purified from 
plasma of a hronic HBV carrier. IgG obtained 
after immunization of BALB/c mice with the 
indicated rSFV was precipitated from the sera 
with Na2SO4  and added at 1.5 mg/ml. 
 
 
 
 
a) Single factor analysis of variance, One way 
ANOVA   
Subtype of rHBsAg used 
for ELISA 
adw2 ayw3 
Immunization, rSFV- 
 
Group means, n=9 
S/adw2 0.71 0.18 
S/ayw2 0.58 0.75 
EGFP 0.06 0.10 
Difference between at least two means exist 
 
b) Tukey’s multiple comparison method 
 rHBsAg used for ELISA 
 adw2 ayw3 
S/adw2 and EGFP Different Not different 
S/ayw2 and EGFP Different Different 
S/adw2 and S/ayw2 Different Different 
0
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3.3.3. Response to rSFV encoding preS1.1-48/S and preS1.1-48/S0 
BALB/c mice were immunized with with rSFV encoding L protein deletion variants - 
preS1.1-48/S or its variant preS1.1-48/S0. Although the increased level of antigen expression 
in vitro by alphavirus replicons does not always correlate with a superior immunogenicity of 
alphavirus replicon vaccines in vivo (Maruggi et al., 2013), the variant with the unmodified 
myristic acid attachment site was chosen for immunization of BALB/c mice for its superior 
secretion compared to Gly2 mutants. Animals were immunized according to the regimen 
described above, see table 13. 
 
Table 13. Groups of BALB/c mice and their immunization regimen with rSFV encoding 
preS1.1-48/S proteins 
 
 
 
 
 
 
 
Sera were collected three weeks after the second immunization. First, serial dilutions 
of the sera were tested by ELISA on microtiter plates coated with a preS1 peptide spanning aa 
10-36, genotype D numeration (correspond to aa 21-47 in genotype A, which contains extra 
11 aa at N-terminus). Additionally, to determine anti-HBs, microtiter plates were coated with 
rHBsAg ayw2, because in the deleted L proteins SHBs subtype was ayw2 and it was 
demonstrated above that anti-S response should be determined using a rHBsAg of a 
homologous subdeterminant. Along with the sera obtained after immunization with rSFV-
preS1.1-48/S and rSFV-preS1.1-48/S0, sera from rSFV-S/ayw2 mice was tested to compare 
the anti-HBs titers in order to test the notion that presence of preS1 affects anti-S titer. Anti-
preS1 specific responses in rSFV-preS1.1-48/S and rSFV-preS1.1-48/S0 immunized mice 
were detected in all of the immunized animals. The anti-preS1 titers were 1:1500 in preS1.1-
48/S immunized mice and 1:1000 in preS1.1-48/S0 immunized animals. Although mice were 
immunized with an equal number of infectious rSFV, antisera generated to preS1.1-48/S0 
protein contained less anti-preS1 which is in line with its inhibited secretion (Fig. 16B). The 
preS1 fragment did not significantly increased nor impaired the detectable anti-S titers (Fig. 
28). Only 4 of 7 mice immunized with rSFV/preS1.1-48/S showed a detectable anti-S 
response (titer : >100). Mice immunized with the S0 protein variant did not develop detectable 
anti-S titers. Anti-preS1 titer were higher than the anti-S titer in preS1.1-48/S immunized 
mice (Fig. 28). 
 
 
Figure 28. Anti-preS1 (peptide 10-36, 
genotype D numeration) and  anti-S/ayw2 
(rHBsAg) end point titers. 9 mice were 
immunized with rSFV-S/ayw2, 7 mice with 
rSFV-preS1.1-48/S and 7 with rSFV-preS1.1-
48/S0. In rSFV-S/ayw2 group all mice were 
responders. In rSFV-preS1.1-48/S or rSFV-
preS1.1-48/S0 group all mice demonstrated 
specific anti-preS1 titers. Bars represent SD. 
The horizontal line denotes a titer of 1:100 
above which mice were classified as 
responders. 
 
Group rSFV- Immunization 
scheme 
Route of 
immunization 
1 preS1.1-48/S 107 followed by 108 
after three weeks 
i.v. 
2 preS1.1-48/S0 As above As above 
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Antisera to deleted L proteins were subjected to ELISA using HBsAg/ayw2 particles 
purified from plasma of a hronic HBV carrier. Antibodies to the translational start site mutant 
protein preS1.1-48/S0 showed 48.8% less binding to subviral particles than antibodies induced 
to preS1.1-48/S protein (Fig. 29).  
 
 
                                                                                    Figure 29. Binding of anti-preS1.1-48/S 
and anti-preS1.1-48/S0 to subviral HBs 
particles purified from purified from a 
plasma of a chronic HBV carrier. 
Microtiter plates were coated with 
subviral HBsAg/ayw2 particles purified 
from plasma of a hronic HBV carrier. IgG 
obtained after immunization of BALB/c 
mice with the indicated rSFV was 
precipitated from the pooled sera with 
Na2SO4  and added at 1.5 mg/ml. 
  
 
 
3.3.4.Isotyping of IgG antibodies  
The determination of IgG subclasses IgG1 and IgG2a serves as an indirect tool to 
evaluate the activation and involvement of Th cell subsets/subpopulations in the generation of 
the immune response: IgG1 dominance signals that Th2 cells are activated, whereas IgG2a 
dominance indicates activation of Th1 subpopulation. The Th1 subpopulation assists in 
generation of antibody mediated immune response, while the Th2 cells - a CTL response. 
Therefore dominance of IgG2a serves as an indirect test for the involvement of CTLs. For 
isotyping of IgG subclasses of rSFV-S/adw2 and rSFV-S/ayw2 immunized mice sera, pooled 
sera of each group collected 6 weeks after the first immunization were tested using the 
homologous HBsAg subtype which the group was immunized with. Sera obtained from mice 
immunized with the preS1.1-48/S fusion proteins were tested with a synthetic preS1 derived 
peptide 10-36 (genotype D numeration). The ratio of IgG1/IgG2a in all rSFV immunized 
groups was below one and immunization by rSFV vectors induced more prominent IgG2a 
than IgG1 responses, but the degree of IgG2a preponderance over IgG1 differed among the 
immunized groups. IgG2a was most predominant in rSFV-preS1.1-48/S immunized mice 
(IgG1/IgG2a ratio 0.28) whereas mice immunized with rSFV-preS1.1-48/S0 showed the 
lowest proportion of IgG2a (ratio 0.88). The two IgG subclasses were more balanced in the 
other two immunized groups (ratios 0.54 in both, see Fig. 30).  
 
 
Figure 30. Ratio of IgG1/IgG2a 
in sera of rSFV-S/adw2, rSFV-
S/ayw2, rSFV-preS1.1-48/S and 
rSFV-preS1.1-48/So immunized 
BALB/c mice. Microtiter plates 
were coated with rHBsAg adw2 
and ayw3 and with a synthetic 
peptide aa 10-36 (genotype D 
numeration).  
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3.4. HBV neutralizing antibodies 
The Tupaia belangeri used for the isolation of livers were males or females, and 
between less than a year and 6 years of age. 3 days after plating PTH could be infected with 
HBV. To evaluate the HBV infection neutralizing potential of the antibodies induced by rSFV 
immunization, 5.5 x 105 ge HBV were incubated with antisera prior infection of PTH. The 
capacity of the antisera to inhibit HBV infection of PTH was evaluated for all the sera 
obtained after rSFV-mediated immunization: S/adw2, S/ayw2, preS1.1-48/S, preS1.1-48/S0 
and EGFP as a control serum. Serum obtained from mice before immunization was also 
included in the experiments, along with monoclonal antibodies MA18/7 and C20/02. These, 
antibodies inhibit HBV infection of PTH by 100% (Glebe et al., 2003). After incubation, PTH 
cultures were infected with virus/antibody mixtures, and after 18 hours the virus inoculum 
was removed and PTH medium added. The PTH medium was removed at days 3, 6, 10 and 
14. Markers of HBV infection – secreted HBsAg and HBeAg were quantitatively determined 
in the PTH culture medium collected at the above mentioned time points. It must be noted 
that HBsAg in minor quantities is present in virus inoculum, therefore PTH cultures were 
extensively washed after removal of the viral inoculum 18 hours after infection. At day 14 
after infection the experiments were terminated and WST-1 test was performed (see Materials 
and Methods section) in order to assess the cell viability, which exclusively distinguishes 
metabolically intact cells. The HBsAg (ng/ml) and HBeAg (S/CO) accumulated from day 10 
to day 14 after infection was normalized to the OD 450 nm values of the WST-1 test. 
Additionally, after the WST-1 test PTH were extensively washed and lysed, followed by 
separation of nucleic and cytoplasmic fractions for the detection of cccDNA and HBV 
mRNA. The duration of each experiment was 17 days. Figure 31 depicts PTH at various time 
points after isolation. 
The quantity of secreted HBV infection markers HBsAg and HBeAg was directly 
dependent on the quality of the PTH cultures, which was variable between the experiments. 
For example, the quantity of the secreted HBsAg in PTH between the infection experiments 
ranged between 35 ng/ml to 5 ng/ml for the pre-immune serum diluted 10 fold in PTH (10 
fold diluted pre-immune serum mixed with 5.5 x 105 ge HBV), the HBeAg varied from 32 
S/CO and 4 S/CO for the afore mentioned serum. The results depicted below (Fig. 32, 33 and 
34) showing HBsAg and HBe Ag in the PTH medium are from one of five experiments. The 
results depicting the quantification of HBV cccDNA (Fig. 34) and mRNA and (Fig. 35) show 
the results of one of two experiments.  
First, 5.5 x 105 ge HBV were incubated with BALB/c mice sera diluted in PTH 5 fold, 
10 fold, 30 fold and 100 fold. In the first neutralization experiments with the untreated mice 
sera it could be observed that mouse serum exerts HBV infection enhancing effect. We could 
observe that 10 fold diluted untreated BALB/c mice serum at day 10 after infection was able 
to raise HBsAg concentration mored than five fold. 100 fold diluted serum could lead to 3.5 
fold increase of HBsAg concentation (Fig. 32A). These findings were confirmed by 
determining HBeAg in the hepatocyte medium at day 14 after infection (Fig. 32B). Therefore 
IgG were semi-purified from mice sera by precipitation with 36 % Na2SO4  and 0.5 mg/ml, 
1.0 mg/ml and 2.5 mg/ml total IgG from the precipitated sera were incubated with 5.5 x 105 
ge HBV. The enhancing effect on HBV infection was also observed with Na2SO4 precipitated 
mouse sera (Fig. 32C) in a dose dependent manner. Dynamics of HBV infection during 14 
day period reflected that already at day 6 post infection concentration of HBsAg was 
markedly higher in primary hepatocyte medium infected with HBV which was incubated with 
1.0 and 0.2 mg/ml mice sera than in the medium from hepatocytes infected with HBV in the 
presence of PTH medium only (Fig. 32C). Therefore, in the light of these observations, it has 
to be taken into account that in the given experimental model, the component in the BALB/c 
mice sera was present which was able to enhance HBV infection of the primary Tupaia 
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hepatocytes. Thus, to determine HBV infection neutralization capacity of the tested antisera, 
infection in the presence of pre-immune serum or in the presence of EGFP antiserum (in case 
when it exceeded the pre-immune serum) was referred as 100% infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Primary hepatocytes of Tupaia belangeri at various time points after plating on 
MatrigelTM -coated 12-well plates. (Magnification, x 320). 
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Figure 32. Effect of pre-immune 
BALB/c mice serum on the course of 
HBV infection. 5 ge of HBV/hepatocyte 
were incubated with various dilutions of 
BALB/c mice sera in PTH, obtained from 
mice before immunization with rSFV, 
followed by infection of PTH. (A) PTH 
medium was collected on days 3, 6, 10 and 
14 after infection and replaced by fresh PTH 
medium, except day 14 after infection when 
the experiment was terminated. Newly 
synthesised HBsAg in PTH medium was 
detected as described in Methods and   
              Materials section. The HBsAg and HBe Ag 
was below the cut-off for the 
PTH infected with HBV in 
the presence of 0.02 mg/ml 
of monoclonal antibodies 
MA18/7 and C20/02 (shown 
only in B). The numbers (5, 
10, 30, 100) in the legend 
represent “fold” dilutions of 
the mice sera, “HBV 
only”denotes the mean of 
three wells, infected with 
HBV without the presence of 
mice serum, the SD was ± 
0.11 for day 6, ±1.27 for day  
10 and ±3.14 for day 14. (B) HBe Ag,  accumulated from day 10 to day 14 in PTH medium was measured  as 
described in Materials and Methods section. The bar denotes the SD of the three wells. The numbers in the 
legend of (A) and on the x axis of (B) denote the fold dilutions of mice sera in PTH.(C) Pre-immune BALB/c 
mice sera was precipitated with 36% Na2SO4 as described in Materials and Methods section and added at  1.0, 
0.2, 0.1 and 0.02 mg/ml total IgG to 5 ge of HBV/hepatocyte prior infection of PTH. PTH were obtained from a 
male animal, 4 years old (A and B) and from a 6 years old female animal (C).  
                                                                                                                       
 
Antisera obtained with all four rSFV vectors contained well detectable amounts of 
HBV neutralizing antibodies, but the HBV infection inhibition potential differed among the 
four antisera. Antisera obtained with vectors for HBsAg/ayw2 and HBsAg/adw2 neutralized 
completely at 2.5 and 0.5 mg/ml as shown by complete suppression of HBsAg or HBeAg 
secretion (Fig. 34) and HBV mRNA synthesis (Fig. 36). Antiserum to preS1.1-48/S inhibited 
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completely the infection of HBV at 2.5 mg/ml, and the HBsAg and HBe Ag was only 
marginally above the cut-off at 0.5 mg/ml (Fig. 33A, B, Fig. 34). According to quantitative 
determination of HBV mRNA, the afore mentioned antiserum neutralized completely at 1.0 
and 2.5 mg/ml (Fig. 36).  
The absence of the conformational anti-S antibodies in the serum generated after 
immunization with preS1.1-48/S0 lead to the weakest HBV infection inhibition capacity at 0.5 
mg/ml (Fig. 33A, Fig. 34). The difference in neutralization capacity between antibodies 
induced to two variants of the preS1.1-48/S fusion protein could be diminished if antibodies 
to preS1.1-48/S0 were incubated in 5 fold higher concentration (2.5 mg/ml) with HBV, the 
inhibitory capacity being completely neutralizing and comparable to antibodies generated to 
preS1.1-48/S protein (Fig. 32B, Fig. 34B). This result suggests that the anti-preS1 antibodies 
alone mediated the neutralization if present in sufficient concentration since the antisera did 
not contain anti-S antibodies (Fig. 26).  
Surprisingly, antibodies generated to S/adw2 neutralized infectivity of HBV of 
genotype D, subtype ayw2, with an equal efficiency as the antibodies to S/ayw2. This is in 
line with the ELISA data of Figure 25 obtained with natural HBsAg particles but in 
contradiction with the ELISA data obtained with yeast-derived HBsAg (Fig. 26A). Inclusion 
of the preS1 region directly responsible for the binding of HBV to hepatocytes did not favour 
more potent infection neutralization capacity of the generated antibodies. 
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Figure 33. HBsAg detected in PTH medium. 5 ge of HBV/hepatocyte were incubated with 0.5 
mg/ml (A) and 2.5 mg/ml (B) total IgG from the Na2SO4 precipitated sera, with PTH only (HBV), or 
0.02 mg/ml of monoclonal antibodies MA18/7 or C20/02 followed by infection of PTH cultures. PTH 
medium was collected at indicated days post infection and HBsAg was measured by ELISA as 
described in Methods and Materials section. HBsAg was measured also in the inoculum, which was 
removed from PTH 18 hours after infection.  
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Figure 34. Markers of HBV infection in PTH cultures after inoculation with virus/antibody 
mixtures. Results are represented as percentage of the control infection with HBV in the presence of 
0.5 mg/ml pre-immune serum. HBsAg (A) and HBe Ag (B) accumulated from day 10 to day 14 after 
infection in the medium of PTH cultures were measured by ELISA. HBV (5 ge/hepatocyte) was 
incubated with 0.5 mg/ml (light bars) and 2.5 mg/ml (dark bars) total IgG from the Na2SO4 
precipitated sera before infection, or with PTH only (HBV), or 0.02 mg/ml of monoclonal antibodies 
MA18/7 or C20/02. The horizontal dashed line denotes cut-off, which was 0.7 ng/ml for HBsAg and 1 
S/CO (signal/cut-off ratio) for HBeAg. The PTH were isolated from male Tupaia belangeri, less than 
a year old.  
 
Upon infection of hepatocytes, including primary Tupaia belangeri hepatocytes, ccc 
DNA is formed in infected hepatocytes from the relaxed circular DNA which is a sign of 
infection and start of the HBV replication cycle. It is the earliest marker of HBV infection. 
The discrimination of relaxed circular DNA and ccc DNA depends on the use of a special 
temperature protocol with very rapid temperature changes in the quartz capillaries (Glebe et 
al., 2003). Only the cloned dimeric HBV DNA samples within the plasmid (log 2 – log 7) 
could be quantified in the experimental conditions described. Purified HBV from human 
plasma (2 x 105 ge) served as a serum standard and, as expected, was negative (Fig. 35A), 
since the virion DNA is relaxed circular with a nick-and-gap. In the experimental setting 
described where viral DNA had been extracted from PTH initially infected with 5 HBV ge per 
one hepatocyte the detection limit for the quantification of cccDNA could not be reached. 
Glebe et al. (Glebe et al., 2003) have described detection of cccDNA from PTH infected with 
10 ge/hepatocyte, but not with 1 ge/hepatocyte. It was demonstrated by the negative signals 
obtained from viral DNA extracted from PTH infected with HBV in the presence of PTH 
medium only. The infection of PTH hepatocytes with HBV in the presence of pre-immune 
serum, which showed and HBV infection enhancing effect also failed to reach the detection 
limit necessary for cccDNA quantification. 
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Figure 35. 2% agarose gel electrophoresis of real-time PCR reaction mixes after amplification 
and quantification of ccc DNA in Tupaia belangeri primary hepatocytes infected with HBV, 
which was preincubated with the antisera. 734 bp amlplificate could be detected only in HBV 
plasmid samples, indicated by a triangle in panel A. The viral DNA isolated from 105  PTH initially 
infected with  5 x 105 ge HBV and amplified as described in Materials and Methods section  was too 
low to be detectable by real-time PCR in the above described experimental conditions. Agarose gel 
electrophoresis confirms only presence of HBV plasmid standart pBs HB 991 T7 Dimer (107 – 102 
copies), (see panel A). Panel B – only samples obtained from 105 PTH infected with 5 x 105 HBV ge 
in the presence of preS1.1-48/S0, EGFP and pre-immune serum are shown. Next three lanes (5 x105 
HBV) represent PTH infected with HBV in the presence of PTH medium, MA 18/7, C20/02 - PTH 
infected with with 5 x 105 ge HBV, but in the presence of HBV infection inhibiting MAbs MA18/7 
(anti-preS1) and C20/02 (anti-S). 735 bp amplificate could also not be detected from PTH infected 
with 250 µg IgG from precipitated sera and 1:10 diluted sera during the incubation step of HBV with 
the antisera (not shown).  
 
With 5 ge/cell HBV mRNA was detectable in HBV-infected PTH 14 days after 
infection. 1 ge/hepatocyte is enough to detect mRNA in cytoplasmic extracts of PTH 12 days 
p.i. (Glebe et al., 2003). The detection limit of HBV mRNA real-time PCR is 104 copies per 
105 cells. For quantification of HBV mRNA 5 ge/hepatocyte were incubated with antisera 
diluted 1:10 with PTH, as well as with 1.0 mg/ml and 2.5 mg/ml of IgG from the Na2SO4 
precipitated sera. HBV was incubated with PTH only, and additionally with 0.02 mg/ml 
MAbs MA/187 and C20/02. The results of the HBV mRNA quantification are shown in 
Figure 26 A and B. The mRNA analysis shows that the four anti-rSFV sera encoding HBV 
surface proteins were completely HBV infection neutralizing, when applied in dilution 1:10. 
The mRNA isolated from PTH infected with HBV incubated in the presence of anti-
rSFV/EGFP sera showed the highest number of HBV mRNA copies in the cell cytoplasm.  
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Figure 36. Quantification of HBV mRNA by real-time RT-PCR from cytoplasmic fractions of 
PTH 14 days after infection. 5 ge of HBV per hepatocyte before infection were incubated with sera 
diluted 10 fold with PTH (A), and with 1.0 mg/ml (light bars) and 2.5 mg/ml (dark bars) of IgG from 
the Na2SO4 precipitated sera (B), with PTH only (HBV) and with 0.02 mg/ml monoclonal antibodies 
MA/187 and C20/02. No bar means that the mRNA was below the detection level of 104 copies per 
105 cells or 1% of the anti-rSFV-EGFP value for A and 1.5% for B. The PTH were isolated from male 
Tupaia belangeri, less than a year old.  
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4. DISCUSSION 
 
The aim of the study was the generation of constructs based on the vector derived 
from SFV for immunization against HBV which would present broadly neutralising epitopes 
of SHBs and LHBs with the background of strong innate immune reactions provoked by the 
vector.  
The SFV1 vectors encoding two subtypes of SHBs were selected for immunization 
along with vectors coding for two variants of deleted L proteins. Antibodies to HBsAg 
subtypes adw2 or ayw2, and to deleted L proteins with wt myristic acid attachment site have 
been generated via two i.v. injections of rSFV to inbred mouse strain BALB/c. The 
neutralizing potential in an in vitro HBV infection model using primary Tupaia belangeri 
hepatocytes was investigated.  
Antibodies formed after vaccination with the currently available HBV vaccine 
(MacAleer 1984) consisting of recombinant SHBs produced in yeast are completely infection 
neutralizing and protective. Moreover, monoclonal, conformation dependent anti-HBs 
antibodies can neutralize HBV infection with an equal efficiency as monoclonal antibodies 
recognizing preS1 aa 20-23 in vitro (Glebe et al., 2003). But, interestingly, subviral particles 
consisting of only SHBs do not bind to primary Tupaia belangeri hepatocytes, while particles 
with added 48 N-terminal aa of preS1 exhibited efficient binding (Glebe et al., 2005). 
There are numerous reasons for improvement of the current HBV vaccine. One of the 
problems is that HBsAg is highly variable under immune selection and the inclusion of the 
HBV infection neutralizing preS1 epitope is of major significance because the current vaccine 
cannot provide protection to escape mutants with the exchanges in the antigenic loop (Grethe 
et al., 2000). Indeed, widespread HBV vaccination is one of the major driving forces for 
selection and propagation of immune-escape mutants. Appearance of HBV mutants with 
exchanges in the SHBs antigenic loop has been frequently reported from areas of high 
endemicity with high coverage of immunization programs (Lazarevic, 2014).  
One of the crucial drawbacks is the non-respnse and/or poor anti-HBs response to the 
vaccine - anti-HBs levels of 5-10% of the vaccinated individuals (Alper, 1995) do not exceed 
the borderline of sufficient immunoprotective level of anti-HBs which is generally considered 
as 10 mIU/ml. The occurrence of non-response or poor response is even more pronounced in 
elderly people (Wolters et al., 2003), where it can reach up to 60% (W.H.Gerlich, personal 
communication) and immunosuppressed, for example HIV infected individuals (Wolters et 
al., 2009; Landrum et al., 2010). Other concerns associated with the vaccine are vaccine 
breakthrough infections which are continually observed despite successful implementation of 
HBV vaccination programmes (Stramer et al., 2011). Appearance of S gene mutants has been 
detected in breakthrough infections in vaccinated individuals (Chang, 2010). Breakthrough 
HBV infections of non-vaccine genotype have been also documented (Abushady et al. 2011; 
Seed et al. 2012). Escape mutants with aa exchanges in the antigenic loop of SHBs which 
may evade anti-HBs mediated protection establish ground for addition of preS1 epitopes. 
Studies in highly endemic regions of South-East Asia showed that breakthrough infections 
may occur in the second decade after vaccination which had been performed in infancy, with 
incidence of occult infections (Poovorawan et al., 2011;Su et al., 2012). This shows waning 
HBV immunity over time. In the light of newly discovered zoonotic reservoir of HBV-like 
virus in tent-making bats which is able to infect human hepatocytes via HBs protein-mediated 
infection and cannot be neutralized by sera from vaccinated humans (Drexler et al., 2013), 
search for improvements of the current HBV vaccine appear even more significant and 
relevant. 
PreS containing vaccines, expressed in mammalian cells, have already been 
successfully used as vaccines in humans (Shapira et al., 2001; Bertino, Jr. et al., 1997), 
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(Shouval et al., 1994; Zuckerman et al., 2001;Hellstrom et al., 2009). It is not known whether 
their superior anti-HBs induction is due to the inclusion of preS or the better folding of the 
conformational S epitopes by mammalian cells.  
Numerous studies have been carried out towards an improved HBV vaccine so far. 
Various immunization platforms or carriers for delivery of HBs proteins have been employed 
in small animal models. The vaccination platforms may be distinguished as those enabling  
“direct” delivery to experimental animals of purified HBs proteins. The other group is the 
vaccine vehicles allowing for intracellular or endogenous expression mimicking a “natural” 
infection and processing of HBs proteins in the experimental animal. HBs proteins have been 
delivered solely as SHBs particles, and with preS2 and preS1 domains. PreS2 and preS1 
containing HBsAg has been expressed in Chinese hamster ovary  cells as an alternative HBV 
vaccine and delivered to human recipients (Shapira et al., 2001). Immunization of 
experimental animals with HBsAg has often been carried out together with oligonucleotides 
containing immunostimulatory CpG motifs as adjuvants (Weeratna et al., 2003; Malanchere-
Bres et al., 2001; Siegrist et al., 2004). Vesicular carriers, like liposomes and ethosomes, have 
attracted attention as vehicles for delivery of antigens, including also HBsAg (Mishra et al., 
2008). HBsAg has been efficiently encapsulated into nanoparticles based on polymers of 
polylactic acid and PEG (Jain et al., 2009) and delivered to experimental animals by s.c. and 
oral routes. HBs Ag can also be encapsulated by lectin-linked polylactic-co-glycolic acid 
nanoparticles specifically targeted for oral administration (Mishra et al., 2011). Importantly, 
HBsAg loaded liposomes and ethosomes can be efficiently taken up by human dendritic cells 
(Mishra et al., 2010).  
Virus-like particle carriers play a prominent role as non-infectious vaccine carriers and 
gene therapy tools of particulate nature. They are virus-protein derived multimeric structures 
that lack the virus genome. Among the VLPs, which have been developed from more than 30 
viruses (Roldao et al., 2010). Among them HBc protein has evolved as a promising carrier of 
immunological epitopes (Pumpens and Grens, 2001). For example, preS1 aa 13-59 linked to 
90-119 (genotype A numeration) have been inserted into the major immunodominant region 
of HBc protein (Skrastina et al., 2008). Due to ability to incorporate foreign epitopes without 
hindering the self-assembly ability SHBs itself has served as a vaccine carrier of foreign 
epitopes (Vietheer et al., 2007; Netter et al., 2001; Pumpens et al., 2002b).  
Genetic immunization has evolved rapidly since the first studies in 1990’s and 
involves delivery of antigen coding gene as plasmid DNA or mRNA for expression and 
processing of the antigen in the experimental animal. Several studies describe immunization 
with plasmid DNA encoding SHBs (Davis et al., 1994; Michel et al., 1995). DNA may be 
delivered naked or encapsulated into liposomes. Intranasal delivery of plasmid DNA encoding 
HBsAg encapsulated into glycol chitosan coated liposomes (Khatri et al., 2008) resulted in 
systemic and mucosal humoral specific immune response. While studies in small animals 
have been promising, the experiments with chimpanzees have not been satisfactory (Payette et 
al., 2006). Although, there are clear benefits of the approach, like ease of production, ability 
to prime both CD8+ and CD4+ cells, a potential risk of integration into host cell genome exists 
(Nichols et al., 1995). Alternatively, use of whole bacteriophage lambda particles containing 
expression cassette of a DNA vaccine has been reported (March et al., 2004). HBsAg has 
been successfully expressed in transgenic plants and delivered to human recipients as an 
edible HBV vaccine (Thanavala et al., 2005; Guan et al., 2010), but has delivered 
disappointing results with 40% of the volunteers being nonresponders (Thanavala et al., 
2005). 
Viruses are excellent stimulators of immune system due to a number of features. 
Vaccines based on attenuated viruses have proven to be extremely successful (Röhn and 
Bachmann, 2008 ). Therefore viral vectors have evolved as potential delivery tools of antigens 
or immunodominant epitopes. The immunogenicity of live recombinant human adenoviruses  
Ad4 and Ad7 encoding HBsAg in a chimpanzee model has been tested (Lubeck et al., 1989), 
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unfortunately the use of recombinant adenoviruses is accompanied by significant humoral 
response to the adenovirus (Lubeck et al., 1989) and very often a strong acute inflammatory 
response (Bangari and Mittal, 2006). Immunogenicity of adenovirus vector encoded antigens 
is significantly impaired by adenovirus protein specific T-cell immunity (Schirmbeck et al., 
2008). Application of Ad5 in human recipients is hindered by the widespread immunity in 
population (Seregin and Amalfitano, 2009). Modified vaccinia virus Ankara (MVA) vectors, 
based on a highly attenuated strain of vaccinia virus encoding MHBs (Hutchings et al., 2005; 
Wu et al., 2007) induced a vigorous T cell response, but a negligible anti-HBs titer when used 
as a “booster” immunization after priming BALB/c mice with a DNA vaccine. By 
simultaneous intradermal administration of rHBsAg (5 µg/mouse) and MVA (5 x 106 
pfu/animal), and boosting animals with the same combination, anti-HBs titer was increased 
about 6-fold compared to rHBsAg alone. Cell mediated response as measured by IFN-γ 
secreting cells from spleen and distal lymph nodes was considerable , while rHBs Ag alone 
administered as a vaccine formulation resulted in a negligible number of IFN-γ secreting cells 
after specific stimulation with a peptide. Importantly, as shown by co-administration of 
rHBsAg and non-recombinant, “empty” MVA, the enhanced CD8+ responses were due to 
intracellular production of the antigen. Thus, the co-administered recombinant MVA 
encoding the M protein of HBV can exert a potent  adjuvant effect on the co-administered 
HBsAg (Hutchings et al., 2005). A single intramuscular injection of 107 integrating and non-
integrating lentivirus particles vectors encoding HBsAg resulted in an elevated humoral 
response compared to a DNA injection (Karwacz et al., 2009). The antibody response 
remained stable up to 8 weeks after injection, but decreased in mice immunized with the 
plasmid DNA. 
It has long been recognized that for efficient induction of robust immune response of 
both arms of the immune system other factors than a presence of antigen encoding sequences 
is required. Although, plasmid DNA contains immunostimulatory motifs like unmethylated 
CpG dinucleotides (Klinman et al., 1997), additional adjuvant signals are necessary to mimick 
a “natural” infection. In concert with the search for novel vaccine strategies employing the 
adjuvant signals, a study with the aim to generate a live attenuated vaccine described an 
attenuated strain of Mycobacterium smegmatis which is transformed with the genes for fusion 
protein consisting of a truncated core protein and preS1 peptide aa 1-55. The study found that 
after vaccination with live recombinant M. smegmatis a stronger cellular immune response 
was induced accompanied by a longer duration of humoral immune response compared to the 
DNA vaccination (Yue et al., 2007). Attempts have been made to enhance the 
immunogenicity of DNA vaccines by co-transfection of interferon regulatory factors (Sasaki 
et al., 2002) to resemble a virus infection. 
rSFV vectors deliver potent adjuvant signals to the immune system – induction of type 
I interferons (Hidmark et al., 2005) and induction of apoptosis. rSFV replicons generate 
robust and protective immune responses to important human viral pathogens in various 
animal models including mice, rabbits and rhesus macaques (Ljungberg and Liljeström, 
2015). In addition, alphavirus replicons have been used as vaccine platforms to extremely 
pathogenic viruses, like Ebola, Lassa and Marburg virus (Hevey et al., 1998; Pushko et al., 
2001; Hevey et al., 2001). Immunization with recombinant alphavirus replicons has been 
addressed primarily to viral targets, although there are several studies describing use of 
alphavirus vectors for bacterial targets. SIN replicon has been used in a study contributing to 
research in the improvement of vaccines to Mycobacterium tuberculosis. C57BL/6 mice were 
injected twice with an interval of two weeks subcutaneously with SIN replicon plasmid 
encoding antigen 85A. 28 days after the last injection mice were challenged with M. 
tuberculosis. An enhanced long-term protection against M. tuberculosis was achieved 
compared to the conventional DNA vector. Sindbis replicon-based plasmid was highly 
immunogenic at much lower doses than the conventional DNA plasmid: doses from 2 to 5 µg 
the IFN-γ production equaled to that of the conventional DNA plasmid at 100 µg. Attempts 
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have been undertaken to develop alphavirus vector-based malaria vaccine. However, a study 
by Andersson C. (Andersson et al., 2001) showed that the conventional DNA plasmid elicited 
a higher antibody response than SFV RNA or rSFV encoding part of Plasmodium falciparum 
antigen Pf332. On the other hand, use of replication-competent recombinant SIN expressing a 
CD8+ T-cell epitope of the circumsporozoite protein of Plasmodium yoelii showed that the 
CD8+ response achieved in this study exceeded that of studies using recombinant vaccinia, 
influenza, and adenovirus vectors (Murata et al., 1996; Tsuji et al., 1998). The expressed 
SHBs and preS1.1-48/S proteins by SFV1 vectors did not interfere with the packaging and 
release of the recombinant SFV particles, and rSFV could be recovered in sufficient titers. It 
has been described that Rift Valley fever virus glycoprotein strongly intervened with the 
packaging and release of the recombinant VEE (Gorchakov et al., 2007). The titers of 
recombinant SFV encoding HBV surface proteins were up to 109 infectious units/ml, while 
titers of replication proficient VEE virions, reach 107- 108 and in some cases 1010 plaque 
forming units/ml (Gorchakov et al., 2007). 
The intracellular distribution of the SHBs expressed by rSFV was diffuse (Fig 15). Chua 
et al. showed a granular staining pattern of SHBs in transfected Huh-7 cells (Chua et al., 
2005). In contrast, Patient et al. (Patient et al., 2007) demonstrated a compact, perinuclear 
localization of SHBs, colocalization with an ER marker, and ERGIC53, a specific ERGIC 
marker. We observed an efficient secretion of SHBs by SFV1-S/adw2 infected BHK-21 (Fig. 
14) and Huh-7 cells (not shown), while Patient et al. report limited secretion of SHBs after 
BHK-21 cell electroporation with SFV1 encoding SHBs, compared to HBsAg signal provided 
by the MHBs protein transfected cells (Patient et al., 2007). In this study MHBs showed a 
diffuse distribution within the cell. The authors attribute the limited secretion of SHBs to the 
cytotoxicity of SFV1 expression system that prevents culture longer than 24 hours after 
transfection, fast protein synthesis and accumulation of SHBs in the early compartments of 
the secretory pathway. Patient et al. (Patient et al., 2007) used electroporation with 
recombinant RNA, whereas in the study described here infection with rSFV was employed. 
We noted that electroporation with recombinant SFV RNA is more cytotoxic to transfected 
cells compared to infection with rSFV particles.  
 We observed internal translation initiation at the next translational start codon at the 
beginning of SHBs coding sequence, as shown by expression of the characteristic doublet of 
glycosylated and non-glycosylated SHBs in Huh7 cells infected with rSFV-preS1.1-48/S 
proteins and detection by specific antibodies (Fig. 16). Patient et al. could show internal 
initiation of SHBs and its secretion by MHBs expressing SFV1 vector . 
The expression of preS1.1-48/S protein in vitro unexpectedly revealed presence of three  
N-glycans. While the partial glycosylation at Asn146 of S was expected, the glycosylation at 
Asn4 of preS1 was unexpected. In natural LHBs the entire preS is not translocated to the ER 
and not N- glycosylated (Bruss et al., 1994). In contrast, an artificially added signal sequence 
at the N-terminus of L protein enables the translocation of preS1 to the ER lumen where 
glycosylation at Asn4 takes place (Bruss and Vieluf, 1995). The preS1.1-48/S proteins 
resemble M protein, where the 55 aa preS2 sequence of M can be cotranslationally 
translocated to the ER lumen under the control of signal I in S (Eble et al., 1987; Eble et al., 
1990), and is glycosylated at Asn4. Apparently, this signal can also translocate the shortened 
preS1 sequence of the preS1.1-48/S proteins. The preS1 sequence of wildtype LHBs bears a 
Met-Gly-myristoylation motif and is modified by N-myristoyl transferase by addition of 
myristic acid (Persing et al., 1987). Likewise, Prange et al. reported secretion and 
glycosylation at the Asn 4 of a protein consisting of the first 41 aa of preS1 (subtype ayw) 
joined N-terminally to the S protein (Prange et al., 1995), but with already substituted N-
terminal Gly with Ala to prevent myristoylation, which is implicated in retention of the L 
protein (Prange et al., 1991). Chai et al., however, did not detect glycosylation at the Asn4 
(Asn 15 in subtype adw2, genotype A, used in the study) in the chimeric preS1 proteins 
consisting of aa 1-59 and 1-30 of preS1 fused to Fc domain of a rabbit immunoglobulin G 
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(Chai et al., 2007). Moreover, the chimeric preS1 proteins are efficiently secreted by 
unconventional pathway, which by-passed ER and glycosylation. Our data obtained with 
preS1.1-48/S0 mutant suggest that the linkage of preS1.1-48 to S suppresses this 
unconventional pathway and leads, in contrast, to inhibition of the S domain-mediated 
secretion. Importantly, Chai et al. report myristoylation at preS1. Thus, it appears that 
myristoylation and glycosylation of preS1 at Asn4 in these constructs is mutually exclusive 
(Chai et al., 2007). This is noteworthy in light of the results demonstrated here, which showed 
that all preS1.1-48/S proteins are glycosylated at Asn4. Although, myristoylation directly was 
not shown, the intracellular distribution of the preS1.1-48/S bearing N-terminal Gly showed 
clear difference to Gly2Ala and Gly2Ser mutants. The glycosylation pattern shown in Fig. 4 
suggests that the glycosylation site at Asn3 of S in the preS1.1-48 protein with or without 
SHBs start codon is partially occupied. Possibly, the 7 aa-spacer between preS1 and SHBs has 
increased accessibility of this site for the N-glycan transferase. 
It appears that there are two determinants affecting the intracellular distribution of the 
preS1.1-48./S proteins – the myristoylation motif at the N-terminus and the presence of the in-
frame expressed SHBs. These two determinants also affect the release of the subviral 
particles. The change of Gly in the myristoylation motif to Ala ensures myristoylation block 
(Towler et al., 1988). The presence of the myristoylation motif at the N-terminus of the 
preS1.1-48/S protein seems to facilitate release of subviral particles, because the secreted 
Ser2.preS1.1-48/S protein was not released so efficiently from the cells as the wt protein (Fig. 
18B) with the myristoylation motif, although was efficiency of expression was equal of both 
wt and Gly2Ser mutant BHK-21 (not shown) and Huh-7 cells (Fig. 18A). These results are in 
line with the published studies that myristoylation is necessary for VLP formation by several 
viruses. Myristoylation is formation by Moloney murine leukemia virus (Rein et al., 1986) 
formation and release of VLPs of Arenavirus Z protein (Strecker et al., 2006), and significant 
for virus particle assembly of poliovirus (Marc et al., 1991). N-terminal myristic acid serves 
as a membrane anchor for a number of proteins and confines affinity to membrane bilayers 
(Resh, 1999). With the present evidence it is not known whether absence of the 
myristoylation motif interferes to a more extent with subviral particle formation or with 
release. For the Gly2Ser mutant the preS1 signal was in a similar level as for the wt protein, 
while for the Gly2Ala mutant there preS1 signal was considerably less (Fig. 18A). But, both 
mutants displayed reduced release of subviral particles compared to wt protein. Whether the 
N-terminal myristic acid facilitates the passage of subviral particles from the site of their 
formation to ERGIC, Golgi, constitutive secretory pathway or at the final stage of budding of 
subviral particles at the plasma membrane, must be investigated. 
Of the two determinants affecting secretion of subviral preS1.1-48./S particles, the 
presence of in-frame expressed SHBs is essential and was shown to rescue the secretion of 
prS1.1-48/S, possibly the presence of internally translated SHBs facilitates the trafficking of 
preS1.1-48/S subviral particles. Presence of the myristoylation motif plays a secondary role, 
and the myristic acid possibly facilatites the interaction with the cellular membranes at the 
sites of subviral particle fomation. Importantly, myristoylation is not necessary for formation 
of complete HBV virions (Gripon et al., 1995), but myristil anchor is necessary for HBV 
infectivity. Transfer of myristic acid attachment site to MHBs lead to loss of infectivity of 
hepatitis D virus (Abou-Jaoude et al., 2007). 
Another factor which can possibly affect the secretion of preS1.1-48/S proteins are the 
presence of N-glycans. N-glycosylation is necessary for the release of virions (Mehta A. 
1997). Glycosylation did not affect secretion of preS1.1-48/S, because preS1.1-48/S0, which 
was completely retained, was glycosylated identically to the wt protein (Fig. 17). MHBs, 
which largely resembles the preS1.1-48/S, and is glycosylated at the Asn4 in the preS2, 
requires the glycan at Asn 4 for efficient secretion, while glycan at the S domain is not 
necessary (Werr and Prange, 1998). However, the release of preS1.1-48/S was completely 
blocked by abolishing internal translation initiation of S, while it does not block the secretion 
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of M protein (Werr and Prange, 1998). Since it is known that the glycan at the S domain is 
dispensible for release of subviral particles, the effect of the two glycans of the preS1.1-48./S 
protein on secretion in the presence of internally translated SHBs is a subject of future studies. 
It appears that the preS1 stretch is sufficient for translocation, but does not govern release, 
which requires internally translated SHBs. N-glycan at Asn-4 in the preS2 domain mediates 
binding of MHBs with ER chaperone calnexin, it is known that calnexin assists formation of 
HBV viral envelope. Therefore, role of the N-glycan at Asn-4 in the preS1.1-48/S protein 
must be investigated. Interestingly, Lambert et al. could identify two additional forms of L 
protein of about 48 kDa and 51 kDa by analyzing microsomal fractions obtained from 
transfected Cos-7, Hek 293T and Huh-7 cells. Digestion with PNGase F and Endo H confirms 
that the isoforms have resulted from N-glycosylation of Asn 4 and Asn112. The authors 
propose unconventional posttranslational N-glycosylation, which is segregated from protein 
synthesis (Lambert and Prange, 2007). 
Although alphavirus vector system enables three ways of replicon delivery both in 
vitro and in vivo, we chose rSFV for delivery of HBs encoding genes, since studies have 
indicated the superiority of injection of rSFV in inducing immune responses and protecting 
mice from lethal challenge over injection of naked SFV RNA or rSFV replicon plasmids 
(Fleeton et al., 2000; Brand et al., 1998). Delivery via rSFV to mice ensures relatively short 
time of antigen persistence and exposure in the lymph nodes and spleen - 1 day and 16 h 
respectively (Morris-Downes et al., 2001). The disappearance of HBsAg in mice sera 72 h 
after systemic delivery is in conjunction with the published data. Assuming that presence of 
circulating HBsAg indicate SFV replicon driven synthesis of HBsAg in vivo, which can be 
detected in the bloodstream, our findings can be put in line with Colmenero et al. (Colmenero 
et al., 2001) who detected the presence of abundant vector RNA at day 1 post immunization 
which decreased by day 3 in spleen, local lymph nodes and brain, being almost undetectable 
by day 6. Significant levels of HBsAg up to 3 ng/ml are detected in murine sera after 
immunization with 100 µg of plasmid DNA immunization encoding S protein, but the amount 
of injected nucleic acid (Davis et al., 1993; Geissler et al., 1997) exceeded the amount of 
nonreplicating vector RNA in the study described here by a factor of ca. 100,000. The 
relatively short time of persistence of HBV surface proteins in BALB/c mice was sufficient to 
induce neutralizing HBV neutralizing antibodies. The desirable length of antigen exposure is 
dependent on the aim of the study. For an effective CD8+ response longer persistence of 
antigen would be favourable (Rohn and Bachmann, 2008).  
Virus particles injected into the bloodstream are susceptible to inactivation by 
complement proteins, uptake by the reticuloendothelial system, and neutralization by 
circulating antibodies (Power et al., 2007). The second dose of rSFV was higher in order to 
circumvent the eventual humoral immunity to SFV which might have evolved after the first 
injection of rSFV.  Although rSFV are not replicating, response to structural proteins and 
replicase is acknowledged, but development of immune responses directed against the vector 
itself do not inhibit generation of immune response after subsequent immunization (Berglund 
et al., 1999). The anti-SFV response of BALB/c mice after administration of rSFV was not 
determined in this study. Generally, rSFV is successfully used in repeated administrations, 
while repeated administration is not possible for adenovirus derived viral vectors, because of 
the evolved potent immunity after the first administration prevents repeated administrations. 
Another hurdle for adenovirus  is the pre-existing immunity (Worgall et al., 1997; Tsai et al., 
2004), while pre-existing immunity to vaccinia virus can lower the magnitude of immune 
response in case of recombinant modified vaccinia Ankara (Gudmundsdotter et al., 2009). 
Several techniques have been described so far to conceal the virus vector from the circulating 
neutralizing antibodies (Power et al., 2007). Use of carrier cells as delivery platforms to 
deliver oncolytic VSV to the dessiminated tumor sites is reported. Other reported strategies to 
encapsulate viruses are coating with polymers (Fisher et al., 2001), complexing with 
polyethylene glycol and cationic lipids (Chillon et al., 1998). Encapsulation of SFV replicon 
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particles coding for IL-12 in cationic liposomes has been taken to phase II clinical trials (Ren 
et al., 2003) in adult patients with glioblastoma multiform, an incurable brain tumor. 
BALB/c mice are considered good responders to SHBs, but Geissler et al. (Geissler et 
al., 1997) report that anti-HBs titer was 1.5 – 2 fold higher in C57BL/6 (H-2b) mice than in 
BALB/c (H-2b) mice. As expected, anti-HBs titers after two immunizations with rSFV could 
not reach the magnitude of anti-HBs titers which are generated by immunization of mice with 
plasmid DNA encoding SHBs. Reported titers after plasmid DNA based immunization are 
variable and not well standardised. Michel et al. (Michel et al., 1995) report anti-HBs titer 
more than 1:10,000 6 weeks after immunization of C57BL/6 mice with SHBs encoding CMV 
based plasmid. Wu et al reported that 6 weeks after initial immunization the the anti-HBsAg 
titer achieved by two injections of plasmid DNA (50 µg in each T.A. muscle) was 1:100, 
while the titer generated by initial immunization of recombinant vaccinia virus vaccine 
followed by two booster immunizations at weeks 2 and 5, was 1:1000 and could be 
comparable with the titer when mice were boosted with DNA after priming with the 
recombinant vaccinia vaccine (Wu et al., 2007). Weeratna R. et al. show that (Weeratna et al., 
2000a) 6 weeks after immunization with 10 µg DNA plasmid encoding HBsAg/ay, a titer of 
1:500 between 1:1000 could be achieved, addition of immunostimulatory motifs did not 
significantly increase the anti-HBs titer. The anti-HBs titer could be significantly increased 
with DNA prime-protein boost (1 µg HBsAg) strategy (Weeratna et al., 2000a). Immunization 
three times at two week intervals with 50 µg recombinant HBs resulted in anti-HBs response 
of up to to 1:10,000 (Skrastina et al., 2008). Single intramuscular immunization of CB6F1 
mice with recombinant VSV encoding preS2 resulted in anti-HBs of up to 1000 IU/L 
(Cobleigh et al., 2010). In our study the end point titers of anti-HBs against S protein with the 
same subtype were between 1:200 and 1:1800 (Fig. 26B), the quantitative determination of 
anti-HBs in rSFV-adw2 immunized mice resulted in 1150 IU/L anti-HBs. The lower 
magnitude of the preS1 specific response generated by rSFV encoding preS1.1-48/S0 may be 
linked to non-secretability of the protein. Geissler et al. reported also that nonsecreted LHBs 
was less immunogenic than a secreted version of HBsAg (Geissler et al., 1999). The 
comparatively low dose of the HBsAg deliverd by rSFV and the short life span of the 
transduced cells must be taken into account, therefore immunogenicity appears to be good in 
our system. However, induction of the anti-HBs and anti-preS1 titers seems to require higher 
doses of rSFV particles than reported for other viral antigens (Berglund et al., 1999; Fleeton 
et al., 2000).  
rSFV system could be exploited to increase the magnitude of the humoral anti-HBs 
response after rSFV mediated delivery of HBs coding sequences. SFVC vector contains the 
translational enancer element which consists of the first 103 nt of SFV subgenomic RNA 
capsid–coding region (Sjoberg et al., 1994). It is placed downstream of the subgenomic 
promoter, upstream of foreign antigens. The vector provides higher expression level of 
foreign antigens. However, there is a view that the translational enhancer element derived 
from the SFV C coding sequence is not desirable for rSFV vectors intended for application in 
vivo due to possibly undesirable immune response to virus structural proteins. Nevertheless, a 
study by Forsell et al. describes insertion of internal signal sequence, derived from the SFV 
E1 spike protein, for increased expression and secretion of solube antigens between the 
enhancer element and the gp120 of HIV-1 and administration of 1 x107 rSFV s.c. at 3 week 
interval to mice. The authors observed considerable increase in ELISA end-point titres, 
compared to the parental vector without the enhancer element and internal signal sequence. 
Markedly higher levels of gp120 were synthesized in case of the enhanced rSFV vectors, 
which subsequently produced 1-3 logs higher humoral response, additionally 90-100% of 
immunized animals had responded, compared to 14-17% respondees immunized with the 
parental vector (Forsell et al., 2007).  
Humoral response to HBs proteins was determined 3 weeks after the second injection 
with rSFV, therefore it is not possible to evaluate kinetics of antibody production and 
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sustainability of the induced anti-HBs response over longer period of time. Detection of 
specific IgGs indicate a class switch from IgM. The anti-S antibodies generated via rSFV 
mediated immunization exhibited a strong subdeterminant preference in ELISAs employing 
yeast-expressed HBsAg (Fig. 26A, B). Davis and others (Davis et al., 1995) also showed 
higher anti-HBs titers after DNA immunisation when using the homologous HBsAg subtype 
for assessment of anti-HBs response. Such differences between the HBsAg subtypes were not 
observed in this study when human plasma-derived HBsAg was used for ELISA of the rSFV 
induced anti-HBs. Although the generated anti-HBs/adw2 antibodies in this study showed 
preference to recombinant adw2, they neutralized the binding of HBV/ayw2 to primary 
Tupaia belangeri hepatocytes equally well with anti-HBs/ayw2 (Fig. 33A, B). These results 
must be considered in context of the present vaccination policy and the protective power of 
the current HBV vaccine. The most widely used vaccine bears HBsAg subtype adw2 
(genotype A2) (De et al., 1985;McAleer et al., 1984), but the prevailing HBs subtype is ayw, 
genotype D. It is generally considered that 10 IU/L anti-HBs are believed to protect against 
infection of all HBV subtypes (Fitzsimons et al., 2005), however, recent findings suggest that 
the protective titer of 10 IU/L anti-HBs is only able to completely protect against genotype A2 
(vaccine genotype), whereas against other genotypes >100 IU/L anti-HBs were required. 
Importantly, only 47% of the vaccinated American blood donors had >100 IU/L anti-HBs 
(Stramer et al., 2011). The results presented in this study suggest that the yeast-derived HBV 
vaccine bears a strong subtype dependency, which, possibly, could be overcome with 
mammalian cell-derived or vector-type vaccines. The difference between yeast and 
mammalian-derived HBsAg rests presumably in the folding of the HBsAg loop. Anti-HBs 
from yeast–dervied vaccine recipients is highly reactive with denatured SHB or with SHBs 
peptides in Western blots, while anti-HBs induced by mammalian-derived HBs is non-
reactive (W.H. Gerlich, personal communication, C. M. Bremer, unpublished data).  
 It is known that the deficient response to current HBV vaccine of non-responders, who 
develop less than 10 IU/L anti-HBs has been attributed to the absence of HBsAg-specific 
Th1-like cells or their anergy (Chedid et al., 1997). Disposition to Th1 activity shown by 
IgG1/IgG2a sublass ratios was shown in this study. The response was IgG2a biased, but to a 
different scale for each of the immunized groups. The IgG2a dominance is in line with other 
studies employing rSFVvectors (Berglund et al., 1999;Andersson et al., 2001). IgG2a is 
dominant after a single intramuscular injection of integrating and non-integrating lentivirus 
vector (Karwacz et al., 2009). rSFV-preS1.1-48/S0 does not allow the secretion of HBsAg 
particles, and mice immunized with this rSFV induced the most prominent IgG1 while the 
isogenic vector with expression of SHBs had most IgG2a. In contrast, VLPs, including 
recombinant HBs induce predominantly Th2-type response (Skrastina et al., 2008). Th1 
dominance after immunization with SHBs could be achieved only after co-administration with 
synthetic oligodeoxynucleotides containing CpG motifs (Weeratna et al., 2000b), while 
delivery of SHBs by polylactic acid and PEG copolymer nanapoarticles resulted in a mixed 
Th1/Th2 response (Jain et al., 2009).   
Primary Tupaia hepatocyte cultures of Tupaia belangeri were successfully used in this 
study as in vitro model for evaluation of the neutralization capacity of antibodies generated to 
HBs via rSFV mediated immunization. Elevated efficiency of HBV infection of primary 
Tupaia belangeri hepatocytes using pre-immune BALB/c mice sera and sera from rSFV-
EGFP immunized mice compared to infection with HBV in the presence of PTH medium 
only was observed, while, interestingly, in presence of human serum the HBV infection of 
PTH is inhibited (Kock et al., 2001). Numerous serum associated proteins have been found to 
interact with HBV, including polymerized serum albumin (Imai et al., 1979; Dash et al., 
1991) and apolipoprotein H, which have been shown to be involved in HBV surface antigen 
(Mehdi et al., 1996) and HBV particle binding (Stefas et al., 2001). It has been suggested that 
lipoprotein lipase, an enzyme involved in lipoprotein metabolism might bind with preS and 
HBV particles (Deng et al., 2007).  
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 The preS1.1-48 component reduced the secretion of the HBsAg and resulted in 
slightly lower anti-HBs titers in immunized mice. Such a negative effect of reduced HBsAg 
secretion on immunogenicity of HBsAg expression vectors was reported previously (Geissler 
et al., 1999). The HBV neutralization capacity of preS1.1-48/S antisera was equal with that of 
antisera generated to anti-S only. This is in line with the observation that monoclonal, 
conformation dependent anti-HBs antibodies can neutralize the HBV infection with an equal 
efficiency as monoclonal antibodies recognizing preS1 20-23 in vitro (Glebe et al., 2003). The 
results obtained here with the rSFV-preS1.1-48/S0 indicate that for efficient neutralization of 
HBV infection presence of anti-S is necessary. Although, the primary determinant of HBV 
infectivity is preS1, the efficient neutralization potential of anti-S observed here underlines 
the significance of antigenic loop as the second infectivity determinant of HBV. Antigenic 
loop contains conformation dependent HBV entry determinant. The aa residues responsible 
for infectivity are conserved in the sequences of all human HBV genotypes and are clustered 
in close proximity of cysteines forming the disulfide bridges. The infectivity determinant can 
be separeted from antigenicity of „a” determinant, as shown by the most frequently occuring 
HBV „escape mutant” G145R. Aa exchange has detrimental effects on antigenicity, without 
affecting the infectivity: the G145R mutant was even more infectious than wt (Salisse and 
Sureau, 2009). Therefore inclusion of the HBV infection neutralizing preS1 epitope is of 
major significance, since anti-preS1 can interfere with another entry determinant - N terminal 
part of preS1.   
For a long time primary human hepatocytes have served as in vitro model for HBV-
related research. The availability of primary human hepatocytes was scarce, the low infection 
efficiency of in vitro cultures with HBV had to be increased by use of dimethylsulfoxide 
(DMSO) and polyethyleneglycol (PEG) (Gripon et al., 1988; Gripon et al., 1993). The quality 
of hepatocytes was extremely heterogenous as well as susceptibility to infection between 
preparations (Glebe, 2006). In 2002 a permissive cell line HepaRG was developed, however, 
before infection cells have to be cultivated in presence of DMSO and hydrocortisone to 
promote and sustain their differentiation and HBV infection is effective in presence of PEG 
only (Gripon et al., 2002). For efficient infection of PTH with HBV the fusogenic agent PEG 
and DMSO is not used (Glebe et al., 2003), nor it was used in this study. Efficiency of PTH 
infection with HBV also depends on the quality of isolated hepatocytes, which is variable 
between experiments, although the reproduceability between experiments is greater, 
compared to primary human hepatocytes (D. Glebe, personal communication). Cell lines 
stably transfected for HBV receptor sodium taurocholate co-transporting polypeptide can now 
also serve as an in vitro model of HBV infection (Ko et al., 2015). 
In this study hepatocytes of Asian tree shrew have been used for studies in vitro, for 
considering studies in vivo using Tupaia belangeri model of HBV infection it has to be taken 
into account that infection with HBV does not result in a chronic carrier state (Walter et al., 
1996). Primary hepatocytes of Tupaia belangeri have contributed in establishment of a model 
of chronic HBV infection – for repopulation of immunodeficient urokinase-type plasminogen 
activator mice in order to obtain a model for assessment of antivirals (Dandri et al., 2005) and 
HBV entry inhibitors (Petersen et al., 2008). Woodchuck (Marmota monax) model presents 
another small animal model of hepadnavirus infection, infection of woodchucks with 
Woodchuck Hepatitis virus results in a chronic infection (Menne and Cote, 2007). 
Woodchuck  model has served to unravel many aspects of disease pathogenesis, immune 
response of the host, as well as for evaluation of therapeutic vaccines (Roggendorf et al., 
2007), antivirals and immunomodulators in a setting of chronic hepatitis and hepatocellular 
carcinoma (Tennant et al., 2004).  
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5. CONCLUDING REMARKS AND OUTLOOK 
Prophylactic vaccination of HBV with the current vaccine is aimed at generation of 
neutralizing antibodies able to prevent the spread of the virus. This study has outlined 
approaches for improvement. The rSFV replicon may contribute to design and development 
of a therapeutic approach for chronic hepatitis B. Chronic hepatitis B is one of the major 
public health threats, since the chronic carriers represent a reservoir of HBV and a permanent 
source of infection. Significant proportion of chronic carriers develop liver cirrhosis and 
hepatocellular carcinoma, which is one of the most common cancers worldwide (Tan, 2011). 
Current therapy using IFN-α is able to reduce viral load only in 30 – 40% chronic HBV 
patients  and is dependent on HBV genotype as one of the factors affecting the outcome 
(Buster et al., 2009), while use of HBV polymerase inhibitors result in emergence of resistant 
HBV variants (Tillmann, 2007), and recurrence after completion of a long-term therapy 
(Reijnders et al., 2010). An effective therapeutic strategy for chronic hepatitis still remains an 
important goal. Chronic carrier state is linked to weak and narrowly directed virus specific 
CD8+ and CD4+ cell response (Chisari and Ferrari, 1995; Rouse and Sehrawat, 2010). T cell-
mediated response to HBV antigens, including HBs, is crucial in clearance of HBV from the 
liver. The weak T cell responses has been attributed to T-cell tolerance or exhaustion due to 
high viral load (Bertoletti and Gehring, 2013). Broadly specific CD8+ cells are essential for 
elimination of HBV infected hepatocytes, assisted by CD4+ cells (Yang et al., 2010). 
Induction of HBV-specific T cells is a goal of therapeutic vaccination (Bertoletti and Gehring, 
2009). The current and other conventional HBsAg vaccines, even with preS antigens, which 
contain additional T cell epitopes, are not able to induce curative Th1 or CTL immune 
response in HBV carriers (Pol et al., 2001; Jung et al., 2002; Yalcin et al., 2003). rSFV might 
contribute to development of immunotherapeutic strategies with the well documented ability 
of SFV replicons to provide enhanced antigen presentation by cross-priming (Huckriede et al., 
2004) and to break immunological tolerance and anergy (Leitner et al., 2003). rSFV replicons 
were shown to induce HBs specific IgG2a in this study - an indirect indication of a Th1 
dominant immune response. This is crucial for viral clearance in a persistent infection (Rossol 
et. al. 1997). Moreover, evidence about the suppression of innate immune response signalling 
(induced via pattern recognition receptors), among which are blockage of TLR receptor, RIG, 
-1 and IFN-β signalling pathways, during persistent HBV infection is mounting (Wu et al., 
2009; Kondo et al., 2011; Busca and Kumar, 2014). rSFV may represent an excellent tool for 
activation of innate antiviral pathways (Leitner et al., 2003) due to activation of pattern 
recognition receptors (Schulz et al., 2005). Generation of neutralizing antibodies was shown 
in this study, importantly, neutralizing antibodies play an important role in a persistent HBV 
setting by neutralizing the circulating virus particles and thus preventing the infection of yet 
non-infected hepatocytes (Chisari and Ferrari, 1995). High viral load of chronic HBV patients 
was found to be linked with non-reactive virus-specific CD8+ cells (Webster et al., 2004), 
therefore elimination of virus particles and circulating HBsAg by neutralizing antibodies is 
crucial. Kutscher et al. conclude that vaccines aimed at T cell induction were not effective in 
recipients with high viral and antigenic load and propose a two-step strategy: first reducing 
the high viraemia and antigenaemia by generation of neutralizing antibodies with the protein-
based vaccine, which would be followed by viral vector-based vaccines known to induce 
HBV-specific CTLs (Kutscher et al., 2011). Generation of neutralizing, HBs subtype 
independent antibodies was shown in this study, along with the indication of a Th1 dominant 
response. rSFV replicons may offer an immunization strategy of a single modality without the 
need of protein-based priming. However, the potential of rSFV replicons to provoke HBV-
specific CTLs in a chronic HBV infection animal model has to be yet investigated. Some 
promising results have been delivered by Rodriguez-Madoz et al. (Rodriguez-Madoz et al., 
2009), who showed transient reduction of intrahepatic tumours and viraemia in woodchucks 
treated intratumorally with rSFV encoding immunostimulatory cytokine IL-12. To achieve 
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broad CTL responses, additional HBV antigens must be included, for example HBc, either by 
insertion in the existing constructs after introduction of the second subgenomic promoter, or 
by additional administration of rSFV encoding HBc. The potential of rSFV replicon approach 
for the development of a therapeutic approach for chronic HBV infection must be further 
carefully evaluated. 
6. CONCLUSIONS 
 
1. Recombinant SFV encoding two SHBs subtypes adw2 and ayw2 representing HBV 
genotypes A2 and D were produced effectively in BHK-21 cells, along with rSFV encoding 
internally deleted LHBs protein (LHBs∆49-163, i. e. preS1.1-48/S and it’s variants), and 
resulted in titres up to 109 infectious units/ml of rSFV after sedimentation through 20% (w/v) 
sucrose. SHBs proteins and deleted LHBs proteins were expressed in vitro by various 
continuous cell lines and primary Tupaia belangeri hepatocytes after infection with rSFV at 
MOI 10-20. The SHBs protein had appropriate post-translational modifications and was 
efficiently secreted.  
 
2. The LHBs∆49-163 protein (preS1.1-48/S) and it’s variants demonstrated presence of two 
N-linked glycans present at ectopic sites (N4 in preS1 and N3 in S) and one N-linked glycan 
at the normal site Asn146 in the S domain. Glycosylation occurred in presence and absence of 
the aminoterminal myristoylation motif of LHBs. The S domain retained the native 
conformation in preS1.1-48/S and preS1.1-48/S0 proteins. 
 
3. Co-expressed LHBs∆49-163 and SHBs proteins were capable of efficient formation of 
subviral particles, displaying preS1 antigenicity on the surface and to a lesser extent SHBs 
antigenicity. The efficiency of subviral particle formation and secretion was dependent on the 
presence of SHBs protein expressed from the second internal initiation codon downstream of 
the preS1 start codon and was enhanced by the presence of the myristoylation motif at the 
amino-terminus of LHBs. Contrary to expectations proteins with an inactivated 
myristoylation motif displayed reduced efficiency of subviral particle formation and secretion. 
 
4. Immunization of BALB/c mice with 107 and 3 weeks later with 108 rSFV encoding 
SHBs/adw2 and SHBs/ayw2, preS1.1-48/S and preS1.1-48/S0 generated after three weeks 
end-point antibody titres in enzyme-linked immune assays up to 1:1,800 to SHBs proteins.  
 
5. The anti-preS1 titers were 1:1,500 in preS1.1-48/S immunized mice and higher than the 
anti-SHBs titers. Mice immunized with an equal number of infectious units of rSFV encoding 
preS1.1-48/S0 protein produced less, but still detectable anti-preS1 which is in line with 
inhibited secretion of this protein. 
 
6. The antibodies induced to SHBs/adw2 and SHBs/ayw2 reacted preferentially with 
homologous subtype determinants of yeast-derived rSHBs, demonstrating a strong rSHBs 
subtype dependency. However, anti-SHBs/adw2 and anti-SHBs/ayw2 reacted equally well 
with patient-derived HBsAg, subtype ayw2. Here, the reactivity was not HBsAg subtype-
dependent. This suggested a lack of group-specific a-determinants in the yeast-derived 
rHBsAg. 
 
7. Inclusion of the preS1 aminoterminal 48 aa did not elevate the anti-SHBs titre in mice 
immunized with rSFV vectors. Immunization with the preS1.1-48/S0 without the SHBs start 
codon did not induce detectable amounts of SHBs specific antibodies.  
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8. The in vitro model of primary Tupaia belangeri hepatocytes infected with highly purified 
patient-derived HBV provided a valuable tool for assessment of the neutralizing potential of 
the induced L- and S-HBs specific antibodies. The infection of these cells was measured by 
detection of the typical markers of an established HBV infection: secreted HBsAg, HBeAg 
and viral mRNA. Antibodies induced to SHBs/adw2 or SHBs/ayw2 neutralized HBV with the 
SHBs subtype ayw2 with equal efficiency. The potential of antibodies against preS1.1-48/S to 
neutralize HBV infection was comparable to anti-SHBs antibodies. Antisera obtained with 
vectors for SHBs/adw2, SHBs/ayw2, and preS1.1-48/S neutralized 5 HBV 
particles/hepatocyte completely at 1.0 and 0.5 mg/ml IgG. The antibodies generated to 
preS1.1-48/S0 lacking the presence of conformation dependent anti-SHBs neutralized only 
partially at 1.0 mg/ml, but could neutralize completely when present at 2.5 mg/ml IgG. 
 
9. rSFV replicon-mediated generation of antibodies to SHBs led predominantly to SHBs 
subtype-independent neutralizing antibodies. Addition of the aminoterminal 48 aa of preS1 - 
the most essential hepatocellular HBV attachment site - to the neutralizing epitopes of SHBs 
protein in the rSFV vector may provide escape-mutant resistant antibodies.  
 
10. The IgG1/IgG2a ratios of the induced antibodies indicated IgG2a dominance and thus a 
Th1 type response. The indirect evidence presented for a Th1 type dominant response after 
rSFV-mediated immunization may suggest use of this vector for studies on resolution of non-
response or hypo-response to HBV.  
 
7. THESES FOR DEFENCE 
 
1. The formation of secretable subviral particles by LHBs protein deletion variants (preS1.1-
48/S) is more efficient in presence of the myristoylation motif at the amino-terminus of preS1, 
and dependent on the in-frame co-expressed SHBs protein. Inactivation of the myristoylation 
motif did not enhance secretion in LHBs protein deletion variants consisting of aminoterminal 
48 aa of preS1 and SHBs protein as opposed to full length wt LHBs protein. 
 
2. Reactivity of the anti-SHBs/adw2 and anti-SHBs/ayw2 generated by rSFV-mediated 
immunization of BALB/c mice with rHBsAg from yeast is strongly rSHBs subtype 
dependent, while binding of anti-SHBs/adw2 and anti-SHBs/ayw2 to patient-derived HBsAg 
is not dependent on SHBs subtype.  
 
3. The neutralizing potential of SHBs antibodies induced with rSFV mediated immunization 
is not SHBs subtype dependent. Sera containing antibodies to SHBs/adw2 and SHBs/ayw2 
neutralize with equal efficiency as serum containing anti-SHBs and anti-preS1 neutralizing 
epitopes. PreS1-specific antibodies alone generated after rSFV mediated immunization also 
can confer protection. 
 
4. The well-documented evidence of alphavirus replicons in activating innate and cellular 
immunity in conjunction with the presented data on humoral immunity and Th1 type 
dominant response may provide a platform for immunotherapy of chronic hepatitis B. 
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